<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Adv Pharmacol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Adv Pharmacol Sci</journal-id>
<journal-id journal-id-type="publisher-id">APS</journal-id>
<journal-title-group>
<journal-title>Advances in Pharmacological Sciences</journal-title>
</journal-title-group>
<issn pub-type="ppub">1687-6334</issn>
<issn pub-type="epub">1687-6342</issn>
<publisher>
<publisher-name>Hindawi</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30719038</article-id>
<article-id pub-id-type="pmc">6335777</article-id>
<article-id pub-id-type="doi">10.1155/2019/7943481</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-8511-0230</contrib-id>
<name>
<surname>Chávez-Castillo</surname>
<given-names>Mervin</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-4365-1458</contrib-id>
<name>
<surname>Núñez</surname>
<given-names>Victoria</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-9769-1693</contrib-id>
<name>
<surname>Nava</surname>
<given-names>Manuel</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-7180-4765</contrib-id>
<name>
<surname>Ortega</surname>
<given-names>Ángel</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-2764-8846</contrib-id>
<name>
<surname>Rojas</surname>
<given-names>Milagros</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-1880-8887</contrib-id>
<name>
<surname>Bermúdez</surname>
<given-names>Valmore</given-names>
</name>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-4994-075X</contrib-id>
<name>
<surname>Rojas-Quintero</surname>
<given-names>Joselyn</given-names>
</name>
<email>jrojasquintero@bwh.harvard.edu</email>
<xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
</contrib>
</contrib-group>
<aff id="I1">
<sup>1</sup>Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo, Venezuela</aff>
<aff id="I2">
<sup>2</sup>Psychiatric Hospital of Maracaibo, Maracaibo, Venezuela</aff>
<aff id="I3">
<sup>3</sup>Universidad Simón Bolívar, Departamento de Ciencias Sociales y Humanas, Cúcuta, Colombia</aff>
<aff id="I4">
<sup>4</sup>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA</aff>
<author-notes>
<fn fn-type="other">
<p>Academic Editor: Masahiro Oike</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>3</day>
<month>1</month>
<year>2019</year>
</pub-date>
<volume>2019</volume>
<elocation-id>7943481</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>27</day>
<month>11</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>12</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Mervin Chávez-Castillo et al.</copyright-statement>
<copyright-year>2019</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>Depression is currently recognized as a crucial problem in everyday clinical practice, in light of ever-increasing rates of prevalence, as well as disability, morbidity, and mortality related to this disorder. Currently available antidepressant drugs are notoriously problematic, with suboptimal remission rates and troubling side-effect profiles. Their mechanisms of action focus on the monoamine hypothesis for depression, which centers on the disruption of serotonergic, noradrenergic, and dopaminergic neurotransmission in the brain. Nevertheless, views on the pathophysiology of depression have evolved notably, and the comprehension of depression as a complex neuroendocrine disorder with important systemic implications has sparked interest in a myriad of novel neuropsychopharmacological approaches. Innovative pharmacological targets beyond monoamines include glutamatergic and GABAergic neurotransmission, brain-derived neurotrophic factor, various endocrine axes, as well as several neurosteroids, neuropeptides, opioids, endocannabinoids and endovanilloids. This review summarizes current knowledge on these pharmacological targets and their potential utility in the clinical management of depression.</p>
</abstract>
<funding-group>
<award-group>
<funding-source>Technological, Humanistic, and Scientific Development Council</funding-source>
<award-id>CC-0437-10-21-09-10</award-id>
</award-group>
<award-group>
<funding-source>University of Zulia</funding-source>
<award-id>FZ-0058-2007</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
<body>
<sec id="sec1">
<title>1. Introduction</title>
<p>Depression is one of the most frequent mental disorders in everyday clinical practice and is currently regarded as the leading cause of disability worldwide [<xref ref-type="bibr" rid="B1">1</xref>]. In addition to the profoundly debilitating condition of this disorder, major depressive disorder (MDD) entails an increased risk of medical comorbidities [<xref ref-type="bibr" rid="B2">2</xref>] and very high direct and indirect financial costs [<xref ref-type="bibr" rid="B3">3</xref>]; profiling this disorder as an important problem for public health.</p>
<p>In spite of this outlook, pharmacotherapy alternatives for MDD remain insufficient: Currently available antidepressant drugs (AD) have only been shown to achieve remission rates around 56% after four successive treatment stages [<xref ref-type="bibr" rid="B4">4</xref>]. Moreover, a majority of the available AD at present display problematic side-effect profiles and a delayed onset of action, further complicating the management of this disorder [<xref ref-type="bibr" rid="B5">5</xref>]. The development of newer, more effective, and tolerable agents is a pressing matter in neuropsychopharmacology, yet relatively few new drugs have been approved for MDD in recent decades [<xref ref-type="bibr" rid="B6">6</xref>].</p>
<p>Both the limited effectivity of existing AD and the scarcity of novel options may stem from a once revolutionary, yet—in retrospect—excessive and misguided focus on the monoamine hypothesis for the pathophysiology of depression, which centers on defective neurotransmission of serotonin (5-hydroxytriptamine, 5HT), noradrenaline (NA), and dopamine (DA) in the brain [<xref ref-type="bibr" rid="B7">7</xref>]. Indeed, the serendipitous discovery of tricyclic AD drove the “reverse engineering” of this hypothesis, which in turn has guided much of the development of all AD throughout history [<xref ref-type="bibr" rid="B8">8</xref>]. Nevertheless, the monoamine hypothesis has been heavily contested regarding its validity and the relative importance of its components [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>]. At present, advances in molecular psychiatry have reframed neuronal monoamine dysregulation to be the end state of a complex interplay among pathophysiologic pathways involving several nonmonoamine neurotransmitters, as well as several endocrine-metabolic components [<xref ref-type="bibr" rid="B11">11</xref>].</p>
<p>This more holistic understanding of the pathophysiology of MDD has allowed for the design and investigation of novel and promising AD candidates, with activity outside the monoamine dysregulation end state, thus providing provocative windows for intervention [<xref ref-type="bibr" rid="B12">12</xref>]. As preclinical and clinical studies progress at various rates for these molecules, this review aims to summarize current views on the neurobiology of depression, with an emphasis on emerging pharmacological targets beyond monoamine neurotransmission.</p>
</sec>
<sec id="sec2">
<title>2. Expanding Views on the Neurobiology of Depression</title>
<p>The understanding of depression as a clinical entity has evolved radically, from the early descriptions of Hippocrates' <italic>melancholia</italic> and other primitive pre-Kraepelinian conceptualizations to the rich variety of descriptions derived from various psychological currents during the 20th century, to the revolutionizing contributions of psychopharmacology and neurobiology in more recent history [<xref ref-type="bibr" rid="B13">13</xref>]. Research advances in the latter fields have particularly propelled medical models for depression and mental disorders in general, marking a transition in the understanding of these diagnoses from rather intangible, elusive concepts, to more concrete biological terms, especially centering on the monoamine hypothesis [<xref ref-type="bibr" rid="B14">14</xref>]. However, novel approaches exceed and intertwine with this central dysfunction in monoamine neurotransmission, by involving other neural, endocrine and metabolic pathophysiologic components (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Firstly, neurotransmitters beyond the three classic monoamines will be discussed in the following paragraphs.</p>
<sec id="sec2.1">
<title>2.1. Glutamate: A Versatile Regulator</title>
<p>Glutamate (Glu) is the major excitatory neurotransmitter in the mammalian brain [<xref ref-type="bibr" rid="B15">15</xref>]. In normal circumstances, Glu plays a prominent role in synaptic plasticity, learning, and memory. However, in pathological conditions, it is known to be a potent trigger for rapid or delayed neurotoxicity [<xref ref-type="bibr" rid="B16">16</xref>]. With emerging findings of antidepressant effects for glutamatergic drugs, speculation has arisen about the role of Glu in the pathophysiology of mood disorders [<xref ref-type="bibr" rid="B17">17</xref>]. In particular, depressed patients appear to have increased basal glutamatergic activity. As a result, preclinical and clinical studies with drugs directly targeting glutamatergic neurotransmission present new and provocative opportunities for antidepressant treatment [<xref ref-type="bibr" rid="B18">18</xref>].</p>
<p>Glu receptors are divided into two major families: ionotropic and metabotropic glutamate receptors (mGluRs). The ionotropic group includes NMDA, AMPA, and kainate receptors [<xref ref-type="bibr" rid="B19">19</xref>]. In resting conditions, NMDA receptors are blocked by magnesium until membrane depolarization, when the combined binding of two Glu molecules and two molecules of glycine or D-serine allows the influx of calcium, serving as a functional marker of converging excitatory input and ultimately producing excitation over longer periods of time [<xref ref-type="bibr" rid="B20">20</xref>]. AMPA receptors mediate the fast rapidly desensitizing excitations at most synapses and are responsible for the initial reaction to Glu in the synapse. Their activation permits the influx of sodium resulting in the depolarization of the neuronal membrane. Like AMPA receptors, kainate receptors are associated with voltage-dependent channels that primarily allow for the influx of sodium ions that mediate fast excitatory neurotransmission, but they appear to be less widespread and have a distinct distribution [<xref ref-type="bibr" rid="B21">21</xref>]. On the other hand, the metabotropic family consists of group I receptors (mGluR1 and mGluR5), which potentiate both presynaptic glutamate release and postsynaptic NMDA currents, and group II (mGluR2 and mGluR3), and group III receptors (mGluR4, mGluR6, mGluR7, and mGluR8), which tend to suppress glutamate function [<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B22">22</xref>].</p>
<p>To date, evidence has emerged indicating that NMDA receptor antagonists, group I metabotropic glutamate receptor (mGluR1 and mGluR5) antagonists, and positive modulators of AMPA receptors have antidepressant-like activity in a variety of preclinical models [<xref ref-type="bibr" rid="B23">23</xref>]. Historically, the preclinical antidepressant-like effects of the NMDA receptor antagonists AP-7 and MK-801 first suggested Glu signaling to be a potential therapeutic approach [<xref ref-type="bibr" rid="B24">24</xref>].</p>
<p>This research led to the experimental use of ketamine a noncompetitive NMDA receptor antagonist, which was profiled as a reasonable candidate for psychiatry given the previous years of safe and well-tolerated use in the fields of anesthesia and neurology [<xref ref-type="bibr" rid="B25">25</xref>]. Ketamine has been shown to induce rapid antidepressant effects within 24 hours of use at subanesthetic doses, lasting for at least several days after a single infusion in various blind pilot clinical trials, which has led to the coining of the term “rapid-acting antidepressants” (RAA) [<xref ref-type="bibr" rid="B26">26</xref>–<xref ref-type="bibr" rid="B28">28</xref>]. This effect has been reported to begin after the initial psychotomimetic, dissociative, and euphoric effects have subsided, suggesting that the antidepressant effects are not just a result of acute elevated mood [<xref ref-type="bibr" rid="B29">29</xref>]. Nonintravenous ketamine preparations, such as oral and intramuscular forms, have also shown antidepressant efficacy [<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>]. Intranasal ketamine appears most promising, owing to its high penetrance into the central nervous system and ease of administration [<xref ref-type="bibr" rid="B32">32</xref>]. This rapid action has prompted speculation posting glutamatergic neurotransmission as the key pharmacological target to bypass the delay in the onset of action of classic monoaminergic drugs. Nonetheless, concerns remain surrounding the use of ketamine as an antidepressant due to its pharmacological similarity to the potent psychotomimetic drug, phencyclidine (PCP), and its abuse liability as a hallucinogenic club drug [<xref ref-type="bibr" rid="B33">33</xref>].</p>
<p>Ketamine displays an interesting pharmacologic profile, as it is a <italic>µ</italic>-opioid receptor agonist with superior affinity for NMDA receptors [<xref ref-type="bibr" rid="B33">33</xref>]. Ketamine antagonizes NMDA receptors on GABAergic interneurons and on postsynaptic neurons, resulting in disinhibition of cortical glutamatergic neurons through the former [<xref ref-type="bibr" rid="B34">34</xref>] and increased synthesis of intracellular growth factors through the latter [<xref ref-type="bibr" rid="B22">22</xref>]. In addition, ketamine promotes inhibition of spontaneous NMDA receptor-mediated excitatory postsynaptic currents. In turn, this leads to suppression of elongation factor 2 kinase activity (eEF2K), permitting a rapid increase in the translation of brain-derived neurotrophic factor (BDNF), an important mediator for neuroplasticity and neuroprotection [<xref ref-type="bibr" rid="B35">35</xref>]. Ketamine has also been noted to inhibit signaling by nitric oxide, which allows for the stabilization of nitrergic Rheb, a small G protein that enhances intracellular signaling [<xref ref-type="bibr" rid="B36">36</xref>]. Indeed, ketamine seems to activate many intracellular cascades, including the mammalian target of rapamycin (mTOR) pathway, which has been observed to lead to an increased number and function of new synapses in the prefrontal cortex (PFC) of rats, reverting the synaptic deficits that result from exposure to stress [<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B37">37</xref>]. Furthermore, ketamine appears to increase p70 s6 kinase (p70s6K) and 4E-binding protein phosphorylation, both involved in the modulation of synaptogenesis (<xref ref-type="fig" rid="fig2">Figure 2</xref>) [<xref ref-type="bibr" rid="B37">37</xref>].</p>
<p>The promising results with ketamine have ignited considerable research on other rapid-acting antidepressant molecules [<xref ref-type="bibr" rid="B38">38</xref>]. Esketamine and arketamine—the <italic>(S)</italic> and <italic>(R)</italic> isomers of ketamine—have also been evaluated in both preclinical and clinical studies. In particular, in animal models, arketamine appears to induce more potent and longer-lasting antidepressant effects than esketamine without psychotomimetic effects [<xref ref-type="bibr" rid="B39">39</xref>]. Nevertheless, clinical research on arketamine is scarce to date, while esketamine appears to be effective for the acute improvement of depressive symptoms, yet less potent than ketamine, and with a similar side-effect profile [<xref ref-type="bibr" rid="B40">40</xref>]. Finally, <italic>(S)</italic>-norketamine, another ketamine derivate, has been reported to induce rapid and long-lasting antidepressant effects in rodent models with lower potency than esketamine, yet without psychotomimetic and other detrimental biochemical and neurophysiologic effects [<xref ref-type="bibr" rid="B41">41</xref>]. Indeed, with further investigation, ketamine-related molecules could strike a balance between clinical effectivity and tolerability in the relatively near future.</p>
<p>Repastinel is another RAA unrelated to ketamine, a tetrapeptide derived from the light chain of the B6B21 monoclonal antibody which acts as a NMDA receptor modulator and glycine-site partial agonist [<xref ref-type="bibr" rid="B41">41</xref>]. In animal models, repastinel appears to promote long-term potentiation of electrophysiological activity in the hippocampus and PFC by enhancing NMDA receptor-dependent signaling [<xref ref-type="bibr" rid="B42">42</xref>]. Although clinical research on repastinel is only in its early stages, repastinel appears to induce rapid and sustained antidepressant effects and be well-tolerated with no psychotomimetic effects [<xref ref-type="bibr" rid="B43">43</xref>].</p>
<p>In contrast with these rather selective glutamatergic agents, scopolamine, a nonselective muscarinic receptor antagonist, also displays Glu-modulating activity, which may correlate with antidepressant effects [<xref ref-type="bibr" rid="B44">44</xref>]. Animal models show that, like ketamine, scopolamine is a RAA, increasing glutamatergic neurotransmission and activation of mTORC1 signaling in the PFC [<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B45">45</xref>]. This enhancement is thought to occur via blockade of muscarinic receptors located on GABAergic interneurons in the medial PFC, similar to the initial cellular target underlying the actions of ketamine [<xref ref-type="bibr" rid="B46">46</xref>]. Several clinical studies have reported rapid antidepressant effects following intravenous infusion of low doses of scopolamine, and repeated doses (3 doses over 5–7 days) produced long-lasting improvements in mood for up to two weeks [<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>]. In this scenario, scopolamine has shown more efficacy in treatment-naïve patients, although treatment-resistant patients still show significant reductions in depressive symptoms [<xref ref-type="bibr" rid="B49">49</xref>].</p>
<p>Because of the current limitations of ketamine, its derivatives, and other emerging RAA, such as psilocybin, which is unrelated to ketamine and its associated mechanisms of action, yet also presents the clinical dilemma of rapid clinical effectivity vs tolerability and psychotomimetic effects [<xref ref-type="bibr" rid="B50">50</xref>–<xref ref-type="bibr" rid="B52">52</xref>], research has been conducted to seek more tolerable NMDA receptor antagonists that could replicate its antidepressant effect with less adverse effects. Memantine, a NMDA receptor antagonist currently approved for the management of Alzheimer's disease, has been studied in mood disorders. Preclinical reports in rodent models of depression have noted antidepressant-like effects [<xref ref-type="bibr" rid="B53">53</xref>]. However, currently available clinical placebo-controlled trials have failed to demonstrate efficacy on depressive symptoms in humans [<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>].</p>
<p>Riluzole, an FDA-approved medication for the treatment of amyotrophic lateral sclerosis, has also been used in some ketamine extension studies [<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B57">57</xref>]. It is a Glu receptor modulator [<xref ref-type="bibr" rid="B58">58</xref>] with apparent efficacy as both monotherapy [<xref ref-type="bibr" rid="B52">52</xref>] and adjunctive therapy in patients with treatment-resistant major depressive disorder (MDD) [<xref ref-type="bibr" rid="B59">59</xref>]. Research has found this antidepressant effect to be especially notable at 4 weeks in treatment-resistant populations, although placebo-controlled studies tend to deny any significant differences [<xref ref-type="bibr" rid="B60">60</xref>]. Therefore, further investigation is required to better characterize the clinical efficacy of riluzole in this context. Pharmacodynamic studies suggest riluzole is not an open-channel antagonist of the NMDA receptor and rather acts by enhancing the surface expression of AMPA receptor subunits in cultured hippocampal neurons, resembling the activity of lamotrigine in this aspect [<xref ref-type="bibr" rid="B61">61</xref>]. Riluzole has also been reported to stimulate BDNF expression [<xref ref-type="bibr" rid="B62">62</xref>] and accelerate Glu clearance from the synaptic cleft by facilitating Glu reuptake by astrocytes [<xref ref-type="bibr" rid="B63">63</xref>]. Both of these effects have been associated with antidepressant-like effects in preclinical rodent models [<xref ref-type="bibr" rid="B64">64</xref>].</p>
<p>There are currently several other Glu-modulating molecules under early experimental study for depression. Ro(25)-6981, an NMDA receptor antagonist with selectivity for the NR2B subunit has shown antidepressant-like effects, possibly mediated by increased expression of postsynaptic cascades such as the mTOR pathway [<xref ref-type="bibr" rid="B21">21</xref>]. A similar candidate, MK-801 (dizocilpine), is a high-affinity, noncompetitive antagonist of NMDA receptors with comparatively inconsistent antidepressant effects [<xref ref-type="bibr" rid="B65">65</xref>]. Although both appear to have significant antidepressant effects in the short term, neither appear to be as long-acting as ketamine [<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B66">66</xref>].</p>
<p>Metabotropic Glu receptors have also been examined as potential therapeutic targets in depression [<xref ref-type="bibr" rid="B67">67</xref>]. LY341495, an mGlu2/3 receptor antagonist, and not LY379268, an agonist for this receptor group, has been associated with an antidepressant effect [<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. This appears to involve activation of the mTORC1 pathway, in a similar fashion to MGS0039, another mGlu2/3 receptor antagonist, as well as ketamine. LY341495 also rapidly reverses anhedonia caused by chronic stress exposure in animal models, a rigorous rodent test of rapid antidepressant actions [<xref ref-type="bibr" rid="B70">70</xref>].</p>
<p>Indeed, stimulation of the mTOR cascade, as well as concurrent activation of AMPA receptors in the PFC may be essential for the antidepressant effect linked to Glu modulators [<xref ref-type="bibr" rid="B71">71</xref>]. The importance of AMPA receptors as mediators of antidepressant effects has been highlighted by Alt et al. [<xref ref-type="bibr" rid="B72">72</xref>]: Certain structural variants of AMPA receptors may be associated with modulation of AMPA receptor-mediated currents. In turn, this appears to facilitate monoaminergic neurotransmission by promoting BDNF signaling.</p>
<p>On the other hand, a study by Palucha-Poniewiera et al. in rats reported short-lived antidepressant effects for both MTEP, an mGlu5 receptor antagonist, and AMN802, an mGlu7 receptor agonist. Their onset of action began within 60 minutes of administration and disappeared at around 23 hours after. Results showed MTEP did not promote mTORC1 signaling; whereas AMN802 stimulated this pathway, yet failed to concurrently activate AMPA receptors [<xref ref-type="bibr" rid="B66">66</xref>]. Insights into this class of molecules are still in early experimental phases and further research is required.</p>
<p>Lastly, both zinc and magnesium have shown antidepressant activity in preclinical [<xref ref-type="bibr" rid="B73">73</xref>–<xref ref-type="bibr" rid="B75">75</xref>] and clinical studies [<xref ref-type="bibr" rid="B76">76</xref>–<xref ref-type="bibr" rid="B78">78</xref>] and may be valuable adjunctive agents in the pharmacotherapy of depression. Zinc and magnesium appear to decrease the activity of NMDA receptors, in association with increased BDNF and glycogen synthase kinase-3 (GSK-3) signaling.</p>
</sec>
<sec id="sec2.2">
<title>2.2. GABA: From Anticonvulsants to Mood Stabilizers to Antidepressants?</title>
<p>
<italic>γ</italic>-Aminobutyric acid (GABA) is the main inhibitory neurotransmitter on the mammalian brain, and its various receptors are widespread in the central nervous system [<xref ref-type="bibr" rid="B79">79</xref>]. Two general classes of GABA receptors are known: in the GABA-A family, the receptor is part of a ligand-gated ion channel complex where each isoform consists of five homologous or identical subunits surrounding a central chloride ion-selective channel gated by GABA. They are located in the postsynaptic membrane and drive immediate neuronal inhibition, while those located in extrasynaptic membranes respond to ambient GABA conferring long-term inhibition [<xref ref-type="bibr" rid="B80">80</xref>]. In contrast, the GABA-B family includes metabotropic G protein-coupled receptors that open or close ion channels via a second messenger system [<xref ref-type="bibr" rid="B81">81</xref>]. GABA-modulating agents, such as anticonvulsant drugs (ACD), are widely known to be effective in the management of depression [<xref ref-type="bibr" rid="B82">82</xref>]. This effect has been proposed to be due to a more favorable Glu-GABA balance driven by ACD. However, the distinct mood-regulating pattern of each ACD, as well as the absence of mood regulation by some ACD, suggests the antidepressant pharmacodynamics of GABAergic drugs to be more complex than solely a shift in the Glu-GABA equilibrium [<xref ref-type="bibr" rid="B83">83</xref>].</p>
<p>Reports have demonstrated increased GABA-B receptor binding in rodent brains after chronic administration of several antidepressant drugs [<xref ref-type="bibr" rid="B84">84</xref>], supporting a GABAergic hypothesis of antidepressant drug action. Nevertheless, further research has been inconsistent regarding the purported antidepressant effect of GABA-B receptor binding [<xref ref-type="bibr" rid="B85">85</xref>]. Currently, the proven clinical efficacy of ACD in mood disorders continues to fuel the study of GABAergic modulation in this context [<xref ref-type="bibr" rid="B86">86</xref>].</p>
<p>Virtually, all of the known molecular components of the GABA and Glu systems have been considered as potential therapeutic targets [<xref ref-type="bibr" rid="B87">87</xref>]. In particular, negative allosteric modulators of GABA-A receptors containing <italic>α</italic>5 subunits (<italic>α</italic>5 GABA-NAMs) have been proposed as a novel class of rapid-acting antidepressants. These produce a similar net effect to that of ketamine in the forebrain, yet with reduced side effects due to the comparatively lower expression of <italic>α</italic>5 subunits in this region. In a study on male mice, MRK-016, a <italic>α</italic>5 GABA-NAM, was associated with an antidepressant-like response, without changes in side effect-monitoring parameters, such as rota-rod performance, conditioned-place preference, and locomotion [<xref ref-type="bibr" rid="B88">88</xref>]. Further research is required to better characterize the usefulness and suitability of this promising molecule in humans.</p>
</sec>
<sec id="sec2.3">
<title>2.3. Brain-Derived Neurotrophic Factor</title>
<p>Decreased hippocampal expression of BDNF is a well-recognized component of the neurobiology of depression, anxiety, and stress, and antidepressant treatment has been observed to increase levels of this messenger [<xref ref-type="bibr" rid="B89">89</xref>]. By activating signaling mediated by tropomyosin-related kinase receptor (TrkB), BDNF plays a central role in neurogenesis and neuronal survival and growth [<xref ref-type="bibr" rid="B90">90</xref>, <xref ref-type="bibr" rid="B91">91</xref>]. Although BDNF was initially proposed as a therapeutic alternative for depression, clinical trials with recombinant BDNF have failed to achieve significant antidepressant efficacy [<xref ref-type="bibr" rid="B92">92</xref>, <xref ref-type="bibr" rid="B93">93</xref>].</p>
<p>Recent efforts have been directed to find other ways to exploit the beneficial effects of BDNF signaling, specifically through the study of TrkB ligands [<xref ref-type="bibr" rid="B94">94</xref>]. In particular, the use of 7,8-dihydroxyflavone, a TrkB agonist, has shown antidepressant activity in mice models [<xref ref-type="bibr" rid="B95">95</xref>, <xref ref-type="bibr" rid="B96">96</xref>], along with promotion of neurogenesis [<xref ref-type="bibr" rid="B97">97</xref>, <xref ref-type="bibr" rid="B98">98</xref>]. On the other hand, ANA-12 is a selective TrkB antagonist that can inhibit its neurotrophic activity in the nucleus accumbens without compromising neuronal survival. Paradoxically, this antagonist has also been linked with antidepressant and anxiolytic activity in mice models [<xref ref-type="bibr" rid="B99">99</xref>, <xref ref-type="bibr" rid="B100">100</xref>]. Therefore, further research is needed to clarify the pharmacology and clinical correlates of the use of TrkB ligands for depression.</p>
</sec>
</sec>
<sec id="sec3">
<title>3. Endocrine Pharmacotherapeutic Targets in Depression</title>
<p>The fields of psychiatry and endocrinology have long been known to be largely interrelated with various mental and endocrine disorders often displaying bidirectional relationships [<xref ref-type="bibr" rid="B101">101</xref>]. Depressive and anxious symptoms are common in subjects with hormonal disturbances and may represent a challenge for clinicians [<xref ref-type="bibr" rid="B102">102</xref>]. Although patients with depression do not always have overt or severe endocrine disease, hormonal changes are frequent in this population, with accumulating evidence supporting a pathophysiologic role in the context of depression, and by extension, endocrine disturbances may be a therapeutic target in this disorder [<xref ref-type="bibr" rid="B103">103</xref>].</p>
<p>Thyroid hormone is notoriously involved in brain development and function, and neuropsychiatric manifestations are hallmarks of thyroid disease [<xref ref-type="bibr" rid="B104">104</xref>]. Conversely, psychiatric disorders often feature disruptions of the hypothalamus-pituitary-thyroid axis (HPTA): Patients with depression have been found to show abnormal responses to thyroid-stimulating hormone (TSH) and thyrotropin-releasing hormone (TRH), as well as elevated TRH concentrations in cerebrospinal fluid and increased prevalence of antithyroid antibodies [<xref ref-type="bibr" rid="B105">105</xref>]. Available data to date indicates overt thyroid pathology is rare in subjects with depression [<xref ref-type="bibr" rid="B106">106</xref>]. On the contrary, subclinical thyroid pathology appears to be a significant risk factor for psychiatric disorders [<xref ref-type="bibr" rid="B105">105</xref>], with multiple studies demonstrating depressive symptoms to be significantly more frequent or severe in patients with subclinical hypothyroidism than in age- and sex-matched controls [<xref ref-type="bibr" rid="B107">107</xref>–<xref ref-type="bibr" rid="B109">109</xref>]. This outlook outlines the complexity of the involvement of the HPTA in the pathophysiology of depression.</p>
<p>Indeed, the role of the HPTA in depression may be subtler than gross thyroid disease, articulated by the ubiquity of thyroid hormone receptors in all tissues, and the susceptibility of this system to stress. Dynamic adjustments of the HPTA represent a physiological response in stress conditions, such as intense physical activity and pregnancy [<xref ref-type="bibr" rid="B110">110</xref>]. However, in depression, a chronic state of low-grade systemic inflammation appears to disrupt the HPTA and many other endocrine and immune axes [<xref ref-type="bibr" rid="B111">111</xref>]. In vitro and in vivo studies have shown T3 to stimulate microglial migration and activation, a prominent phenomenon seen in depression, schizophrenia, and autism spectrum disorders [<xref ref-type="bibr" rid="B112">112</xref>, <xref ref-type="bibr" rid="B113">113</xref>]. In this context, T3 signaling appears to result in disruptions in the PI3K, and MAPK/ERK cascades, as well as potentiated nitric oxide-mediated microglial migration and activation [<xref ref-type="bibr" rid="B114">114</xref>–<xref ref-type="bibr" rid="B116">116</xref>]. These events could contribute to the dysfunctions in neurotrophism, neuroplasticity, and neurotransmission seen in depression [<xref ref-type="bibr" rid="B117">117</xref>].</p>
<p>Administration of thyroid hormone is a well-supported augmenting strategy in the management of refractory depression, even in euthyroid patients [<xref ref-type="bibr" rid="B118">118</xref>–<xref ref-type="bibr" rid="B120">120</xref>]. However, hormone replacement alone may be insufficient to treat depression in hypothyroid patients, and further research is needed to better characterize the profile of patients who would benefit most from this intervention [<xref ref-type="bibr" rid="B121">121</xref>].</p>
<p>Corticosteroids have also been widely recognized to play a role in the neuroendocrine disturbances found in depression. Cortisol, the final product of the hypothalamus-pituitary-adrenal axis (HPAA), is broadly regarded as the “stress hormone,” mediating a myriad of essential functions across all organ systems under acute and chronic stress conditions [<xref ref-type="bibr" rid="B122">122</xref>]. However, cortisol is also a notorious participant in the pathophysiology of chronic stress-related illnesses, as seen in depression [<xref ref-type="bibr" rid="B123">123</xref>]. Central corticotropin-releasing hormone (CRH) hyperstimulation appears to be a key perpetuating factor of chronic stress and depression, and it has been suggested that suppression of CRH activity might be the final and common step of antidepressant action that is necessary for the stable remission of MDD [<xref ref-type="bibr" rid="B124">124</xref>]. Two primary CRH receptor subtypes—CRHR1 and CRHR2—have been described in the central nervous system (CNS) according to their neuroanatomical expression patterns; with CRHR1 appearing to play a key role in mediating the CRH-elicited effects in depression and anxiety [<xref ref-type="bibr" rid="B125">125</xref>]. Specific CRHR1 haplotypes have been linked with the development of MDD [<xref ref-type="bibr" rid="B126">126</xref>]. Therefore, the CRHR1 gene may be considered a candidate gene for antidepressant pharmacogenetics [<xref ref-type="bibr" rid="B127">127</xref>].</p>
<p>Evidence over the years for increased CRH activity initially led to the development of CRH receptor antagonists as putative treatments for depression [<xref ref-type="bibr" rid="B123">123</xref>]. A prominent member of this group is R121919, which has been shown to alleviate anxiety in rats and primates, as well as reduce depression scores with good tolerability in a small study with 20 subjects diagnosed with MDD [<xref ref-type="bibr" rid="B128">128</xref>]. NBI-30775/R121919, another CRH1 receptor antagonist, has been reported to have a clinical profile and efficacy comparable to paroxetine [<xref ref-type="bibr" rid="B129">129</xref>]. In contrast, CP-316,311, a selective nonpeptide CHRH1 antagonist, has failed to show efficacy in the treatment of MDD, despite being well-tolerated [<xref ref-type="bibr" rid="B130">130</xref>]. NBI-34041, another CRH1 receptor antagonist, has been reported to reduce stress-related secretion of cortisol upon administration, without systemic adverse effects [<xref ref-type="bibr" rid="B131">131</xref>]. Thus, CRH1 receptor antagonists may be promising novel therapeutic options for depression and anxiety in the future. These advancements will need to circumvent certain currently recognized difficulties regarding the pharmaceutic formulations and pharmacokinetics of these compounds, in order to assure sufficient bioavailability and penetration of the blood-brain barrier [<xref ref-type="bibr" rid="B132">132</xref>].</p>
<p>Sexual hormones have also been implicated in the neurobiology of depression, particularly regarding their very characteristic fluctuations throughout the life cycle and their correlation with mood disorders, in both sexes [<xref ref-type="bibr" rid="B133">133</xref>]. Episodes of mood disorders have been found to be more prevalent during key life periods with important hormonal changes, such as puberty, menopause, and the postpartum period [<xref ref-type="bibr" rid="B133">133</xref>–<xref ref-type="bibr" rid="B135">135</xref>]. Indeed, females are subject to a wider array of fluctuations with more dramatic consequences, in consonance with a more than doubled risk of mood disorders, in comparison to men [<xref ref-type="bibr" rid="B136">136</xref>, <xref ref-type="bibr" rid="B137">137</xref>]. This disparity highlights a potential role for gonadal hormones in the etiology of mood disorders. Estrogen receptors are thoroughly distributed in the brain [<xref ref-type="bibr" rid="B138">138</xref>], with these hormones participating in the organization of developing neurons, and the activation of mature neurons. Estrogens drive neurite growth and synaptogenesis, augment BDNF activity, and modulate neurotransmission of 5HT, NA, DA, Glu and Ach [<xref ref-type="bibr" rid="B139">139</xref>]. In particular, estrogens increase serotonergic activity by regulating 5HT metabolism and 5HT receptor expression, as well as modulating the spontaneous firing of the serotonergic neurons in the raphe nuclei [<xref ref-type="bibr" rid="B139">139</xref>].</p>
<p>In a clinical context, the role of estrogens in depression has been more thoroughly studied during the perimenopausal period. Several studies have focused on estrogen replacement therapy (ERT) as a way to alleviate depression, with interesting results. In a placebo-controlled trial on perimenopausal women by Schmidt et al. [<xref ref-type="bibr" rid="B140">140</xref>], ERT was linked with partial or full remission of depressive symptoms as early as 3 weeks after initiating treatment, while Klaiber et al. [<xref ref-type="bibr" rid="B141">141</xref>] reported similar benefits for high-dose ERT in perimenopausal women with MDD over 3 months. A larger study included 661 perimenopausal women who were divided into various groups: receiving oral estrogens and progesterone, receiving transdermal estradiol and progesterone, and a placebo group. After a 48-month follow-up, women who received oral ERT showed significant relief of depressive symptoms in comparison to the placebo group [<xref ref-type="bibr" rid="B142">142</xref>].</p>
<p>Nevertheless, a meta-analysis of 10 studies with 1,208 perimenopausal women ascertained supplementation with bioidentical estrogens to have no significant effects on depressive symptoms, even with adjunctive progestogens, despite being effective in the management of vasomotor symptoms [<xref ref-type="bibr" rid="B143">143</xref>]. Furthermore, the KNHANES study determined prolonged oral contraceptive use and ERT usage to be linked with a significantly higher risk of depression [<xref ref-type="bibr" rid="B144">144</xref>]. Therefore, the clinical use of estrogens for depression remains controversial and requires further research.</p>
<p>Similar to what occurs in menopause, the sudden drop in estradiol levels seen after delivery has been hypothesized to contribute prominently to postpartum depression (PPD) [<xref ref-type="bibr" rid="B138">138</xref>]. Moreover, fluctuations in progestogen levels may also intervene significantly: Progesterone and other progestogens have been related to negative mood states, possibly by disrupting GABAergic neurotransmission [<xref ref-type="bibr" rid="B145">145</xref>]. In postmenopausal women treated with progesterone and animals treated with allopregnanolone (APG), there is a bimodal association between serum APG concentration and adverse mood, resembling an inverted U-shaped curve. Moreover, in humans, the maximal effective concentration of APG for producing negative mood is within the range of physiological luteal-phase serum concentrations [<xref ref-type="bibr" rid="B146">146</xref>].</p>
<p>Clinical data on the use of estrogens or progestogens in PPD is currently scarce, although available results suggest treatment with sublingual estradiol to be linked with rapid reduction of depressive symptoms [<xref ref-type="bibr" rid="B147">147</xref>]. Administration of transdermal E2 has also been considered as a possible therapeutic pathway, considering that in this way, hepatic metabolism is by-passed and risk for venous thromboembolism decreases. However, recent pilot studies have been unsuccessful as of yet [<xref ref-type="bibr" rid="B148">148</xref>]. What has been considered a promising target in postpartum depression has been the aforementioned APG. In a randomized controlled trial, Kanes et al. researched the use of an intravenous dose of APG, finding scarce adverse events and significant improvement of the symptoms [<xref ref-type="bibr" rid="B149">149</xref>]. Further studies are required to elucidate the role of hormone therapy in PPD, as this entity continues to be recognized as remarkably difficult to treat.</p>
<p>Finally, androgens of both adrenal and gonadal origin can cross the blood-brain barrier, with multiple effects on the brain, and various androgens, including testosterone, can be synthesized <italic>de novo</italic> in the brain [<xref ref-type="bibr" rid="B150">150</xref>, <xref ref-type="bibr" rid="B151">151</xref>]. Androgens act as allosteric modulators of GABA-A receptors, increasing the duration and frequency of the opening of their associated chloride channel [<xref ref-type="bibr" rid="B152">152</xref>], modulating various neurotransmitter systems and neuronal excitability, with important implications in the neurobiology of mood disorders [<xref ref-type="bibr" rid="B152">152</xref>–<xref ref-type="bibr" rid="B155">155</xref>]. This profile appears to have significant clinical correlations: Testosterone levels decline progressively with age, in association with symptoms intriguingly similar to those seen in depression, including negative mood, fatigue, irritability, and low libido [<xref ref-type="bibr" rid="B156">156</xref>]. In addition, men treated with antiandrogen drugs have shown greater risk of developing MDD [<xref ref-type="bibr" rid="B157">157</xref>].</p>
<p>Interestingly, clinical studies have failed to show effectiveness for testosterone administration as an augmentation strategy in the management of depression in men [<xref ref-type="bibr" rid="B158">158</xref>], whereas administration of low-dose testosterone in women with treatment-resistant MDD has been observed to significantly improve depressive symptoms in comparison to placebo [<xref ref-type="bibr" rid="B159">159</xref>]. These paradoxical findings are consistent with the higher sensitivity of females to androgens, as higher androgen exposure has been noted to exert a definite negative influence in mood in females [<xref ref-type="bibr" rid="B160">160</xref>, <xref ref-type="bibr" rid="B161">161</xref>]. Future studies should address these differences between gender and their clinical relevance.</p>
</sec>
<sec id="sec4">
<title>4. Neurosteroid Pharmacotherapeutic Targets in Depression</title>
<p>Many neuron types—especially glutamatergic and GABAergic neurons—have shown <italic>de novo</italic> synthesis of steroidal messengers, termed neurosteroids, which have been observed to modulate neuronal excitability [<xref ref-type="bibr" rid="B162">162</xref>]. Allopregnanolone is the most well described of these molecules at present, which has been noted to have sedative and anesthetic effects as well as an impact in mood regulation [<xref ref-type="bibr" rid="B163">163</xref>]. As with all steroids, synthesis of APG requires the expression of several CYP enzymes in neurons [<xref ref-type="bibr" rid="B164">164</xref>].</p>
<p>APG appears to act as an allosteric modulator of the GABA-A receptor, as well as a negative feedback signal for the HPAA: In chronic stress conditions, lower APG levels have been linked with greater activation of the HPAA and a slower recovery towards homeostasis [<xref ref-type="bibr" rid="B165">165</xref>]. This in turn may be influenced by decreased basal activation of GABA-A receptors, a hypothesis consistent with the lower levels of APG found in the cerebrospinal fluid (CSF) and peripheral blood found in patients with various affective disorders, including MDD [<xref ref-type="bibr" rid="B166">166</xref>]. Selective serotonin reuptake inhibitors, tricyclic antidepressants, and mirtazapine have been observed to elevate APG levels, whereas electroconvulsive therapy, repeated transcranial magnetic stimulation, and sleep deprivation appear to have no such effect [<xref ref-type="bibr" rid="B167">167</xref>]. SAGE-217, a synthetic derivate of APG, is currently undergoing phase 2 clinical trials, with preliminary findings showing modest improvements in clinical scores for depression after short-term use [<xref ref-type="bibr" rid="B168">168</xref>]. Further studies are needed to explore the use of APG or its synthetic analogues in MDD.</p>
<p>The role of other neurosteroids in depression remains less clearly understood. Androstenedione may be particularly relevant as a regulator of the HPAA and androgen metabolism, but current findings are contradictory: Both direct and inverse relationships have been described between androstenedione and depressive symptoms [<xref ref-type="bibr" rid="B169">169</xref>, <xref ref-type="bibr" rid="B170">170</xref>]. Future research may clear these discrepancies and present further potential therapeutic strategies involving neurosteroids.</p>
</sec>
<sec id="sec5">
<title>5. Neuropeptide Pharmacotherapeutic Targets in Depression</title>
<sec id="sec5.1">
<title>5.1. Oxytocin and Arginine Vasopressin</title>
<p>In parallel to the study of neurosteroids, modern psychiatric research for future therapies has shown prominent interest in neuropeptides (<xref ref-type="fig" rid="fig3">Figure 3</xref>), especially oxytocin (OXT) and arginine vasopressin (AVP) [<xref ref-type="bibr" rid="B171">171</xref>]. Central oxytocin signaling exerts anxiolytic and antidepressant effects, whereas vasopressin tends to promote anxious and depressive behaviors. These opposing effects may underline the importance of the balanced activity of these neuropeptides regarding emotional regulation. Shifting this equilibrium towards oxytocin through positive social stimuli and psychopharmacotherapy may aid in the management of depression [<xref ref-type="bibr" rid="B172">172</xref>].</p>
<p>Indeed, in rodent studies, OXT has been clearly associated with positive social interaction [<xref ref-type="bibr" rid="B173">173</xref>, <xref ref-type="bibr" rid="B174">174</xref>], and synthetic OXT has been shown to shift stress responses in rodents towards a more active coping style, after both central and peripheral administration [<xref ref-type="bibr" rid="B172">172</xref>]. Furthermore, OXT but not AVP, was recently shown to stimulate neuronal growth and to rescue glucocorticoid- or stress-induced suppression of neurogenesis in the hippocampus of adult rats [<xref ref-type="bibr" rid="B175">175</xref>]. In humans, OXT levels have been observed to be significantly lower in both psychotic and nonpsychotic depression [<xref ref-type="bibr" rid="B176">176</xref>], as well as bipolar depression [<xref ref-type="bibr" rid="B177">177</xref>]. Moreover, OXT appears to be particularly lower in subjects with the melancholic phenotype of depression, as ascertained in an mRNA expression study by Meynen et al. [<xref ref-type="bibr" rid="B178">178</xref>].</p>
<p>In addition, there is preclinical and clinical evidence that OXT may also contribute to the improvement of other depression-related symptoms, including sexual dysfunction: a study with ventral injections of OXT in male rats showed that stimulation of paraventricular DA receptors not only induces penile erection but also increases mesolimbic DA neurotransmission by activating oxytocin neurons. These findings suggest these mediators can powerfully influence both the consummatory and motivational/rewarding aspects of sexual behavior [<xref ref-type="bibr" rid="B179">179</xref>], anhedonia. [<xref ref-type="bibr" rid="B180">180</xref>], and possibly, sleep disturbances [<xref ref-type="bibr" rid="B181">181</xref>]. Furthermore, OXT but not AVP, was recently shown to stimulate neuronal growth and to rescue glucocorticoid- or stress-induced suppression of neurogenesis in the hippocampus of adult rats [<xref ref-type="bibr" rid="B175">175</xref>].</p>
<p>On the other hand, AVP appears to be an anxiogenic mediator [<xref ref-type="bibr" rid="B182">182</xref>]. AVP receptors have been long identified—AVPR1A, AVPR1B and AVPR2 [<xref ref-type="bibr" rid="B183">183</xref>]—though AVP can also bind to the structurally related OXT receptor (OXTR) with high affinity. AVR1A receptors are widely distributed on blood vessels and have also been found in the CNS, including the paraventricular nucleus, whereas AVPR2 receptors are predominantly located in the principal cells of the renal collecting system [<xref ref-type="bibr" rid="B172">172</xref>]. The AVP receptor family is G protein-coupled receptors: AVPR1A and AVPR1B are both coupled to Gq/11 and signal via phospholipase C [<xref ref-type="bibr" rid="B184">184</xref>, <xref ref-type="bibr" rid="B185">185</xref>]. AVPR2 is coupled to Gs which, when activated, elevates cAMP levels by recruiting adenylate cyclase [<xref ref-type="bibr" rid="B186">186</xref>].</p>
<p>Studies on AVPR1B antagonists have yielded favorable results such as alleviation of anxiety and depression in animal and human models [<xref ref-type="bibr" rid="B187">187</xref>, <xref ref-type="bibr" rid="B188">188</xref>]. In rat models, the AVP gene has been strongly correlated with trait anxiety [<xref ref-type="bibr" rid="B189">189</xref>]. Furthermore, clinical trials have associated the use of AVPR1B antagonists to HPAA modulation in subjects with MDD, along with amelioration of clinical symptoms [<xref ref-type="bibr" rid="B190">190</xref>].</p>
</sec>
<sec id="sec5.2">
<title>5.2. Other Neuropeptides</title>
<p>Neurokinin 1 (NK1) antagonists were some of the earliest alternatives proposed for nonmonoamine-related biologic treatments for depression, following findings that linked chronic administration of MK-869, one of these molecules, with improvement of depressive symptoms [<xref ref-type="bibr" rid="B91">91</xref>, <xref ref-type="bibr" rid="B191">191</xref>]. This led to the clinical study of aprepitant, another NK1 antagonist. Although initial reports were favorable, it failed to demonstrate efficacy in phase III clinical trials, discouraging further scientific interest in this matter [<xref ref-type="bibr" rid="B192">192</xref>].</p>
<p>However, more recent research suggests almost full central blockade of NK1 receptors is required for efficacy in the treatment of depression [<xref ref-type="bibr" rid="B193">193</xref>, <xref ref-type="bibr" rid="B194">194</xref>]. Casopitant and orvepitant, two NK1 antagonists capable of much greater blockade have shown antidepressant efficacy in various isolated randomized trials [<xref ref-type="bibr" rid="B193">193</xref>–<xref ref-type="bibr" rid="B195">195</xref>]. This promising data have renewed interest in NK1 antagonists and other neuropeptide-related alternatives for depression.</p>
<p>Neuropeptide Y (NPY) is a very widespread neurotransmitter in the CNS, acting through a wide array of receptors [<xref ref-type="bibr" rid="B196">196</xref>–<xref ref-type="bibr" rid="B198">198</xref>]. In recent years, NPY has been reported to be decreased in depression, anxiety, and stress, in both plasma [<xref ref-type="bibr" rid="B199">199</xref>] and CSF [<xref ref-type="bibr" rid="B200">200</xref>]. Conversely, antidepressant treatment has been linked with increased NPY levels [<xref ref-type="bibr" rid="B201">201</xref>].</p>
<p>NPY-related therapeutic interventions have gained attention I light of these findings. Data from mice models are abundant: central administration of NPY has been associated with reduced immobility and longer swimming times in forced swim tests [<xref ref-type="bibr" rid="B202">202</xref>], along with other similar correlates [<xref ref-type="bibr" rid="B203">203</xref>–<xref ref-type="bibr" rid="B205">205</xref>], while Y1 receptor knockout mice tend to show opposite results [<xref ref-type="bibr" rid="B206">206</xref>]. In contrast, Y2 and Y4 receptor knockout mice have shown more resilient phenotypes in these tests [<xref ref-type="bibr" rid="B206">206</xref>, <xref ref-type="bibr" rid="B207">207</xref>], and the infusion of Y2 antagonists—as well as Y1 agonists—has been related with antidepressant effects [<xref ref-type="bibr" rid="B202">202</xref>]. This would suggest a differential role for distinct NPY receptor types, a promising hypothesis for future research.</p>
<p>Galanin has also been proposed to intervene in the neurobiology of depression [<xref ref-type="bibr" rid="B208">208</xref>, <xref ref-type="bibr" rid="B209">209</xref>]. The galanin system includes three major G protein-coupled receptors (GALR1, GALR2, and GALR3), all which are widespread in the CNS and tend to colocalize with monoamine receptors, forming heteroreceptor complexes [<xref ref-type="bibr" rid="B210">210</xref>]. Thus, galanin signaling is an important modulator of neurotransmission. Galanin overexpression has been described in depression and stress [<xref ref-type="bibr" rid="B211">211</xref>], and serum galanin levels have been suggested as a biomarker for depression [<xref ref-type="bibr" rid="B212">212</xref>]. In a siRNA GALR1 and GALR2 knockdown rat model, coadministration of fluoxetine with the Gal (1–16) fragment obtained greater antidepressant effects [<xref ref-type="bibr" rid="B213">213</xref>]. Several other studies have found similar results with various galanin ligands [<xref ref-type="bibr" rid="B214">214</xref>–<xref ref-type="bibr" rid="B217">217</xref>]. Nevertheless, understanding of the neurobiology of galanin is still incipient, in particular regarding mood regulation.</p>
</sec>
</sec>
<sec id="sec6">
<title>6. Pharmacotherapeutic Targets for Depression in Reward Neurocircuits</title>
<p>The reward system encompasses various neurocircuits which mediate motivational behavior and learning in response to external and internal stimuli [<xref ref-type="bibr" rid="B218">218</xref>]. Anatomically, this system originates in the ventral tegmental area (VTA) and projects to the nucleus accumbens (NAcc), lateral hypothalamus, lateral septum, hippocampus, amygdala, PFC, and anterior cingulate cortex (ACC) [<xref ref-type="bibr" rid="B219">219</xref>]. Preclinical and clinical findings in neuroimaging have demonstrated that the anhedonia and loss of motivation found in depression is closely linked with decreased size and functionality of several of the nuclei in the reward system, in particular the NAcc and ACC [<xref ref-type="bibr" rid="B220">220</xref>, <xref ref-type="bibr" rid="B221">221</xref>], along with reduced dopaminergic neurotransmission, one of the pillars of the monoamine hypothesis [<xref ref-type="bibr" rid="B222">222</xref>, <xref ref-type="bibr" rid="B223">223</xref>].</p>
<p>Functionally, reward processing involves two interrelated components: motivational processing, which centers attention and behavior on rewarding stimuli and fundamentally involves dopaminergic neurotransmission; and hedonic processing, which mediates the pleasurable reaction to these stimuli, and involves GABAergic, opioid, endocannabinoid (EC), and endovanilloid (EV) signaling throughout the NAcc, ventral pallidum, insular cortex, and orbitofrontal cortex [<xref ref-type="bibr" rid="B224">224</xref>, <xref ref-type="bibr" rid="B225">225</xref>]. The crosstalk among these systems is complex and remains to be fully elucidated [<xref ref-type="bibr" rid="B226">226</xref>, <xref ref-type="bibr" rid="B227">227</xref>]. However, specific components in these circuits have already emerged as potential targets in the neuropsychopharmacological approach to depression (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p>
<p>Dysregulation of opioid signaling has long been associated with depression, as indeed, opioids were historically trialed in the management of this disorder long before the introduction of modern AD [<xref ref-type="bibr" rid="B228">228</xref>–<xref ref-type="bibr" rid="B230">230</xref>]. Opioid receptors are in the G protein-coupled receptor superfamily, including three distinct types—mu (<italic>µ</italic>), delta (<italic>δ</italic>), and kappa (κ)—with different physiologic roles. Endogenous opioids are their native ligands, a group of peptides characterized by sharing a specific NH-terminal sequence (Tyr-Gly-Gly-Phe). Endogenous opioids have been classified as enkephalins, dynorphins, and <italic>β</italic>-endorphin according to their structure and their affinity for different receptor types [<xref ref-type="bibr" rid="B231">231</xref>].</p>
<p>Opioid peptides and their receptors are amply distributed in the central and peripheral nervous systems, intervening in nociception, analgesia, endocrine, and immunologic regulation, mood regulation, as well as hedonic and motivational processing, and modulation of addictive behavior [<xref ref-type="bibr" rid="B229">229</xref>]. In the CNS, opioid receptors are predominantly expressed in the brainstem, limbic nuclei, and cortex; the latter two being particularly relevant to mood disorders [<xref ref-type="bibr" rid="B232">232</xref>]. Indeed, neuroimaging and pathology studies—both in living subjects and <italic>postmortem</italic>—in subjects with depression and suicidal behavior, have shown structural and functional alterations in opioid signaling, especially in the PFC, NAcc, and ACC [<xref ref-type="bibr" rid="B233">233</xref>–<xref ref-type="bibr" rid="B237">237</xref>].</p>
<p>Although both misuse and chronic, high-dose treatment with opioids have been consistently linked increased incidence, relapse, and recurrence of depression [<xref ref-type="bibr" rid="B238">238</xref>–<xref ref-type="bibr" rid="B241">241</xref>], more nuanced used may be beneficial in this regard. In preclinical research, various opioid agonists such as morphine, codeine, levorphanol, methadone, and tramadol have been observed to yield better outcomes than commonly available antidepressants in mice models evaluating depressive behavior, with these effects being reversible by naloxone, an opioid antagonist [<xref ref-type="bibr" rid="B242">242</xref>]. The antidepressant efficacy of opioids may depend specifically on δ-receptor agonism, as observed in mice and rats treated with intracerebroventricular and intraperitoneal UFP-512, a <italic>δ</italic>-selective opioid agonist [<xref ref-type="bibr" rid="B243">243</xref>]. Because of the tolerance, dependence and abuse potential associated with unopposed and selective <italic>δ</italic> agonism [<xref ref-type="bibr" rid="B244">244</xref>], interest for the use of opioids in this situation has shifted to combined opioid agonists/antagonists. In particular, the coadministration of buprenorphine, a <italic>δ</italic>-receptor partial agonist and antagonist of <italic>δ</italic> and κ receptors, along with samidorfan, a <italic>δ</italic>-selective antagonist, has been associated with rapid antidepressant effects [<xref ref-type="bibr" rid="B245">245</xref>].</p>
<p>Another opioid-related potential pharmacological target for depression has been found in opiorphin, an inhibitor of Zn-ectopeptidase, neutral endopeptidase, and aminopeptidase N, all of which intervene in the rapid inactivation of enkephalins [<xref ref-type="bibr" rid="B246">246</xref>]. In preclinical models, opioid administration has been linked with attenuated depressive responses, with this effect being reversible by the administration of naldrindole, a <italic>δ</italic>-selective antagonist [<xref ref-type="bibr" rid="B247">247</xref>], or naloxone [<xref ref-type="bibr" rid="B248">248</xref>]. Despite these promising results, research in humans remains scarce, and further study is required to assuage concerns related to misuse of these substances.</p>
<p>The endocannabinoid system also has an important role in mood regulation, and levels of EC metabolites in CSF have been correlated with severity of depression [<xref ref-type="bibr" rid="B237">237</xref>]. EC are lipophilic substances synthesized on demand in various nuclei within the reward circuits, the principal molecules being anandamide, which also shows affinity for vanilloid receptors, and 2-arachidonoylglycerol [<xref ref-type="bibr" rid="B249">249</xref>, <xref ref-type="bibr" rid="B250">250</xref>]. Cannabinoid receptor 1 is localized in glutamatergic and GABAergic synapses throughout basal nuclei, while cannabinoid receptor 2 can be found both in the CNS and in immune cells, posing a provocative link between depression and systemic health [<xref ref-type="bibr" rid="B251">251</xref>]. Polymorphisms in the genes encoding these receptors have been correlated with specific treatment resistance [<xref ref-type="bibr" rid="B252">252</xref>], severe depression symptoms, [<xref ref-type="bibr" rid="B253">253</xref>] anxiety, and suicidal behavior [<xref ref-type="bibr" rid="B254">254</xref>]. Furthermore, levels of cannabinoid receptor ligands in CSF have been determined to be increased in subjects with depression after undergoing electroconvulsive therapy [<xref ref-type="bibr" rid="B255">255</xref>].</p>
<p>Although clinical research remains scarce regarding EC modulation in depression, preclinical findings appear promising. Recently, Xiaolie et al. investigated the role of curcumin, a cannabinoid receptor modulator, and dexanabinol-loaded solid lipid nanoparticles in depression treatment in mice and cultured cells. Their findings showed this compound increased EC expression and potentiated cannabinoid receptor activation, with increased activity in the ERK1/2 pathway, a key cascade in the activity of many AD [<xref ref-type="bibr" rid="B256">256</xref>].</p>
<p>Finally, endovanilloids are endogenous substances which possess a vanillyl group and show affinity for the TRPV1 receptor, the main molecules in this category being anandamide, <italic>n-</italic>acylethanolamines, <italic>n</italic>-acyldopamines, <italic>n</italic>-oleoyl-dopamine, and <italic>n</italic>-arachidonoyl-dopamine, as well as some lipoxygenase derivatives of arachidonic acid like 12-hydroperoxyeicosatetraenoic acid [<xref ref-type="bibr" rid="B257">257</xref>]. Though their physiology remains obscure, endovanilloids have been implicated in locomotion, pain modulation, and regulation of emotion, cognition, and behavior; pharmacological modulation of TRPV1 receptors has been speculated to be useful in the treatment of pain, anxiety, depression, and various neurological disorders [<xref ref-type="bibr" rid="B258">258</xref>]. TRPV1 receptors have been shown to modulate input to the locus coeruleus, a key area implicated in the regulation of mood, the stress response, and memory processing [<xref ref-type="bibr" rid="B259">259</xref>].</p>
<p>In preclinical studies, TRPV1 knockout mice tend to exhibit reduced immobility time and reduced latency times in the novelty-suppressed feeding paradigm, consistent with a decreased depressive response [<xref ref-type="bibr" rid="B260">260</xref>]. TRPV1 receptor modulation has been observed to boost the effect of AD [<xref ref-type="bibr" rid="B261">261</xref>], and arvanil, a synthetic agonist ofTRPV1 and cannabinoidreceptors, appears to induce significant antidepressant effects in mice [<xref ref-type="bibr" rid="B262">262</xref>]. Future research in humans in this field should clear the significance and utility of the neuropsychopharmacological modulation of the reward system in depression.</p>
</sec>
<sec id="sec7">
<title>7. Conclusions</title>
<p>Expanding comprehension of depression as a neuroendocrine disorder has injected much-needed hope into the landscape of neuropsychopharmacology. In particular, glutamate-based alternatives may be the most feasible in the near future, with promising and active clinical trials at the moment evaluating the use of both intravenous and oral ketamine, along with several other related molecules [<xref ref-type="bibr" rid="B263">263</xref>, <xref ref-type="bibr" rid="B264">264</xref>]. Likewise, nonpharmacological interventions, both well-established—including lifestyle modifications and electroconvulsive therapy—and more novel, such as deep brain stimulation, transcranial magnetic stimulation, and psychosurgery, should not be discounted, as their place in the treatment of depression has become better characterized in recent years.</p>
<p>Furthermore, evolving views on the pathophysiology of depression suggest pharmacological and nonpharmacological interventions centered on the immunologic, metabolic, and cardiovascular aspects of this disorder may break new ground in the field of psychiatric therapeutics in the future. Therefore, although present therapeutic outcomes require urgent improvement, there may be enough forthcoming innovation to remain optimistic regarding the conundrum of treatment alternatives in depression.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was supported by research grant no. CC-0437-10-21-09-10 from the Technological, Humanistic, and Scientific Development Council (CONDES), University of Zulia, and research grant no. FZ-0058-2007 from Fundacite-Zulia.</p>
</ack>
<sec>
<title>Conflicts of Interest</title>
<p>The authors declare that they have no conflicts of interest.</p>
</sec>
<ref-list>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whiteford</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Degenhardt</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Feigin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>The global burden of mental, neurological and substance use disorders: an analysis from the global burden of disease study 2010</article-title>
<source/>
<italic toggle="yes">PLoS One</italic>
<year>2015</year>
<volume>10</volume>
<issue>2</issue>
<pub-id pub-id-type="publisher-id">e0116820</pub-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0116820</pub-id>
<pub-id pub-id-type="other">2-s2.0-84922740654</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hare</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Toukhsati</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Johansson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jaarsma</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Depression and cardiovascular disease: a clinical review</article-title>
<source/>
<italic toggle="yes">European Heart Journal</italic>
<year>2013</year>
<volume>35</volume>
<issue>21</issue>
<fpage>1365</fpage>
<lpage>1372</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/eht462</pub-id>
<pub-id pub-id-type="other">2-s2.0-84894501936</pub-id>
<pub-id pub-id-type="pmid">24282187</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenberg</surname>
<given-names>P. E.</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>A.-A.</given-names>
</name>
<name>
<surname>Sisitsky</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pike</surname>
<given-names>C. T.</given-names>
</name>
<name>
<surname>Kessler</surname>
<given-names>R. C.</given-names>
</name>
</person-group>
<article-title>The economic burden of adults with major depressive disorder in the United States (2005 and 2010)</article-title>
<source/>
<italic toggle="yes">The Journal of Clinical Psychiatry</italic>
<year>2015</year>
<volume>76</volume>
<issue>2</issue>
<fpage>155</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="doi">10.4088/jcp.14m09298</pub-id>
<pub-id pub-id-type="other">2-s2.0-84928429007</pub-id>
<pub-id pub-id-type="pmid">25742202</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dale</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bang-Andersen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sánchez</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs</article-title>
<source/>
<italic toggle="yes">Biochemical Pharmacology</italic>
<year>2015</year>
<volume>95</volume>
<issue>2</issue>
<fpage>81</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2015.03.011</pub-id>
<pub-id pub-id-type="other">2-s2.0-84932166879</pub-id>
<pub-id pub-id-type="pmid">25813654</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathew</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Manji</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Charney</surname>
<given-names>D. S.</given-names>
</name>
</person-group>
<article-title>Novel drugs and therapeutic targets for severe mood disorders</article-title>
<source/>
<italic toggle="yes">Neuropsychopharmacology</italic>
<year>2008</year>
<volume>33</volume>
<issue>9</issue>
<fpage>2080</fpage>
<lpage>2092</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1301652</pub-id>
<pub-id pub-id-type="other">2-s2.0-45549092746</pub-id>
<pub-id pub-id-type="pmid">18172433</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agid</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Buzsáki</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Diamond</surname>
<given-names>D. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>How can drug discovery for psychiatric disorders be improved?</article-title>
<source/>
<italic toggle="yes">Nature Reviews Drug Discovery</italic>
<year>2007</year>
<volume>6</volume>
<issue>3</issue>
<fpage>189</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="doi">10.1038/nrd2217</pub-id>
<pub-id pub-id-type="other">2-s2.0-33847374225</pub-id>
<pub-id pub-id-type="pmid">17330070</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roth</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Sheffler</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Kroeze</surname>
<given-names>W. K.</given-names>
</name>
</person-group>
<article-title>Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</article-title>
<source/>
<italic toggle="yes">Nature Reviews Drug Discovery</italic>
<year>2004</year>
<volume>3</volume>
<issue>4</issue>
<fpage>353</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="doi">10.1038/nrd1346</pub-id>
<pub-id pub-id-type="other">2-s2.0-4644271084</pub-id>
<pub-id pub-id-type="pmid">15060530</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hillhouse</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>J. H.</given-names>
</name>
</person-group>
<article-title>A brief history of the development of antidepressant drugs: from monoamines to glutamate</article-title>
<source/>
<italic toggle="yes">Experimental and Clinical Psychopharmacology</italic>
<year>2015</year>
<volume>23</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1037/a0038550</pub-id>
<pub-id pub-id-type="other">2-s2.0-84925625537</pub-id>
<pub-id pub-id-type="pmid">25643025</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Uncini</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>The discrediting of the monoamine hypothesis</article-title>
<source/>
<italic toggle="yes">International Journal of General Medicine</italic>
<year>2012</year>
<volume>5</volume>
<fpage>135</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="doi">10.2147/ijgm.s27824</pub-id>
<pub-id pub-id-type="other">2-s2.0-84857065474</pub-id>
<pub-id pub-id-type="pmid">22371656</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lang</surname>
<given-names>U. E.</given-names>
</name>
<name>
<surname>Borgwardt</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms of depression: perspectives on new treatment strategies</article-title>
<source/>
<italic toggle="yes">Cellular Physiology and Biochemistry</italic>
<year>2013</year>
<volume>31</volume>
<issue>6</issue>
<fpage>761</fpage>
<lpage>777</lpage>
<pub-id pub-id-type="doi">10.1159/000350094</pub-id>
<pub-id pub-id-type="other">2-s2.0-84878352105</pub-id>
<pub-id pub-id-type="pmid">23735822</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caraci</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Leggio</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Salomone</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Drago</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>New drugs in psychiatry: focus on new pharmacological targets</article-title>
<source/>
<italic toggle="yes">F1000Research</italic>
<year>2017</year>
<volume>6</volume>
<fpage>p. 397</fpage>
<pub-id pub-id-type="doi">10.12688/f1000research.10233.1</pub-id>
<pub-id pub-id-type="other">2-s2.0-85017168410</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jansson</surname>
<given-names>Å.</given-names>
</name>
</person-group>
<article-title>Mood disorders and the brain: depression, melancholia, and the historiography of psychiatry</article-title>
<source/>
<italic toggle="yes">Medical History</italic>
<year>2012</year>
<volume>55</volume>
<issue>3</issue>
<fpage>393</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="doi">10.1017/s0025727300005469</pub-id>
<pub-id pub-id-type="other">2-s2.0-79961048720</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dean</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Keshavan</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The neurobiology of depression: an integrated view</article-title>
<source/>
<italic toggle="yes">Asian Journal of Psychiatry</italic>
<year>2017</year>
<volume>27</volume>
<fpage>101</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajp.2017.01.025</pub-id>
<pub-id pub-id-type="other">2-s2.0-85015641899</pub-id>
<pub-id pub-id-type="pmid">28558878</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orrego</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Villanueva</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization</article-title>
<source/>
<italic toggle="yes">Neuroscience</italic>
<year>1993</year>
<volume>56</volume>
<issue>3</issue>
<fpage>539</fpage>
<lpage>555</lpage>
<pub-id pub-id-type="doi">10.1016/0306-4522(93)90355-j</pub-id>
<pub-id pub-id-type="other">2-s2.0-0027376339</pub-id>
<pub-id pub-id-type="pmid">7902967</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krystal</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>D’Souza</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Petrakis</surname>
<given-names>I. L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders</article-title>
<source/>
<italic toggle="yes">Harvard Review of Psychiatry</italic>
<year>1999</year>
<volume>7</volume>
<issue>3</issue>
<fpage>125</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="doi">10.1093/hrp/7.3.125</pub-id>
<pub-id pub-id-type="pmid">10483932</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krystal</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Sanacora</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>R. S.</given-names>
</name>
</person-group>
<article-title>Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond</article-title>
<source/>
<italic toggle="yes">Biological Psychiatry</italic>
<year>2013</year>
<volume>73</volume>
<issue>12</issue>
<fpage>1133</fpage>
<lpage>1141</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2013.03.026</pub-id>
<pub-id pub-id-type="other">2-s2.0-84878409579</pub-id>
<pub-id pub-id-type="pmid">23726151</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geddes</surname>
<given-names>S. D.</given-names>
</name>
<name>
<surname>Assadzada</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sokolovski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bergeron</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Haj-Dahmane</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Béïque</surname>
<given-names>J.-C.</given-names>
</name>
</person-group>
<article-title>Time-dependent modulation of glutamate synapses onto 5-HT neurons by antidepressant treatment</article-title>
<source/>
<italic toggle="yes">Neuropharmacology</italic>
<year>2015</year>
<volume>95</volume>
<fpage>130</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.02.027</pub-id>
<pub-id pub-id-type="other">2-s2.0-84925449953</pub-id>
<pub-id pub-id-type="pmid">25747603</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Javitt</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kalivas</surname>
<given-names>P. W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Translating glutamate: from pathophysiology to treatment</article-title>
<source/>
<italic toggle="yes">Science Translational Medicine</italic>
<year>2011</year>
<volume>3</volume>
<issue>102</issue>
<fpage>p. 102mr2</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3002804</pub-id>
<pub-id pub-id-type="other">2-s2.0-80053221118</pub-id>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>W. Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. T.</given-names>
</name>
</person-group>
<article-title>The NMDA receptor complex: a multifunctional machine at the glutamatergic synapse</article-title>
<source/>
<italic toggle="yes">Frontiers in Cellular Neuroscience</italic>
<year>2014</year>
<volume>8</volume>
<fpage>p. 160</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2014.00160</pub-id>
<pub-id pub-id-type="other">2-s2.0-84902331595</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perea</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sur</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Araque</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Neuron-glia networks: integral gear of brain function</article-title>
<source/>
<italic toggle="yes">Frontiers in Cellular Neuroscience</italic>
<year>2014</year>
<volume>8</volume>
<fpage>p. 378</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2014.00378</pub-id>
<pub-id pub-id-type="other">2-s2.0-84908658822</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.-J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists</article-title>
<source/>
<italic toggle="yes">Science</italic>
<year>2010</year>
<volume>329</volume>
<issue>5994</issue>
<fpage>959</fpage>
<lpage>964</lpage>
<pub-id pub-id-type="doi">10.1126/science.1190287</pub-id>
<pub-id pub-id-type="other">2-s2.0-77955909841</pub-id>
<pub-id pub-id-type="pmid">20724638</pub-id>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paul</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Skolnick</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Glutamate and depression</article-title>
<source/>
<italic toggle="yes">Annals of the New York Academy of Sciences</italic>
<year>2003</year>
<volume>1003</volume>
<issue>1</issue>
<fpage>250</fpage>
<lpage>272</lpage>
<pub-id pub-id-type="doi">10.1196/annals.1300.016</pub-id>
<pub-id pub-id-type="other">2-s2.0-0346461630</pub-id>
<pub-id pub-id-type="pmid">14684451</pub-id>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trullas</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Skolnick</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Functional antagonists at the NMDA receptor complex exhibit antidepressant actions</article-title>
<source/>
<italic toggle="yes">European Journal of Pharmacology</italic>
<year>1990</year>
<volume>185</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1016/0014-2999(90)90204-j</pub-id>
<pub-id pub-id-type="other">2-s2.0-0025157918</pub-id>
<pub-id pub-id-type="pmid">2171955</pub-id>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurdi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Theerth</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Deva</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Ketamine: current applications in anesthesia, pain, and critical care</article-title>
<source/>
<italic toggle="yes">Anesthesia: Essays and Researches</italic>
<year>2014</year>
<volume>8</volume>
<issue>3</issue>
<fpage>p. 283</fpage>
<pub-id pub-id-type="doi">10.4103/0259-1162.143110</pub-id>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zarate</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>P. J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression</article-title>
<source/>
<italic toggle="yes">Archives of General Psychiatry</italic>
<year>2006</year>
<volume>63</volume>
<issue>8</issue>
<fpage>p. 856</fpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.63.8.856</pub-id>
<pub-id pub-id-type="other">2-s2.0-33746896935</pub-id>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diazgranados</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ibrahim</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Brutsche</surname>
<given-names>N. E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression</article-title>
<source/>
<italic toggle="yes">Archives of General Psychiatry</italic>
<year>2010</year>
<volume>67</volume>
<issue>8</issue>
<fpage>793</fpage>
<lpage>802</lpage>
<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2010.90</pub-id>
<pub-id pub-id-type="other">2-s2.0-77955891255</pub-id>
<pub-id pub-id-type="pmid">20679587</pub-id>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valentine</surname>
<given-names>G. W.</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>G. F.</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS</article-title>
<source/>
<italic toggle="yes">Psychiatry Research: Neuroimaging</italic>
<year>2011</year>
<volume>191</volume>
<issue>2</issue>
<fpage>122</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1016/j.pscychresns.2010.10.009</pub-id>
<pub-id pub-id-type="other">2-s2.0-78751701060</pub-id>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berman</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Cappiello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Anand</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antidepressant effects of ketamine in depressed patients</article-title>
<source/>
<italic toggle="yes">Biological Psychiatry</italic>
<year>2000</year>
<volume>47</volume>
<issue>4</issue>
<fpage>351</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="doi">10.1016/s0006-3223(99)00230-9</pub-id>
<pub-id pub-id-type="other">2-s2.0-0033969685</pub-id>
<pub-id pub-id-type="pmid">10686270</pub-id>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irwin</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Iglewicz</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care</article-title>
<source/>
<italic toggle="yes">Journal of Palliative Medicine</italic>
<year>2010</year>
<volume>13</volume>
<issue>7</issue>
<fpage>903</fpage>
<lpage>908</lpage>
<pub-id pub-id-type="doi">10.1089/jpm.2010.9808</pub-id>
<pub-id pub-id-type="other">2-s2.0-77954950428</pub-id>
<pub-id pub-id-type="pmid">20636166</pub-id>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanicotti</surname>
<given-names>C. G.</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Glue</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer</article-title>
<source/>
<italic toggle="yes">Journal of Palliative Medicine</italic>
<year>2012</year>
<volume>15</volume>
<issue>4</issue>
<fpage>400</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="doi">10.1089/jpm.2011.0314</pub-id>
<pub-id pub-id-type="other">2-s2.0-84859790090</pub-id>
<pub-id pub-id-type="pmid">22468772</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lapidus</surname>
<given-names>K. A. B.</given-names>
</name>
<name>
<surname>Levitch</surname>
<given-names>C. F.</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>A. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized controlled trial of intranasal ketamine in major depressive disorder</article-title>
<source/>
<italic toggle="yes">Biological psychiatry</italic>
<year>2014</year>
<volume>76</volume>
<issue>12</issue>
<fpage>970</fpage>
<lpage>976</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2014.03.026</pub-id>
<pub-id pub-id-type="other">2-s2.0-84919398586</pub-id>
<pub-id pub-id-type="pmid">24821196</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iadarola</surname>
<given-names>N. D.</given-names>
</name>
<name>
<surname>Niciu</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Richards</surname>
<given-names>E. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review</article-title>
<source/>
<italic toggle="yes">Therapeutic advances in chronic disease</italic>
<year>2015</year>
<volume>6</volume>
<issue>3</issue>
<fpage>97</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1177/2040622315579059</pub-id>
<pub-id pub-id-type="other">2-s2.0-84930516190</pub-id>
<pub-id pub-id-type="pmid">25954495</pub-id>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Homayoun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Moghaddam</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons</article-title>
<source/>
<italic toggle="yes">Journal of Neuroscience</italic>
<year>2007</year>
<volume>27</volume>
<issue>43</issue>
<fpage>11496</fpage>
<lpage>11500</lpage>
<pub-id pub-id-type="doi">10.1523/jneurosci.2213-07.2007</pub-id>
<pub-id pub-id-type="other">2-s2.0-35548991088</pub-id>
<pub-id pub-id-type="pmid">17959792</pub-id>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Autry</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Adachi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nosyreva</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses</article-title>
<source/>
<italic toggle="yes">Nature</italic>
<year>2011</year>
<volume>475</volume>
<issue>7354</issue>
<fpage>91</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1038/nature10130</pub-id>
<pub-id pub-id-type="other">2-s2.0-79960057257</pub-id>
<pub-id pub-id-type="pmid">21677641</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harraz</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Tyagi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cortés</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>S. H.</given-names>
</name>
</person-group>
<article-title>Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation</article-title>
<source/>
<italic toggle="yes">Molecular Psychiatry</italic>
<year>2016</year>
<volume>21</volume>
<issue>3</issue>
<fpage>313</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2015.211</pub-id>
<pub-id pub-id-type="other">2-s2.0-84958907155</pub-id>
<pub-id pub-id-type="pmid">26782056</pub-id>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.-J.</given-names>
</name>
<name>
<surname>Dwyer</surname>
<given-names>J. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure</article-title>
<source/>
<italic toggle="yes">Biological Psychiatry</italic>
<year>2011</year>
<volume>69</volume>
<issue>8</issue>
<fpage>754</fpage>
<lpage>761</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2010.12.015</pub-id>
<pub-id pub-id-type="other">2-s2.0-79953166373</pub-id>
<pub-id pub-id-type="pmid">21292242</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Witkin</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Knutson</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Rapid-acting antidepressants</article-title>
<source/>
<italic toggle="yes">Current Pharmaceutical Design</italic>
<year>2018</year>
<volume>24</volume>
<issue>22</issue>
<fpage>2556</fpage>
<lpage>2563</lpage>
<pub-id pub-id-type="doi">10.2174/1381612824666180730104707</pub-id>
<pub-id pub-id-type="pmid">30058481</pub-id>
</element-citation>
</ref>
<ref id="B38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shirayama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.-c.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects</article-title>
<source/>
<italic toggle="yes">Translational Psychiatry</italic>
<year>2015</year>
<volume>5</volume>
<issue>9</issue>
<fpage>p. e632</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2015.136</pub-id>
<pub-id pub-id-type="other">2-s2.0-84940855007</pub-id>
</element-citation>
</ref>
<ref id="B39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Is (S)-norketamine an alternative antidepressant for esketamine?</article-title>
<source/>
<italic toggle="yes">European Archives of Psychiatry and Clinical Neuroscience</italic>
<year>2018</year>
<volume>268</volume>
<pub-id pub-id-type="doi">10.1007/s00406-018-0922-2</pub-id>
<pub-id pub-id-type="other">2-s2.0-85049889898</pub-id>
</element-citation>
</ref>
<ref id="B40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nakao</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-norketamine</article-title>
<source/>
<italic toggle="yes">Biological Psychiatry</italic>
<year>2018</year>
<volume>84</volume>
<issue>8</issue>
<fpage>591</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2018.05.007</pub-id>
<pub-id pub-id-type="other">2-s2.0-85048859784</pub-id>
<pub-id pub-id-type="pmid">29945718</pub-id>
</element-citation>
</ref>
<ref id="B41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moskal</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Burgdorf</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stanton</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The development of rapastinel (formerly GLYX-13), a rapid acting and long lasting antidepressant</article-title>
<source/>
<italic toggle="yes">Current Neuropharmacology</italic>
<year>2016</year>
<volume>15</volume>
<issue>1</issue>
<fpage>47</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.2174/1570159x14666160321122703</pub-id>
<pub-id pub-id-type="other">2-s2.0-85010640119</pub-id>
</element-citation>
</ref>
<ref id="B42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez</surname>
<given-names>C. I.</given-names>
</name>
<name>
<surname>Zwerling</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kalanthroff</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of a novel NMDA receptor modulator, rapastinel (formerly GLYX-13), in OCD: proof of concept</article-title>
<source/>
<italic toggle="yes">American Journal of Psychiatry</italic>
<year>2016</year>
<volume>173</volume>
<issue>12</issue>
<fpage>1239</fpage>
<lpage>1241</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2016.16080868</pub-id>
<pub-id pub-id-type="other">2-s2.0-85002509814</pub-id>
<pub-id pub-id-type="pmid">27903098</pub-id>
</element-citation>
</ref>
<ref id="B43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frizzo</surname>
<given-names>M. E. d. S.</given-names>
</name>
<name>
<surname>Dall’Onder</surname>
<given-names>L. P.</given-names>
</name>
<name>
<surname>Dalcin</surname>
<given-names>K. B.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>D. O.</given-names>
</name>
</person-group>
<article-title>Riluzole enhances glutamate uptake in rat astrocyte cultures</article-title>
<source/>
<italic toggle="yes">Cellular and Molecular Neurobiology</italic>
<year>2004</year>
<volume>24</volume>
<issue>1</issue>
<fpage>123</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1023/b:cemn.0000012717.37839.07</pub-id>
<pub-id pub-id-type="other">2-s2.0-1242321225</pub-id>
<pub-id pub-id-type="pmid">15049516</pub-id>
</element-citation>
</ref>
<ref id="B44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banasr</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chowdhury</surname>
<given-names>G. M. I.</given-names>
</name>
<name>
<surname>Terwilliger</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole</article-title>
<source/>
<italic toggle="yes">Molecular Psychiatry</italic>
<year>2008</year>
<volume>15</volume>
<issue>5</issue>
<fpage>501</fpage>
<lpage>511</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2008.106</pub-id>
<pub-id pub-id-type="other">2-s2.0-77951880669</pub-id>
<pub-id pub-id-type="pmid">18825147</pub-id>
</element-citation>
</ref>
<ref id="B45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Türck</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Frizzo</surname>
<given-names>M. E.</given-names>
</name>
</person-group>
<article-title>Riluzole stimulates BDNF release from human platelets</article-title>
<source/>
<italic toggle="yes">BioMed Research International</italic>
<year>2015</year>
<volume>2015</volume>
<fpage>6</fpage>
<pub-id pub-id-type="publisher-id">189307</pub-id>
<pub-id pub-id-type="doi">10.1155/2015/189307</pub-id>
<pub-id pub-id-type="other">2-s2.0-84921326728</pub-id>
</element-citation>
</ref>
<ref id="B46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Priestley</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Woodruff</surname>
<given-names>G. N.</given-names>
</name>
<name>
<surname>Iversen</surname>
<given-names>L. L.</given-names>
</name>
</person-group>
<article-title>The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist</article-title>
<source/>
<italic toggle="yes">Proceedings of the National Academy of Sciences</italic>
<year>1986</year>
<volume>83</volume>
<issue>18</issue>
<fpage>7104</fpage>
<lpage>7108</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.83.18.7104</pub-id>
<pub-id pub-id-type="other">2-s2.0-0010748929</pub-id>
</element-citation>
</ref>
<ref id="B47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maeng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zarate</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cellular mechanisms underlying the antidepressant effects of ketamine: role of <italic>α</italic>-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors</article-title>
<source/>
<italic toggle="yes">Biological Psychiatry</italic>
<year>2008</year>
<volume>63</volume>
<issue>4</issue>
<fpage>349</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2007.05.028</pub-id>
<pub-id pub-id-type="other">2-s2.0-38349186799</pub-id>
<pub-id pub-id-type="pmid">17643398</pub-id>
</element-citation>
</ref>
<ref id="B48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ago</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Palucha-Paniewiera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Matrisciano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants</article-title>
<source/>
<italic toggle="yes">Neuropharmacology</italic>
<year>2013</year>
<volume>66</volume>
<fpage>40</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.05.022</pub-id>
<pub-id pub-id-type="other">2-s2.0-84872166978</pub-id>
<pub-id pub-id-type="pmid">22640631</pub-id>
</element-citation>
</ref>
<ref id="B49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahapatra</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Role of psilocybin in the treatment of depression</article-title>
<source/>
<italic toggle="yes">Therapeutic Advances in Psychopharmacology</italic>
<year>2016</year>
<volume>7</volume>
<issue>1</issue>
<fpage>54</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1177/2045125316676092</pub-id>
<pub-id pub-id-type="pmid">28101325</pub-id>
</element-citation>
</ref>
<ref id="B50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carhart-Harris</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Roseman</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bolstridge</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms</article-title>
<source/>
<italic toggle="yes">Scientific Reports</italic>
<year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>p. 13187</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-13282-7</pub-id>
<pub-id pub-id-type="other">2-s2.0-85029764321</pub-id>
</element-citation>
</ref>
<ref id="B51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carhart-Harris</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Bolstridge</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Day</surname>
<given-names>C. M. J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psilocybin with psychological support for treatment-resistant depression: six-month follow-up</article-title>
<source/>
<italic toggle="yes">Psychopharmacology</italic>
<year>2017</year>
<volume>235</volume>
<issue>2</issue>
<fpage>399</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-017-4771-x</pub-id>
<pub-id pub-id-type="other">2-s2.0-85029764277</pub-id>
<pub-id pub-id-type="pmid">29119217</pub-id>
</element-citation>
</ref>
<ref id="B52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quan</surname>
<given-names>M.-N.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.-Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model</article-title>
<source/>
<italic toggle="yes">Neuroscience</italic>
<year>2011</year>
<volume>182</volume>
<fpage>88</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2011.03.026</pub-id>
<pub-id pub-id-type="other">2-s2.0-79955482647</pub-id>
<pub-id pub-id-type="pmid">21440043</pub-id>
</element-citation>
</ref>
<ref id="B53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lenze</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Skidmore</surname>
<given-names>E. R.</given-names>
</name>
<name>
<surname>Begley</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Newcomer</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Butters</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Whyte</surname>
<given-names>E. M.</given-names>
</name>
</person-group>
<article-title>Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study</article-title>
<source/>
<italic toggle="yes">International Journal of Geriatric Psychiatry</italic>
<year>2011</year>
<volume>27</volume>
<issue>9</issue>
<fpage>974</fpage>
<lpage>980</lpage>
<pub-id pub-id-type="doi">10.1002/gps.2813</pub-id>
<pub-id pub-id-type="other">2-s2.0-84864703206</pub-id>
<pub-id pub-id-type="pmid">22173933</pub-id>
</element-citation>
</ref>
<ref id="B54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zarate</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Quiroz</surname>
<given-names>J. A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A double-blind, placebo-controlled study of memantine in the treatment of major depression</article-title>
<source/>
<italic toggle="yes">American Journal of Psychiatry</italic>
<year>2006</year>
<volume>163</volume>
<issue>1</issue>
<fpage>153</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.163.1.153</pub-id>
<pub-id pub-id-type="other">2-s2.0-30044450251</pub-id>
<pub-id pub-id-type="pmid">16390905</pub-id>
</element-citation>
</ref>
<ref id="B55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathew</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Murrough</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>aan het Rot</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Reich</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Charney</surname>
<given-names>D. S.</given-names>
</name>
</person-group>
<article-title>Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial</article-title>
<source/>
<italic toggle="yes">International Journal of Neuropsychopharmacology</italic>
<year>2010</year>
<volume>13</volume>
<issue>1</issue>
<fpage>71</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1017/s1461145709000169</pub-id>
<pub-id pub-id-type="other">2-s2.0-77949625234</pub-id>
<pub-id pub-id-type="pmid">19288975</pub-id>
</element-citation>
</ref>
<ref id="B56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibrahim</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>DiazGranados</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Franco-Chaves</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study</article-title>
<source/>
<italic toggle="yes">Neuropsychopharmacology</italic>
<year>2012</year>
<volume>37</volume>
<issue>6</issue>
<fpage>1526</fpage>
<lpage>1533</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2011.338</pub-id>
<pub-id pub-id-type="other">2-s2.0-84859777474</pub-id>
<pub-id pub-id-type="pmid">22298121</pub-id>
</element-citation>
</ref>
<ref id="B57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niciu</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Kelmendi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sanacora</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Overview of glutamatergic neurotransmission in the nervous system</article-title>
<source/>
<italic toggle="yes">Pharmacology Biochemistry and Behavior</italic>
<year>2012</year>
<volume>100</volume>
<issue>4</issue>
<fpage>656</fpage>
<lpage>664</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2011.08.008</pub-id>
<pub-id pub-id-type="other">2-s2.0-84855549573</pub-id>
</element-citation>
</ref>
<ref id="B58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zarate</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Payne</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Quiroz</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An open-label trial of riluzole in patients with treatment-resistant major depression</article-title>
<source/>
<italic toggle="yes">American Journal of Psychiatry</italic>
<year>2004</year>
<volume>161</volume>
<issue>1</issue>
<fpage>171</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.161.1.171</pub-id>
<pub-id pub-id-type="other">2-s2.0-1442264398</pub-id>
<pub-id pub-id-type="pmid">14702270</pub-id>
</element-citation>
</ref>
<ref id="B59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salardini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zeinoddini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mohammadinejad</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Riluzole combination therapy for moderate-to-severe major depressive disorder: a randomized, double-blind, placebo-controlled trial</article-title>
<source/>
<italic toggle="yes">Journal of Psychiatric Research</italic>
<year>2016</year>
<volume>75</volume>
<fpage>24</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2016.01.003</pub-id>
<pub-id pub-id-type="other">2-s2.0-84961710154</pub-id>
<pub-id pub-id-type="pmid">26800392</pub-id>
</element-citation>
</ref>
<ref id="B60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders</article-title>
<source/>
<italic toggle="yes">Neuropsychopharmacology</italic>
<year>2006</year>
<volume>32</volume>
<issue>4</issue>
<fpage>793</fpage>
<lpage>802</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1301178</pub-id>
<pub-id pub-id-type="other">2-s2.0-33947213976</pub-id>
<pub-id pub-id-type="pmid">16936714</pub-id>
</element-citation>
</ref>
<ref id="B61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pałucha-Poniewiera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test</article-title>
<source/>
<italic toggle="yes">Progress in Neuro-Psychopharmacology and Biological Psychiatry</italic>
<year>2012</year>
<volume>39</volume>
<issue>1</issue>
<fpage>102</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2012.05.015</pub-id>
<pub-id pub-id-type="other">2-s2.0-84864496278</pub-id>
<pub-id pub-id-type="pmid">22651960</pub-id>
</element-citation>
</ref>
<ref id="B62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hascup</surname>
<given-names>E. R.</given-names>
</name>
<name>
<surname>Hascup</surname>
<given-names>K. N.</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex</article-title>
<source/>
<italic toggle="yes">Journal of Neurochemistry</italic>
<year>2010</year>
<volume>115</volume>
<issue>6</issue>
<fpage>1608</fpage>
<lpage>1620</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.07066.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-78650000571</pub-id>
<pub-id pub-id-type="pmid">20969570</pub-id>
</element-citation>
</ref>
<ref id="B63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dwyer</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Lepack</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>R. S.</given-names>
</name>
</person-group>
<article-title>mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure</article-title>
<source/>
<italic toggle="yes">Journal of Molecular Psychiatry</italic>
<year>2013</year>
<volume>1</volume>
<issue>1</issue>
<fpage>p. 15</fpage>
<pub-id pub-id-type="doi">10.1186/2049-9256-1-15</pub-id>
<pub-id pub-id-type="pmid">25408908</pub-id>
</element-citation>
</ref>
<ref id="B64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dwyer</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Lepack</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>R. S.</given-names>
</name>
</person-group>
<article-title>mTOR activation is required for the antidepressant effects of mGluR2/3 blockade</article-title>
<source/>
<italic toggle="yes">The International Journal of Neuropsychopharmacology</italic>
<year>2011</year>
<volume>15</volume>
<issue>4</issue>
<fpage>429</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="doi">10.1017/s1461145711001702</pub-id>
<pub-id pub-id-type="other">2-s2.0-84862669286</pub-id>
<pub-id pub-id-type="pmid">22114864</pub-id>
</element-citation>
</ref>
<ref id="B65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pałucha-Poniewiera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Szewczyk</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats</article-title>
<source/>
<italic toggle="yes">Neuropharmacology</italic>
<year>2014</year>
<volume>82</volume>
<fpage>59</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.03.001</pub-id>
<pub-id pub-id-type="other">2-s2.0-84897994660</pub-id>
<pub-id pub-id-type="pmid">24631968</pub-id>
</element-citation>
</ref>
<ref id="B66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furey</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Drevets</surname>
<given-names>W. C.</given-names>
</name>
</person-group>
<article-title>Scopolamine produces larger antidepressant and antianxiety effects in women than in men</article-title>
<source/>
<italic toggle="yes">Neuropsychopharmacology</italic>
<year>2010</year>
<volume>35</volume>
<issue>12</issue>
<fpage>2479</fpage>
<lpage>2488</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2010.131</pub-id>
<pub-id pub-id-type="other">2-s2.0-77958001705</pub-id>
<pub-id pub-id-type="pmid">20736989</pub-id>
</element-citation>
</ref>
<ref id="B67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voleti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Navarria</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.-J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses</article-title>
<source/>
<italic toggle="yes">Biological Psychiatry</italic>
<year>2013</year>
<volume>74</volume>
<issue>10</issue>
<fpage>742</fpage>
<lpage>749</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2013.04.025</pub-id>
<pub-id pub-id-type="other">2-s2.0-84886730107</pub-id>
<pub-id pub-id-type="pmid">23751205</pub-id>
</element-citation>
</ref>
<ref id="B68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lucas-Meunier</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Baux</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fossier</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Blockade of different muscarinic receptor subtypes changes the equilibrium between excitation and inhibition in rat visual cortex</article-title>
<source/>
<italic toggle="yes">Neuroscience</italic>
<year>2010</year>
<volume>169</volume>
<issue>4</issue>
<fpage>1610</fpage>
<lpage>1620</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.06.019</pub-id>
<pub-id pub-id-type="other">2-s2.0-77955421141</pub-id>
<pub-id pub-id-type="pmid">20600670</pub-id>
</element-citation>
</ref>
<ref id="B69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furey</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Drevets</surname>
<given-names>W. C.</given-names>
</name>
</person-group>
<article-title>Antidepressant efficacy of the antimuscarinic drug scopolamine</article-title>
<source/>
<italic toggle="yes">Archives of General Psychiatry</italic>
<year>2006</year>
<volume>63</volume>
<issue>10</issue>
<fpage>p. 1121</fpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.63.10.1121</pub-id>
<pub-id pub-id-type="other">2-s2.0-33749333018</pub-id>
<pub-id pub-id-type="pmid">17015814</pub-id>
</element-citation>
</ref>
<ref id="B70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alt</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nisenbaum</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Bleakman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Witkin</surname>
<given-names>J. M.</given-names>
</name>
</person-group>
<article-title>A role for AMPA receptors in mood disorders</article-title>
<source/>
<italic toggle="yes">Biochemical Pharmacology</italic>
<year>2006</year>
<volume>71</volume>
<issue>9</issue>
<fpage>1273</fpage>
<lpage>1288</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2005.12.022</pub-id>
<pub-id pub-id-type="other">2-s2.0-33645120386</pub-id>
<pub-id pub-id-type="pmid">16442080</pub-id>
</element-citation>
</ref>
<ref id="B71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drevets</surname>
<given-names>W. C.</given-names>
</name>
<name>
<surname>Furey</surname>
<given-names>M. L.</given-names>
</name>
</person-group>
<article-title>Replication of scopolamine’s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial</article-title>
<source/>
<italic toggle="yes">Biological Psychiatry</italic>
<year>2010</year>
<volume>67</volume>
<issue>5</issue>
<fpage>432</fpage>
<lpage>438</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2009.11.021</pub-id>
<pub-id pub-id-type="other">2-s2.0-75849117116</pub-id>
<pub-id pub-id-type="pmid">20074703</pub-id>
</element-citation>
</ref>
<ref id="B72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gillin</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ruiz</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group</article-title>
<source/>
<italic toggle="yes">Biological Psychiatry</italic>
<year>1991</year>
<volume>30</volume>
<issue>2</issue>
<fpage>157</fpage>
<lpage>169</lpage>
<pub-id pub-id-type="doi">10.1016/0006-3223(91)90170-q</pub-id>
<pub-id pub-id-type="other">2-s2.0-0025879173</pub-id>
<pub-id pub-id-type="pmid">1655072</pub-id>
</element-citation>
</ref>
<ref id="B73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kantak</surname>
<given-names>K. M.</given-names>
</name>
</person-group>
<article-title>Magnesium deficiency alters aggressive behavior and catecholamine function</article-title>
<source/>
<italic toggle="yes">Behavioral Neuroscience</italic>
<year>1988</year>
<volume>102</volume>
<issue>2</issue>
<fpage>304</fpage>
<lpage>311</lpage>
<pub-id pub-id-type="doi">10.1037/0735-7044.102.2.304</pub-id>
<pub-id pub-id-type="other">2-s2.0-0023785024</pub-id>
<pub-id pub-id-type="pmid">3365326</pub-id>
</element-citation>
</ref>
<ref id="B74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murck</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Magnesium and affective disorders</article-title>
<source/>
<italic toggle="yes">Nutritional Neuroscience</italic>
<year>2013</year>
<volume>5</volume>
<issue>6</issue>
<fpage>375</fpage>
<lpage>389</lpage>
<pub-id pub-id-type="doi">10.1080/1028415021000039194</pub-id>
<pub-id pub-id-type="other">2-s2.0-0036904630</pub-id>
</element-citation>
</ref>
<ref id="B75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singewald</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sinner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hetzenauer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sartori</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Murck</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Magnesium-deficient diet alters depression- and anxiety-related behavior in mice-influence of desipramine and <italic>Hypericum perforatum</italic> extract</article-title>
<source/>
<italic toggle="yes">Neuropharmacology</italic>
<year>2004</year>
<volume>47</volume>
<issue>8</issue>
<fpage>1189</fpage>
<lpage>1197</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2004.08.010</pub-id>
<pub-id pub-id-type="other">2-s2.0-9644288037</pub-id>
<pub-id pub-id-type="pmid">15567428</pub-id>
</element-citation>
</ref>
<ref id="B76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eby</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Eby</surname>
<given-names>K. L.</given-names>
</name>
</person-group>
<article-title>Rapid recovery from major depression using magnesium treatment</article-title>
<source/>
<italic toggle="yes">Medical Hypotheses</italic>
<year>2006</year>
<volume>67</volume>
<issue>2</issue>
<fpage>362</fpage>
<lpage>370</lpage>
<pub-id pub-id-type="doi">10.1016/j.mehy.2006.01.047</pub-id>
<pub-id pub-id-type="other">2-s2.0-33744718154</pub-id>
<pub-id pub-id-type="pmid">16542786</pub-id>
</element-citation>
</ref>
<ref id="B77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirov</surname>
<given-names>G. K.</given-names>
</name>
<name>
<surname>Birch</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>Steadman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ramsey</surname>
<given-names>R. G.</given-names>
</name>
</person-group>
<article-title>Plasma magnesium levels in a population of psychiatric patients: correlations with symptoms</article-title>
<source/>
<italic toggle="yes">Neuropsychobiology</italic>
<year>2008</year>
<volume>30</volume>
<issue>2-3</issue>
<fpage>73</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="doi">10.1159/000119139</pub-id>
<pub-id pub-id-type="other">2-s2.0-0028133461</pub-id>
</element-citation>
</ref>
<ref id="B78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zieba</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kata</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dudek</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schlegel-zawadzka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Serum trace elements in animal models and human depression: Part III. Magnesium. Relationship with copper</article-title>
<source/>
<italic toggle="yes">Human Psychopharmacology: Clinical and Experimental</italic>
<year>2001</year>
<volume>15</volume>
<issue>8</issue>
<fpage>631</fpage>
<lpage>635</lpage>
<pub-id pub-id-type="doi">10.1002/hup.231</pub-id>
<pub-id pub-id-type="other">2-s2.0-0034491384</pub-id>
</element-citation>
</ref>
<ref id="B79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Maemura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kanbara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tamayama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hayasaki</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>GABA and GABA receptors in the central nervous system and other organs</article-title>
<source/>
<italic toggle="yes">International Review of Cytology</italic>
<year>2002</year>
<volume>213</volume>
<fpage>1</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1016/s0074-7696(02)13011-7</pub-id>
<pub-id pub-id-type="other">2-s2.0-0036163615</pub-id>
<pub-id pub-id-type="pmid">11837891</pub-id>
</element-citation>
</ref>
<ref id="B80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sigel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Steinmann</surname>
<given-names>M. E.</given-names>
</name>
</person-group>
<article-title>Structure, function, and modulation of GABAAReceptors</article-title>
<source/>
<italic toggle="yes">Journal of Biological Chemistry</italic>
<year>2012</year>
<volume>287</volume>
<issue>48</issue>
<fpage>40224</fpage>
<lpage>40231</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.r112.386664</pub-id>
<pub-id pub-id-type="other">2-s2.0-84869992899</pub-id>
<pub-id pub-id-type="pmid">23038269</pub-id>
</element-citation>
</ref>
<ref id="B81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bettler</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kaupmann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mosbacher</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gassmann</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Molecular structure and physiological functions of GABABReceptors</article-title>
<source/>
<italic toggle="yes">Physiological Reviews</italic>
<year>2004</year>
<volume>84</volume>
<issue>3</issue>
<fpage>835</fpage>
<lpage>867</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00036.2003</pub-id>
<pub-id pub-id-type="other">2-s2.0-3042546515</pub-id>
<pub-id pub-id-type="pmid">15269338</pub-id>
</element-citation>
</ref>
<ref id="B82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanacora</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>G. F.</given-names>
</name>
<name>
<surname>Krystal</surname>
<given-names>J. H.</given-names>
</name>
</person-group>
<article-title>Impairment of GABAergic transmission in depression: new insights from neuroimaging studies</article-title>
<source/>
<italic toggle="yes">Critical Reviews in Neurobiology</italic>
<year>2000</year>
<volume>14</volume>
<issue>1</issue>
<fpage>23</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1615/critrevneurobiol.v14.i1.20</pub-id>
<pub-id pub-id-type="other">2-s2.0-0034484015</pub-id>
<pub-id pub-id-type="pmid">11253954</pub-id>
</element-citation>
</ref>
<ref id="B83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fischell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Van Dyke</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Kvarta</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>LeGates</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>S. M.</given-names>
</name>
</person-group>
<article-title>Rapid antidepressant action and restoration of excitatory synaptic strength after chronic stress by negative modulators of alpha5-containing GABAA receptors</article-title>
<source/>
<italic toggle="yes">Neuropsychopharmacology</italic>
<year>2015</year>
<volume>40</volume>
<issue>11</issue>
<fpage>2499</fpage>
<lpage>2509</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2015.112</pub-id>
<pub-id pub-id-type="other">2-s2.0-84941315564</pub-id>
<pub-id pub-id-type="pmid">25900119</pub-id>
</element-citation>
</ref>
<ref id="B84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lloyd</surname>
<given-names>K. G.</given-names>
</name>
<name>
<surname>Thuret</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Upregulation of gamma-aminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock</article-title>
<source/>
<italic toggle="yes">J Pharmacol Exp Ther</italic>
<year>1985</year>
<volume>235</volume>
<issue>1</issue>
<fpage>191</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="pmid">2995646</pub-id>
</element-citation>
</ref>
<ref id="B85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cross</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Horton</surname>
<given-names>R. W.</given-names>
</name>
</person-group>
<article-title>Effects of chronic oral administration of the antidepressants, desmethylimipramine and zimelidine on rat cortical GABAB binding sites: a comparison with 5-HT2 binding site changes</article-title>
<source/>
<italic toggle="yes">British Journal of Pharmacology</italic>
<year>2012</year>
<volume>93</volume>
<issue>2</issue>
<fpage>331</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.1988.tb11438.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-0023871404</pub-id>
</element-citation>
</ref>
<ref id="B86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berigan</surname>
<given-names>T. R.</given-names>
</name>
</person-group>
<article-title>Psychiatric uses of newer anticonvulsants</article-title>
<source/>
<italic toggle="yes">The Primary Care Companion to The Journal of Clinical Psychiatry</italic>
<year>2001</year>
<volume>3</volume>
<issue>2</issue>
<fpage>82</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.4088/pcc.v03n0207</pub-id>
</element-citation>
</ref>
<ref id="B87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foster</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Glutamate- and GABA-based CNS therapeutics</article-title>
<source/>
<italic toggle="yes">Current Opinion in Pharmacology</italic>
<year>2006</year>
<volume>6</volume>
<issue>1</issue>
<fpage>7</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.coph.2005.11.005</pub-id>
<pub-id pub-id-type="other">2-s2.0-30844463216</pub-id>
<pub-id pub-id-type="pmid">16377242</pub-id>
</element-citation>
</ref>
<ref id="B88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Highland</surname>
<given-names>J. N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A negative allosteric modulator for <italic>α</italic>5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA receptor antagonist ketamine in mice</article-title>
<source/>
<italic toggle="yes">eNeuro</italic>
<year>2017</year>
<volume>4</volume>
<issue>1</issue>
<pub-id pub-id-type="publisher-id">ENEURO.0285-16.2017</pub-id>
<pub-id pub-id-type="doi">10.1523/eneuro.0285-16.2017</pub-id>
<pub-id pub-id-type="other">2-s2.0-85029851700</pub-id>
</element-citation>
</ref>
<ref id="B89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>D. N.</given-names>
</name>
</person-group>
<article-title>Potentiation of the Propunishment, but not the convulsant action of the <italic>β</italic>-carboline DMCM by naltrexone</article-title>
<source/>
<italic toggle="yes">Pharmacology Biochemistry and Behavior</italic>
<year>1986</year>
<volume>25</volume>
<issue>3</issue>
<fpage>595</fpage>
<lpage>598</lpage>
<pub-id pub-id-type="doi">10.1016/0091-3057(86)90147-4</pub-id>
<pub-id pub-id-type="other">2-s2.0-0022912456</pub-id>
</element-citation>
</ref>
<ref id="B90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castrén</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Neurotrophins and psychiatric disorders</article-title>
<source/>
<italic toggle="yes">Neurotrophic Factors</italic>
<year>2014</year>
<volume>220</volume>
<fpage>461</fpage>
<lpage>479</lpage>
<pub-id pub-id-type="doi">10.1007/978-3-642-45106-5_17</pub-id>
<pub-id pub-id-type="other">2-s2.0-84906565721</pub-id>
</element-citation>
</ref>
<ref id="B91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berton</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>E. J.</given-names>
</name>
</person-group>
<article-title>New approaches to antidepressant drug discovery: beyond monoamines</article-title>
<source/>
<italic toggle="yes">Nature Reviews Neuroscience</italic>
<year>2006</year>
<volume>7</volume>
<issue>2</issue>
<fpage>137</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="doi">10.1038/nrn1846</pub-id>
<pub-id pub-id-type="other">2-s2.0-31444441701</pub-id>
<pub-id pub-id-type="pmid">16429123</pub-id>
</element-citation>
</ref>
<ref id="B92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ochs</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Penn</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>York</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis</article-title>
<source/>
<italic toggle="yes">Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</italic>
<year>2009</year>
<volume>1</volume>
<issue>3</issue>
<fpage>201</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.1080/14660820050515197</pub-id>
<pub-id pub-id-type="other">2-s2.0-0034208461</pub-id>
</element-citation>
</ref>
<ref id="B93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thoenen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sendtner</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches</article-title>
<source/>
<italic toggle="yes">Nature Neuroscience</italic>
<year>2002</year>
<volume>5</volume>
<fpage>1046</fpage>
<lpage>1050</lpage>
<pub-id pub-id-type="doi">10.1038/nn938</pub-id>
<pub-id pub-id-type="other">2-s2.0-0036829006</pub-id>
<pub-id pub-id-type="pmid">12403983</pub-id>
</element-citation>
</ref>
<ref id="B94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Leary</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>R. A.</given-names>
</name>
</person-group>
<article-title>Design of potent peptide mimetics of brain-derived neurotrophic factor</article-title>
<source/>
<italic toggle="yes">Journal of Biological Chemistry</italic>
<year>2003</year>
<volume>278</volume>
<issue>28</issue>
<fpage>25738</fpage>
<lpage>25744</lpage>
<pub-id pub-id-type="pmid">12730196</pub-id>
</element-citation>
</ref>
<ref id="B95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>S.-W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yepes</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone</article-title>
<source/>
<italic toggle="yes">Proceedings of the National Academy of Sciences</italic>
<year>2010</year>
<volume>107</volume>
<issue>6</issue>
<fpage>2687</fpage>
<lpage>2692</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0913572107</pub-id>
<pub-id pub-id-type="other">2-s2.0-77249168715</pub-id>
</element-citation>
</ref>
<ref id="B96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>C. B.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders</article-title>
<source/>
<italic toggle="yes">Translational Neurodegeneration</italic>
<year>2016</year>
<volume>5</volume>
<issue>1</issue>
<fpage>p. 2</fpage>
<pub-id pub-id-type="doi">10.1186/s40035-015-0048-7</pub-id>
<pub-id pub-id-type="other">2-s2.0-84953378881</pub-id>
<pub-id pub-id-type="pmid">26740873</pub-id>
</element-citation>
</ref>
<ref id="B97">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>C.-B.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>Q.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Optimization of a small tropomyosin-related kinase B (TrkB) agonist 7,8-dihydroxyflavone active in mouse models of depression</article-title>
<source/>
<italic toggle="yes">Journal of Medicinal Chemistry</italic>
<year>2012</year>
<volume>55</volume>
<issue>19</issue>
<fpage>8524</fpage>
<lpage>8537</lpage>
<pub-id pub-id-type="doi">10.1021/jm301099x</pub-id>
<pub-id pub-id-type="other">2-s2.0-84867352628</pub-id>
<pub-id pub-id-type="pmid">22984948</pub-id>
</element-citation>
</ref>
<ref id="B98">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>H. R.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>O-methylated metabolite of 7,8-dihydroxyflavone activates TrkB receptor and displays antidepressant activity</article-title>
<source/>
<italic toggle="yes">Pharmacology</italic>
<year>2013</year>
<volume>91</volume>
<issue>3-4</issue>
<fpage>185</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="doi">10.1159/000346920</pub-id>
<pub-id pub-id-type="other">2-s2.0-84874263260</pub-id>
<pub-id pub-id-type="pmid">23445871</pub-id>
</element-citation>
</ref>
<ref id="B99">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation</article-title>
<source/>
<italic toggle="yes">Int J Neuropsychopharmacol</italic>
<year>2014</year>
<volume>18</volume>
<issue>4</issue>
<pub-id pub-id-type="doi">10.1093/ijnp/pyu077</pub-id>
<pub-id pub-id-type="other">2-s2.0-84927639238</pub-id>
</element-citation>
</ref>
<ref id="B100">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cazorla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prémont</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Girard</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kellendonk</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rognan</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Investigation</italic>
<year>2011</year>
<volume>121</volume>
<issue>5</issue>
<fpage>1846</fpage>
<lpage>1857</lpage>
<pub-id pub-id-type="doi">10.1172/jci43992</pub-id>
<pub-id pub-id-type="other">2-s2.0-79955489341</pub-id>
<pub-id pub-id-type="pmid">21505263</pub-id>
</element-citation>
</ref>
<ref id="B101">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamagno</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Epelbaum</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Editorial: neurological and psychiatric disorders in endocrine diseases</article-title>
<source/>
<italic toggle="yes">Frontiers in Endocrinology</italic>
<year>2015</year>
<volume>6</volume>
<fpage>p. 75</fpage>
<pub-id pub-id-type="doi">10.3389/fendo.2015.00075</pub-id>
<pub-id pub-id-type="other">2-s2.0-84930935503</pub-id>
</element-citation>
</ref>
<ref id="B102">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badhan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sareen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Trivedi</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Endocrine dysfunctions and psychiatric disorders: understanding an interface</article-title>
<source/>
<italic toggle="yes">Indian Journal of Behavioural Sciences</italic>
<year>2008</year>
<volume>18</volume>
<issue>2</issue>
<fpage>50</fpage>
<lpage>64</lpage>
</element-citation>
</ref>
<ref id="B103">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altemus</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Hormone-specific psychiatric disorders: do they exist?</article-title>
<source/>
<italic toggle="yes">Archives of Women’s Mental Health</italic>
<year>2010</year>
<volume>13</volume>
<issue>1</issue>
<fpage>25</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1007/s00737-009-0123-0</pub-id>
<pub-id pub-id-type="other">2-s2.0-76449104402</pub-id>
</element-citation>
</ref>
<ref id="B104">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stenzel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huttner</surname>
<given-names>W. B.</given-names>
</name>
</person-group>
<article-title>Role of maternal thyroid hormones in the developing neocortex and during human evolution</article-title>
<source/>
<italic toggle="yes">Frontiers in Neuroanatomy</italic>
<year>2013</year>
<volume>7</volume>
<fpage>p. 19</fpage>
<pub-id pub-id-type="doi">10.3389/fnana.2013.00019</pub-id>
<pub-id pub-id-type="other">2-s2.0-84878681293</pub-id>
</element-citation>
</ref>
<ref id="B105">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fountoulakis</surname>
<given-names>K. N.</given-names>
</name>
<name>
<surname>Kantartzis</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Siamouli</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peripheral thyroid dysfunction in depression</article-title>
<source/>
<italic toggle="yes">The World Journal of Biological Psychiatry</italic>
<year>2009</year>
<volume>7</volume>
<issue>3</issue>
<fpage>131</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1080/15622970500474739</pub-id>
<pub-id pub-id-type="other">2-s2.0-33746494118</pub-id>
</element-citation>
</ref>
<ref id="B106">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ordas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Labbate</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Routine screening of thyroid function in patients hospitalized for major depression or dysthymia?</article-title>
<source/>
<italic toggle="yes">Annals of Clinical Psychiatry</italic>
<year>1995</year>
<volume>7</volume>
<issue>4</issue>
<fpage>161</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.3109/10401239509149621</pub-id>
<pub-id pub-id-type="other">2-s2.0-0029552378</pub-id>
<pub-id pub-id-type="pmid">8721889</pub-id>
</element-citation>
</ref>
<ref id="B107">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Flashman</surname>
<given-names>L. A.</given-names>
</name>
</person-group>
<article-title>Cognitive and neuropsychiatric aspects of subclinical hypothyroidism: significance in the elderly</article-title>
<source/>
<italic toggle="yes">Current Psychiatry Reports</italic>
<year>2003</year>
<volume>5</volume>
<issue>5</issue>
<fpage>384</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="doi">10.1007/s11920-003-0073-6</pub-id>
<pub-id pub-id-type="other">2-s2.0-0642336294</pub-id>
<pub-id pub-id-type="pmid">13678560</pub-id>
</element-citation>
</ref>
<ref id="B108">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gulseren</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gulseren</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hekimsoy</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Cetinay</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ozen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tokatlioglu</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction</article-title>
<source/>
<italic toggle="yes">Archives of Medical Research</italic>
<year>2006</year>
<volume>37</volume>
<issue>1</issue>
<fpage>133</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.arcmed.2005.05.008</pub-id>
<pub-id pub-id-type="other">2-s2.0-28444459586</pub-id>
<pub-id pub-id-type="pmid">16314199</pub-id>
</element-citation>
</ref>
<ref id="B109">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chueire</surname>
<given-names>V. B.</given-names>
</name>
<name>
<surname>Romaldini</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>L. S.</given-names>
</name>
</person-group>
<article-title>Subclinical hypothyroidism increases the risk for depression in the elderly</article-title>
<source/>
<italic toggle="yes">Archives of Gerontology and Geriatrics</italic>
<year>2007</year>
<volume>44</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1016/j.archger.2006.02.001</pub-id>
<pub-id pub-id-type="other">2-s2.0-33751025091</pub-id>
<pub-id pub-id-type="pmid">16678286</pub-id>
</element-citation>
</ref>
<ref id="B110">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fekete</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lechan</surname>
<given-names>R. M.</given-names>
</name>
</person-group>
<article-title>Central regulation of hypothalamic-pituitary-thyroid Axis under physiological and pathophysiological conditions</article-title>
<source/>
<italic toggle="yes">Endocrine Reviews</italic>
<year>2014</year>
<volume>35</volume>
<issue>2</issue>
<fpage>159</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1210/er.2013-1087</pub-id>
<pub-id pub-id-type="other">2-s2.0-84897395869</pub-id>
<pub-id pub-id-type="pmid">24423980</pub-id>
</element-citation>
</ref>
<ref id="B111">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hage</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Azar</surname>
<given-names>S. T.</given-names>
</name>
</person-group>
<article-title>The link between thyroid function and depression</article-title>
<source/>
<italic toggle="yes">Journal of Thyroid Research</italic>
<year>2012</year>
<volume>2012</volume>
<fpage>8</fpage>
<pub-id pub-id-type="publisher-id">590648</pub-id>
<pub-id pub-id-type="doi">10.1155/2012/590648</pub-id>
<pub-id pub-id-type="other">2-s2.0-84870234518</pub-id>
</element-citation>
</ref>
<ref id="B112">
<label>112</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizoguchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Seki</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain-derived neurotrophic factor (BDNF) induces sustained intracellular Ca<sup>2+</sup>Elevation through the up-regulation of surface transient receptor potential 3 (TRPC3) channels in rodent microglia</article-title>
<source/>
<italic toggle="yes">Journal of Biological Chemistry</italic>
<year>2014</year>
<volume>289</volume>
<issue>26</issue>
<fpage>18549</fpage>
<lpage>18555</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.m114.555334</pub-id>
<pub-id pub-id-type="other">2-s2.0-84903550539</pub-id>
<pub-id pub-id-type="pmid">24811179</pub-id>
</element-citation>
</ref>
<ref id="B113">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kato</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Yamauchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Horikawa</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurotransmitters, psychotropic drugs and microglia: clinical implications for psychiatry</article-title>
<source/>
<italic toggle="yes">Current Medicinal Chemistry</italic>
<year>2013</year>
<volume>20</volume>
<issue>3</issue>
<fpage>331</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="doi">10.2174/0929867311320030003</pub-id>
<pub-id pub-id-type="pmid">23157624</pub-id>
</element-citation>
</ref>
<ref id="B114">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Honda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ohsawa</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors</article-title>
<source/>
<italic toggle="yes">The Journal of Neuroscience</italic>
<year>2001</year>
<volume>21</volume>
<issue>6</issue>
<fpage>1975</fpage>
<lpage>1982</lpage>
<pub-id pub-id-type="doi">10.1523/jneurosci.21-06-01975.2001</pub-id>
<pub-id pub-id-type="pmid">11245682</pub-id>
</element-citation>
</ref>
<ref id="B115">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalyanaraman</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Schwappacher</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Joshua</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nongenomic thyroid hormone signaling occurs through a plasma membrane-localized receptor</article-title>
<source/>
<italic toggle="yes">Science Signaling</italic>
<year>2014</year>
<volume>7</volume>
<issue>326</issue>
<fpage>p. ra48</fpage>
<pub-id pub-id-type="doi">10.1126/scisignal.2004911</pub-id>
<pub-id pub-id-type="other">2-s2.0-84901202692</pub-id>
</element-citation>
</ref>
<ref id="B116">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mori</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tomonaga</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kalashnikova</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of 3,3′,5-triiodothyronine on microglial functions</article-title>
<source/>
<italic toggle="yes">Glia</italic>
<year>2015</year>
<volume>63</volume>
<issue>5</issue>
<fpage>906</fpage>
<lpage>920</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22792</pub-id>
<pub-id pub-id-type="other">2-s2.0-84925047900</pub-id>
<pub-id pub-id-type="pmid">25643925</pub-id>
</element-citation>
</ref>
<ref id="B117">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joffe</surname>
<given-names>R. T.</given-names>
</name>
</person-group>
<article-title>Is the thyroid still important in major depression?</article-title>
<source/>
<italic toggle="yes">Journal of Psychiatry and Neuroscience</italic>
<year>2006</year>
<volume>31</volume>
<issue>6</issue>
<fpage>367</fpage>
<lpage>368</lpage>
<pub-id pub-id-type="pmid">17136213</pub-id>
</element-citation>
</ref>
<ref id="B118">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agid</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Lerer</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation</article-title>
<source/>
<italic toggle="yes">The International Journal of Neuropsychopharmacology</italic>
<year>2003</year>
<volume>6</volume>
<issue>1</issue>
<fpage>41</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1017/s146114570200322x</pub-id>
<pub-id pub-id-type="other">2-s2.0-0037345048</pub-id>
<pub-id pub-id-type="pmid">12899735</pub-id>
</element-citation>
</ref>
<ref id="B119">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altshuler</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Gitlin</surname>
<given-names>M. J.</given-names>
</name>
</person-group>
<article-title>Acceleration and augmentation strategies for treating bipolar depression</article-title>
<source/>
<italic toggle="yes">Biological Psychiatry</italic>
<year>2003</year>
<volume>53</volume>
<issue>8</issue>
<fpage>691</fpage>
<lpage>700</lpage>
<pub-id pub-id-type="doi">10.1016/s0006-3223(03)00087-8</pub-id>
<pub-id pub-id-type="other">2-s2.0-0038486202</pub-id>
<pub-id pub-id-type="pmid">12706955</pub-id>
</element-citation>
</ref>
<ref id="B120">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pridmore</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Turnier-Shea</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Medication options in the treatment of treatment-resistant depression</article-title>
<source/>
<italic toggle="yes">Australian and New Zealand Journal of Psychiatry</italic>
<year>2004</year>
<volume>38</volume>
<issue>4</issue>
<fpage>219</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="doi">10.1080/j.1440-1614.2004.01335.x</pub-id>
<pub-id pub-id-type="pmid">15038800</pub-id>
</element-citation>
</ref>
<ref id="B121">
<label>121</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Demartini</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ranieri</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Masu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Selle</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Scarone</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gambini</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Depressive symptoms and major depressive disorder in patients affected by subclinical hypothyroidism</article-title>
<source/>
<italic toggle="yes">The Journal of Nervous and Mental Disease</italic>
<year>2014</year>
<volume>202</volume>
<issue>8</issue>
<fpage>603</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="doi">10.1097/nmd.0000000000000168</pub-id>
<pub-id pub-id-type="other">2-s2.0-84905386496</pub-id>
<pub-id pub-id-type="pmid">25010109</pub-id>
</element-citation>
</ref>
<ref id="B122">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Claes</surname>
<given-names>S. J.</given-names>
</name>
</person-group>
<article-title>CRH, stress, and major depression: a psychobiological interplay</article-title>
<source/>
<italic toggle="yes">Vitamins &amp; Hormones</italic>
<year>2004</year>
<volume>69</volume>
<fpage>117</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="doi">10.1016/s0083-6729(04)69005-4</pub-id>
<pub-id pub-id-type="other">2-s2.0-4143096768</pub-id>
<pub-id pub-id-type="pmid">15196881</pub-id>
</element-citation>
</ref>
<ref id="B123">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holsboer</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Stress, hypercortisolism and corticosteroid receptors in depression: implicatons for therapy</article-title>
<source/>
<italic toggle="yes">Journal of Affective Disorders</italic>
<year>2001</year>
<volume>62</volume>
<issue>1-2</issue>
<fpage>77</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1016/s0165-0327(00)00352-9</pub-id>
<pub-id pub-id-type="other">2-s2.0-0035153486</pub-id>
<pub-id pub-id-type="pmid">11172875</pub-id>
</element-citation>
</ref>
<ref id="B124">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holsboer</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Barden</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Antidepressants and hypothalamic-pituitary-adrenocortical regulation</article-title>
<source/>
<italic toggle="yes">Endocrine Reviews</italic>
<year>1996</year>
<volume>17</volume>
<issue>2</issue>
<fpage>187</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="doi">10.1210/edrv-17-2-187</pub-id>
<pub-id pub-id-type="other">2-s2.0-0029926722</pub-id>
<pub-id pub-id-type="pmid">8706631</pub-id>
</element-citation>
</ref>
<ref id="B125">
<label>125</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Pett</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Viau</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bittencourt</surname>
<given-names>J. C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse</article-title>
<source/>
<italic toggle="yes">The Journal of Comparative Neurology</italic>
<year>2000</year>
<volume>428</volume>
<issue>2</issue>
<fpage>191</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1002/1096-9861(20001211)428:2&lt;191::aid-cne1&gt;3.0.co,2-u</pub-id>
<pub-id pub-id-type="pmid">11064361</pub-id>
</element-citation>
</ref>
<ref id="B126">
<label>126</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression</article-title>
<source/>
<italic toggle="yes">Neuroscience Letters</italic>
<year>2006</year>
<volume>404</volume>
<issue>3</issue>
<fpage>358</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2006.06.016</pub-id>
<pub-id pub-id-type="other">2-s2.0-33746317031</pub-id>
<pub-id pub-id-type="pmid">16815632</pub-id>
</element-citation>
</ref>
<ref id="B127">
<label>127</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Licinio</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pasternak</surname>
<given-names>K. I.</given-names>
</name>
<name>
<surname>Gold</surname>
<given-names>P. W.</given-names>
</name>
</person-group>
<article-title>Localization of corticotropin-releasing hormone (CRH) receptor mRNA in adult rat brain by in situ hybridization histochemistry</article-title>
<source/>
<italic toggle="yes">Endocrinology</italic>
<year>1994</year>
<volume>135</volume>
<issue>5</issue>
<fpage>2275</fpage>
<lpage>2278</lpage>
<pub-id pub-id-type="doi">10.1210/endo.135.5.7956950</pub-id>
<pub-id pub-id-type="other">2-s2.0-0028126588</pub-id>
<pub-id pub-id-type="pmid">7956950</pub-id>
</element-citation>
</ref>
<ref id="B128">
<label>128</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zobel</surname>
<given-names>A. W.</given-names>
</name>
<name>
<surname>Nickel</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Künzel</surname>
<given-names>H. E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated</article-title>
<source/>
<italic toggle="yes">Journal of Psychiatric Research</italic>
<year>2000</year>
<volume>34</volume>
<issue>3</issue>
<fpage>171</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1016/s0022-3956(00)00016-9</pub-id>
<pub-id pub-id-type="other">2-s2.0-0034193881</pub-id>
<pub-id pub-id-type="pmid">10867111</pub-id>
</element-citation>
</ref>
<ref id="B129">
<label>129</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holsboer</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ising</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Central CRH system in depression and anxiety - evidence from clinical studies with CRH1 receptor antagonists</article-title>
<source/>
<italic toggle="yes">European Journal of Pharmacology</italic>
<year>2008</year>
<volume>583</volume>
<issue>2-3</issue>
<fpage>350</fpage>
<lpage>357</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2007.12.032</pub-id>
<pub-id pub-id-type="other">2-s2.0-40849130056</pub-id>
<pub-id pub-id-type="pmid">18272149</pub-id>
</element-citation>
</ref>
<ref id="B130">
<label>130</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Binneman</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Feltner</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kolluri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Stiger</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1Antagonist) in the treatment of major depression</article-title>
<source/>
<italic toggle="yes">American Journal of Psychiatry</italic>
<year>2008</year>
<volume>165</volume>
<issue>5</issue>
<fpage>617</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2008.07071199</pub-id>
<pub-id pub-id-type="other">2-s2.0-43949134527</pub-id>
<pub-id pub-id-type="pmid">18413705</pub-id>
</element-citation>
</ref>
<ref id="B131">
<label>131</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ising</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zimmermann</surname>
<given-names>U. S.</given-names>
</name>
<name>
<surname>Künzel</surname>
<given-names>H. E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response</article-title>
<source/>
<italic toggle="yes">Neuropsychopharmacology</italic>
<year>2007</year>
<volume>32</volume>
<issue>9</issue>
<fpage>1941</fpage>
<lpage>1949</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1301328</pub-id>
<pub-id pub-id-type="other">2-s2.0-34547907098</pub-id>
<pub-id pub-id-type="pmid">17287823</pub-id>
</element-citation>
</ref>
<ref id="B132">
<label>132</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanghvi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mogalian</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Machatha</surname>
<given-names>S. G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor</article-title>
<source/>
<italic toggle="yes">Journal of Pharmaceutical Sciences</italic>
<year>2009</year>
<volume>98</volume>
<issue>1</issue>
<fpage>205</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="doi">10.1002/jps.21421</pub-id>
<pub-id pub-id-type="other">2-s2.0-58149267689</pub-id>
<pub-id pub-id-type="pmid">18428980</pub-id>
</element-citation>
</ref>
<ref id="B133">
<label>133</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solomon</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>J. P.</given-names>
</name>
</person-group>
<article-title>Sex differences in psychopathology: of gonads, adrenals and mental illness</article-title>
<source/>
<italic toggle="yes">Physiology &amp; Behavior</italic>
<year>2009</year>
<volume>97</volume>
<issue>2</issue>
<fpage>250</fpage>
<lpage>258</lpage>
<pub-id pub-id-type="doi">10.1016/j.physbeh.2009.02.033</pub-id>
<pub-id pub-id-type="other">2-s2.0-64549097579</pub-id>
<pub-id pub-id-type="pmid">19275906</pub-id>
</element-citation>
</ref>
<ref id="B134">
<label>134</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parker</surname>
<given-names>G. B.</given-names>
</name>
<name>
<surname>Brotchie</surname>
<given-names>H. L.</given-names>
</name>
</person-group>
<article-title>From diathesis to dimorphism</article-title>
<source/>
<italic toggle="yes">The Journal of Nervous and Mental Disease</italic>
<year>2004</year>
<volume>192</volume>
<issue>3</issue>
<fpage>210</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="doi">10.1097/01.nmd.0000116464.60500.63</pub-id>
<pub-id pub-id-type="other">2-s2.0-1542742188</pub-id>
<pub-id pub-id-type="pmid">15091302</pub-id>
</element-citation>
</ref>
<ref id="B135">
<label>135</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Douma</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Husband</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>OʼDonnell</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Barwin</surname>
<given-names>B. N.</given-names>
</name>
<name>
<surname>Woodend</surname>
<given-names>A. K.</given-names>
</name>
</person-group>
<article-title>Estrogen-related mood disorders</article-title>
<source/>
<italic toggle="yes">Advances in Nursing Science</italic>
<year>2005</year>
<volume>28</volume>
<issue>4</issue>
<fpage>364</fpage>
<lpage>375</lpage>
<pub-id pub-id-type="doi">10.1097/00012272-200510000-00008</pub-id>
<pub-id pub-id-type="other">2-s2.0-28144440497</pub-id>
<pub-id pub-id-type="pmid">16292022</pub-id>
</element-citation>
</ref>
<ref id="B136">
<label>136</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kessler</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Demler</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>R. G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prevalence and treatment of mental disorders, 1990 to 2003</article-title>
<source/>
<italic toggle="yes">New England Journal of Medicine</italic>
<year>2005</year>
<volume>352</volume>
<issue>24</issue>
<fpage>2515</fpage>
<lpage>2523</lpage>
<pub-id pub-id-type="doi">10.1056/nejmsa043266</pub-id>
<pub-id pub-id-type="other">2-s2.0-20444501831</pub-id>
<pub-id pub-id-type="pmid">15958807</pub-id>
</element-citation>
</ref>
<ref id="B137">
<label>137</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bekker</surname>
<given-names>M. H. J.</given-names>
</name>
<name>
<surname>van Mens-Verhulst</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Anxiety disorders: sex differences in prevalence, degree, and background, but gender-neutral treatment</article-title>
<source/>
<italic toggle="yes">Gender Medicine</italic>
<year>2007</year>
<volume>4</volume>
<fpage>S178</fpage>
<lpage>S193</lpage>
<pub-id pub-id-type="doi">10.1016/s1550-8579(07)80057-x</pub-id>
<pub-id pub-id-type="other">2-s2.0-37349079946</pub-id>
<pub-id pub-id-type="pmid">18156102</pub-id>
</element-citation>
</ref>
<ref id="B138">
<label>138</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Österlund</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kuiper</surname>
<given-names>G.J.M.</given-names>
</name>
<name>
<surname>Gustafsson</surname>
<given-names>J.-Å.</given-names>
</name>
<name>
<surname>Hurd</surname>
<given-names>Y. L.</given-names>
</name>
</person-group>
<article-title>Differential distribution and regulation of estrogen receptor-<italic>α</italic> and -<italic>β</italic> mRNA within the female rat brain</article-title>
<source/>
<italic toggle="yes">Molecular Brain Research</italic>
<year>1998</year>
<volume>54</volume>
<issue>1</issue>
<fpage>175</fpage>
<lpage>180</lpage>
<pub-id pub-id-type="doi">10.1016/s0169-328x(97)00351-3</pub-id>
<pub-id pub-id-type="other">2-s2.0-0031910162</pub-id>
<pub-id pub-id-type="pmid">9526077</pub-id>
</element-citation>
</ref>
<ref id="B139">
<label>139</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grigoriadis</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>S. H.</given-names>
</name>
</person-group>
<article-title>Role of estrogen in the treatment of depression</article-title>
<source/>
<italic toggle="yes">American Journal of Therapeutics</italic>
<year>2002</year>
<volume>9</volume>
<issue>6</issue>
<fpage>503</fpage>
<lpage>509</lpage>
<pub-id pub-id-type="doi">10.1097/00045391-200211000-00008</pub-id>
<pub-id pub-id-type="other">2-s2.0-0036835137</pub-id>
<pub-id pub-id-type="pmid">12424508</pub-id>
</element-citation>
</ref>
<ref id="B140">
<label>140</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Nieman</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Danaceau</surname>
<given-names>M. A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Estrogen replacement in perimenopause-related depression: a preliminary report</article-title>
<source/>
<italic toggle="yes">American Journal of Obstetrics and Gynecology</italic>
<year>2000</year>
<volume>183</volume>
<issue>2</issue>
<fpage>414</fpage>
<lpage>420</lpage>
<pub-id pub-id-type="doi">10.1067/mob.2000.106004</pub-id>
<pub-id pub-id-type="other">2-s2.0-0033836444</pub-id>
<pub-id pub-id-type="pmid">10942479</pub-id>
</element-citation>
</ref>
<ref id="B141">
<label>141</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klaiber</surname>
<given-names>E. L.</given-names>
</name>
<name>
<surname>Broverman</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Estrogen therapy for severe persistent depressions in women</article-title>
<source/>
<italic toggle="yes">Archives of general psychiatry</italic>
<year>1979</year>
<volume>36</volume>
<issue>5</issue>
<fpage>550</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.1979.01780050060006</pub-id>
<pub-id pub-id-type="other">2-s2.0-0018388568</pub-id>
<pub-id pub-id-type="pmid">219802</pub-id>
</element-citation>
</ref>
<ref id="B142">
<label>142</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gleason</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Dowling</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Wharton</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study</article-title>
<source/>
<italic toggle="yes">PLoS Medicine</italic>
<year>2015</year>
<volume>12</volume>
<issue>6</issue>
<pub-id pub-id-type="publisher-id">e1001833</pub-id>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1001833</pub-id>
<pub-id pub-id-type="other">2-s2.0-84937797319</pub-id>
</element-citation>
</ref>
<ref id="B143">
<label>143</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whedon</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>KizhakkeVeettil</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rugo</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Kieffer</surname>
<given-names>K. A.</given-names>
</name>
</person-group>
<article-title>Bioidentical estrogen for menopausal depressive symptoms: a systematic review and meta-analysis</article-title>
<source/>
<italic toggle="yes">Journal of Women’s Health</italic>
<year>2017</year>
<volume>26</volume>
<issue>1</issue>
<fpage>18</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1089/jwh.2015.5628</pub-id>
<pub-id pub-id-type="other">2-s2.0-85009892627</pub-id>
</element-citation>
</ref>
<ref id="B144">
<label>144</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Hormone-related factors and post-menopausal onset depression: results from KNHANES (2010-2012)</article-title>
<source/>
<italic toggle="yes">Journal of Affective Disorders</italic>
<year>2015</year>
<volume>175</volume>
<fpage>176</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2014.12.061</pub-id>
<pub-id pub-id-type="other">2-s2.0-84921762196</pub-id>
<pub-id pub-id-type="pmid">25622021</pub-id>
</element-citation>
</ref>
<ref id="B145">
<label>145</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brummelte</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Galea</surname>
<given-names>L. A. M.</given-names>
</name>
</person-group>
<article-title>Postpartum depression: etiology, treatment and consequences for maternal care</article-title>
<source/>
<italic toggle="yes">Hormones and Behavior</italic>
<year>2016</year>
<volume>77</volume>
<fpage>153</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="doi">10.1016/j.yhbeh.2015.08.008</pub-id>
<pub-id pub-id-type="other">2-s2.0-84956579737</pub-id>
<pub-id pub-id-type="pmid">26319224</pub-id>
</element-citation>
</ref>
<ref id="B146">
<label>146</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andréen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nyberg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Turkmen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>van Wingen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fernández</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bäckström</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators</article-title>
<source/>
<italic toggle="yes">Psychoneuroendocrinology</italic>
<year>2009</year>
<volume>34</volume>
<issue>8</issue>
<fpage>1121</fpage>
<lpage>1132</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2009.02.003</pub-id>
<pub-id pub-id-type="other">2-s2.0-67650585823</pub-id>
<pub-id pub-id-type="pmid">19272715</pub-id>
</element-citation>
</ref>
<ref id="B147">
<label>147</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahokas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kaukoranta</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wahlbeck</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Aito</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta- estradiol: a preliminary study</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Psychiatry</italic>
<year>2001</year>
<volume>62</volume>
<issue>5</issue>
<fpage>332</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="doi">10.4088/jcp.v62n0504</pub-id>
<pub-id pub-id-type="other">2-s2.0-0034971361</pub-id>
<pub-id pub-id-type="pmid">11411813</pub-id>
</element-citation>
</ref>
<ref id="B148">
<label>148</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wisner</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Sit</surname>
<given-names>D. K. Y.</given-names>
</name>
<name>
<surname>Moses-Kolko</surname>
<given-names>E. L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Transdermal estradiol treatment for postpartum depression: a pilot, randomized trial</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Psychopharmacology</italic>
<year>2015</year>
<volume>35</volume>
<issue>4</issue>
<fpage>389</fpage>
<lpage>395</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0000000000000351</pub-id>
<pub-id pub-id-type="other">2-s2.0-84936935483</pub-id>
<pub-id pub-id-type="pmid">26061609</pub-id>
</element-citation>
</ref>
<ref id="B149">
<label>149</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanes</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Colquhoun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gunduz-Bruce</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial</article-title>
<source/>
<italic toggle="yes">The Lancet</italic>
<year>2017</year>
<volume>390</volume>
<issue>10093</issue>
<fpage>480</fpage>
<lpage>489</lpage>
<pub-id pub-id-type="doi">10.1016/s0140-6736(17)31264-3</pub-id>
<pub-id pub-id-type="other">2-s2.0-85020628247</pub-id>
</element-citation>
</ref>
<ref id="B150">
<label>150</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baulieu</surname>
<given-names>E. E.</given-names>
</name>
<name>
<surname>Robel</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Neurosteroids: a new brain function?</article-title>
<source/>
<italic toggle="yes">The Journal of Steroid Biochemistry and Molecular Biology</italic>
<year>1990</year>
<volume>37</volume>
<issue>3</issue>
<fpage>395</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="doi">10.1016/0960-0760(90)90490-c</pub-id>
<pub-id pub-id-type="other">2-s2.0-0025645557</pub-id>
<pub-id pub-id-type="pmid">2257243</pub-id>
</element-citation>
</ref>
<ref id="B151">
<label>151</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melcangi</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Garcia-Segura</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Mensah-Nyagan</surname>
<given-names>A. G.</given-names>
</name>
</person-group>
<article-title>Neuroactive steroids: state of the art and new perspectives</article-title>
<source/>
<italic toggle="yes">Cellular and Molecular Life Sciences</italic>
<year>2008</year>
<volume>65</volume>
<issue>5</issue>
<fpage>777</fpage>
<lpage>797</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-007-7403-5</pub-id>
<pub-id pub-id-type="other">2-s2.0-40449088635</pub-id>
<pub-id pub-id-type="pmid">18038216</pub-id>
</element-citation>
</ref>
<ref id="B152">
<label>152</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rupprecht</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties</article-title>
<source/>
<italic toggle="yes">Psychoneuroendocrinology</italic>
<year>2003</year>
<volume>28</volume>
<issue>2</issue>
<fpage>139</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.1016/s0306-4530(02)00064-1</pub-id>
<pub-id pub-id-type="other">2-s2.0-0037293399</pub-id>
<pub-id pub-id-type="pmid">12510009</pub-id>
</element-citation>
</ref>
<ref id="B153">
<label>153</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubrovsky</surname>
<given-names>B. O.</given-names>
</name>
</person-group>
<article-title>Steroids, neuroactive steroids and neurosteroids in psychopathology</article-title>
<source/>
<italic toggle="yes">Progress in Neuro-Psychopharmacology and Biological Psychiatry</italic>
<year>2005</year>
<volume>29</volume>
<issue>2</issue>
<fpage>169</fpage>
<lpage>192</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2004.11.001</pub-id>
<pub-id pub-id-type="other">2-s2.0-13444257817</pub-id>
<pub-id pub-id-type="pmid">15694225</pub-id>
</element-citation>
</ref>
<ref id="B154">
<label>154</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eser</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schüle</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Baghai</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Romeo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Uzunov</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Rupprecht</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Neuroactive steroids and affective disorders</article-title>
<source/>
<italic toggle="yes">Pharmacology Biochemistry and Behavior</italic>
<year>2006</year>
<volume>84</volume>
<issue>4</issue>
<fpage>656</fpage>
<lpage>666</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2006.05.020</pub-id>
<pub-id pub-id-type="other">2-s2.0-33947324811</pub-id>
</element-citation>
</ref>
<ref id="B155">
<label>155</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McHenry</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Carrier</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hull</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kabbaj</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Sex differences in anxiety and depression: role of testosterone</article-title>
<source/>
<italic toggle="yes">Frontiers in Neuroendocrinology</italic>
<year>2014</year>
<volume>35</volume>
<issue>1</issue>
<fpage>42</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1016/j.yfrne.2013.09.001</pub-id>
<pub-id pub-id-type="other">2-s2.0-84892883817</pub-id>
<pub-id pub-id-type="pmid">24076484</pub-id>
</element-citation>
</ref>
<ref id="B156">
<label>156</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ford</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Yeap</surname>
<given-names>B. B.</given-names>
</name>
<name>
<surname>Flicker</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prospective longitudinal study of testosterone and incident depression in older men: the health in men study</article-title>
<source/>
<italic toggle="yes">Psychoneuroendocrinology</italic>
<year>2016</year>
<volume>64</volume>
<fpage>57</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2015.11.012</pub-id>
<pub-id pub-id-type="other">2-s2.0-84951737837</pub-id>
<pub-id pub-id-type="pmid">26615472</pub-id>
</element-citation>
</ref>
<ref id="B157">
<label>157</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DiBlasio</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Hammett</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Malcolm</surname>
<given-names>J. B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer</article-title>
<source/>
<italic toggle="yes">The Canadian Journal of Urology</italic>
<year>2008</year>
<volume>15</volume>
<issue>5</issue>
<fpage>4249</fpage>
<lpage>4256</lpage>
<pub-id pub-id-type="pmid">18814813</pub-id>
</element-citation>
</ref>
<ref id="B158">
<label>158</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pope</surname>
<given-names>H. G.</given-names>
</name>
<name>
<surname>Amiaz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Brennan</surname>
<given-names>B. P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Psychopharmacology</italic>
<year>2010</year>
<volume>30</volume>
<issue>2</issue>
<fpage>126</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1097/jcp.0b013e3181d207ca</pub-id>
<pub-id pub-id-type="other">2-s2.0-77952213725</pub-id>
<pub-id pub-id-type="pmid">20520285</pub-id>
</element-citation>
</ref>
<ref id="B159">
<label>159</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Perlis</surname>
<given-names>R. H.</given-names>
</name>
<name>
<surname>Papakostas</surname>
<given-names>G. I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Low-dose transdermal testosterone augmentation therapy improves depression severity in women</article-title>
<source/>
<italic toggle="yes">CNS Spectrums</italic>
<year>2009</year>
<volume>14</volume>
<issue>12</issue>
<fpage>688</fpage>
<lpage>694</lpage>
<pub-id pub-id-type="doi">10.1017/s1092852900023944</pub-id>
<pub-id pub-id-type="other">2-s2.0-77749264383</pub-id>
<pub-id pub-id-type="pmid">20394176</pub-id>
</element-citation>
</ref>
<ref id="B160">
<label>160</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durdiakova</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ostatnikova</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Celec</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Testosterone and its metabolites–modulators of brain functions</article-title>
<source/>
<italic toggle="yes">Acta Neurobiologiae Experimentalis</italic>
<year>2011</year>
<volume>71</volume>
<issue>4</issue>
<fpage>434</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="pmid">22237492</pub-id>
</element-citation>
</ref>
<ref id="B161">
<label>161</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rohr</surname>
<given-names>U. D.</given-names>
</name>
</person-group>
<article-title>The impact of testosterone imbalance on depression and women’s health</article-title>
<source/>
<italic toggle="yes">Maturitas</italic>
<year>2002</year>
<volume>41</volume>
<issue>1</issue>
<fpage>25</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1016/s0378-5122(02)00013-0</pub-id>
</element-citation>
</ref>
<ref id="B162">
<label>162</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Locci</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pinna</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Neurosteroid biosynthesis down-regulation and changes in GABA A receptor subunit composition: a biomarker axis in stress-induced cognitive and emotional impairment: neurosteroids and GABA: biomarkers for emotions</article-title>
<source/>
<italic toggle="yes">British Journal of Pharmacology</italic>
<year>2017</year>
<volume>174</volume>
<issue>19</issue>
<fpage>3226</fpage>
<lpage>3241</lpage>
<pub-id pub-id-type="doi">10.1111/bph.13843</pub-id>
<pub-id pub-id-type="other">2-s2.0-85020717989</pub-id>
<pub-id pub-id-type="pmid">28456011</pub-id>
</element-citation>
</ref>
<ref id="B163">
<label>163</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bäckström</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bixo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Johansson</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Allopregnanolone and mood disorders</article-title>
<source/>
<italic toggle="yes">Progress in Neurobiology</italic>
<year>2014</year>
<volume>113</volume>
<fpage>88</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/j.pneurobio.2013.07.005</pub-id>
<pub-id pub-id-type="other">2-s2.0-84892847479</pub-id>
<pub-id pub-id-type="pmid">23978486</pub-id>
</element-citation>
</ref>
<ref id="B164">
<label>164</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Gibbs</surname>
<given-names>T. T.</given-names>
</name>
<name>
<surname>Farb</surname>
<given-names>D. H.</given-names>
</name>
</person-group>
<article-title>Pregnenolone sulfate as a modulator of synaptic plasticity</article-title>
<source/>
<italic toggle="yes">Psychopharmacology</italic>
<year>2014</year>
<volume>231</volume>
<issue>17</issue>
<fpage>3537</fpage>
<lpage>3556</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-014-3643-x</pub-id>
<pub-id pub-id-type="other">2-s2.0-84930278760</pub-id>
<pub-id pub-id-type="pmid">24997854</pub-id>
</element-citation>
</ref>
<ref id="B165">
<label>165</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schumacher</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mattern</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ghoumari</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors</article-title>
<source/>
<italic toggle="yes">Progress in Neurobiology</italic>
<year>2014</year>
<volume>113</volume>
<fpage>6</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1016/j.pneurobio.2013.09.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-84892874222</pub-id>
<pub-id pub-id-type="pmid">24172649</pub-id>
</element-citation>
</ref>
<ref id="B166">
<label>166</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schiller</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Rubinow</surname>
<given-names>D. R.</given-names>
</name>
</person-group>
<article-title>Allopregnanolone as a mediator of affective switching in reproductive mood disorders</article-title>
<source/>
<italic toggle="yes">Psychopharmacology</italic>
<year>2014</year>
<volume>231</volume>
<issue>17</issue>
<fpage>3557</fpage>
<lpage>3567</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-014-3599-x</pub-id>
<pub-id pub-id-type="other">2-s2.0-84925215654</pub-id>
<pub-id pub-id-type="pmid">24846476</pub-id>
</element-citation>
</ref>
<ref id="B167">
<label>167</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schüle</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nothdurfter</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rupprecht</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>The role of allopregnanolone in depression and anxiety</article-title>
<source/>
<italic toggle="yes">Progress in Neurobiology</italic>
<year>2014</year>
<volume>113</volume>
<fpage>79</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1016/j.pneurobio.2013.09.003</pub-id>
<pub-id pub-id-type="other">2-s2.0-84892892196</pub-id>
<pub-id pub-id-type="pmid">24215796</pub-id>
</element-citation>
</ref>
<ref id="B168">
<label>168</label>
<element-citation publication-type="book">
<collab>National Library of Medicine</collab>
<source/>
<italic toggle="yes">A Study to Evaluate SAGE-217 in Subjects with Moderate to Severe Major Depressive Disorder</italic>
<year>2018</year>
<publisher-loc>Bethesda, MD, USA</publisher-loc>
<publisher-name>ClinicalTrials.gov NCT03000530, National Library of Medicine</publisher-name>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT03000530">http://clinicaltrials.gov/show/NCT03000530</ext-link>
</comment>
</element-citation>
</ref>
<ref id="B169">
<label>169</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kische</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wallaschofski</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>He</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Associations of androgens with depressive symptoms and cognitive status in the general population</article-title>
<source/>
<italic toggle="yes">PLoS One</italic>
<year>2017</year>
<volume>12</volume>
<issue>5</issue>
<pub-id pub-id-type="publisher-id">e0177272</pub-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0177272</pub-id>
<pub-id pub-id-type="other">2-s2.0-85019488084</pub-id>
</element-citation>
</ref>
<ref id="B170">
<label>170</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weber</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lewicka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Deuschle</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Colla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Heuser</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression</article-title>
<source/>
<italic toggle="yes">Psychoneuroendocrinology</italic>
<year>2000</year>
<volume>25</volume>
<issue>8</issue>
<fpage>765</fpage>
<lpage>771</lpage>
<pub-id pub-id-type="doi">10.1016/s0306-4530(00)00023-8</pub-id>
<pub-id pub-id-type="other">2-s2.0-0033849415</pub-id>
<pub-id pub-id-type="pmid">10996472</pub-id>
</element-citation>
</ref>
<ref id="B171">
<label>171</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Insel</surname>
<given-names>T. R.</given-names>
</name>
</person-group>
<article-title>The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior</article-title>
<source/>
<italic toggle="yes">Neuron</italic>
<year>2010</year>
<volume>65</volume>
<issue>6</issue>
<fpage>768</fpage>
<lpage>779</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2010.03.005</pub-id>
<pub-id pub-id-type="other">2-s2.0-77950222543</pub-id>
<pub-id pub-id-type="pmid">20346754</pub-id>
</element-citation>
</ref>
<ref id="B172">
<label>172</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neumann</surname>
<given-names>I. D.</given-names>
</name>
<name>
<surname>Landgraf</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors</article-title>
<source/>
<italic toggle="yes">Trends in Neurosciences</italic>
<year>2012</year>
<volume>35</volume>
<issue>11</issue>
<fpage>649</fpage>
<lpage>659</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2012.08.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-84867916378</pub-id>
<pub-id pub-id-type="pmid">22974560</pub-id>
</element-citation>
</ref>
<ref id="B173">
<label>173</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barraza</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Zak</surname>
<given-names>P. J.</given-names>
</name>
</person-group>
<article-title>Empathy toward strangers triggers oxytocin release and subsequent generosity</article-title>
<source/>
<italic toggle="yes">Annals of the New York Academy of Sciences</italic>
<year>2009</year>
<volume>1167</volume>
<issue>1</issue>
<fpage>182</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.04504.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-67649635332</pub-id>
<pub-id pub-id-type="pmid">19580564</pub-id>
</element-citation>
</ref>
<ref id="B174">
<label>174</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morhenn</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Piper</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zak</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Monetary sacrifice among strangers is mediated by endogenous oxytocin release after physical contact</article-title>
<source/>
<italic toggle="yes">Evolution and Human Behavior</italic>
<year>2008</year>
<volume>29</volume>
<issue>6</issue>
<fpage>375</fpage>
<lpage>383</lpage>
<pub-id pub-id-type="doi">10.1016/j.evolhumbehav.2008.04.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-53749104083</pub-id>
</element-citation>
</ref>
<ref id="B175">
<label>175</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leuner</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Caponiti</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Gould</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Oxytocin stimulates adult neurogenesis even under conditions of stress and elevated glucocorticoids</article-title>
<source/>
<italic toggle="yes">Hippocampus</italic>
<year>2012</year>
<volume>22</volume>
<issue>4</issue>
<fpage>861</fpage>
<lpage>868</lpage>
<pub-id pub-id-type="doi">10.1002/hipo.20947</pub-id>
<pub-id pub-id-type="other">2-s2.0-84858753434</pub-id>
<pub-id pub-id-type="pmid">21692136</pub-id>
</element-citation>
</ref>
<ref id="B176">
<label>176</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuen</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Garner</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>D. S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol</article-title>
<source/>
<italic toggle="yes">Journal of Psychiatric Research</italic>
<year>2014</year>
<volume>51</volume>
<fpage>30</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2013.12.012</pub-id>
<pub-id pub-id-type="other">2-s2.0-84893969667</pub-id>
<pub-id pub-id-type="pmid">24405552</pub-id>
</element-citation>
</ref>
<ref id="B177">
<label>177</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McQuaid</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>McInnis</surname>
<given-names>O. A.</given-names>
</name>
<name>
<surname>Abizaid</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Anisman</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Making room for oxytocin in understanding depression</article-title>
<source/>
<italic toggle="yes">Neuroscience &amp; Biobehavioral Reviews</italic>
<year>2014</year>
<volume>45</volume>
<fpage>305</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.07.005</pub-id>
<pub-id pub-id-type="other">2-s2.0-84904755371</pub-id>
<pub-id pub-id-type="pmid">25025656</pub-id>
</element-citation>
</ref>
<ref id="B178">
<label>178</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meynen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Unmehopa</surname>
<given-names>U. A.</given-names>
</name>
<name>
<surname>Hofman</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Swaab</surname>
<given-names>D. F.</given-names>
</name>
<name>
<surname>Hoogendijk</surname>
<given-names>W. J. G.</given-names>
</name>
</person-group>
<article-title>Hypothalamic oxytocin mRNA expression and melancholic depression</article-title>
<source/>
<italic toggle="yes">Molecular Psychiatry</italic>
<year>2007</year>
<volume>12</volume>
<issue>2</issue>
<fpage>118</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001911</pub-id>
<pub-id pub-id-type="other">2-s2.0-33846474431</pub-id>
<pub-id pub-id-type="pmid">17252002</pub-id>
</element-citation>
</ref>
<ref id="B179">
<label>179</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melis</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Melis</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cocco</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxytocin injected into the ventral tegmental area induces penile erection and increases extracellular dopamine in the nucleus accumbens and paraventricular nucleus of the hypothalamus of male rats: ventral tegmental area, oxytocin and penile erection</article-title>
<source/>
<italic toggle="yes">European Journal of Neuroscience</italic>
<year>2007</year>
<volume>26</volume>
<issue>4</issue>
<fpage>1026</fpage>
<lpage>1035</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2007.05721.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-34547988176</pub-id>
<pub-id pub-id-type="pmid">17672853</pub-id>
</element-citation>
</ref>
<ref id="B180">
<label>180</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantor</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Binik</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Pfaus</surname>
<given-names>J. G.</given-names>
</name>
</person-group>
<article-title>Chronic fluoxetine inhibits sexual behavior in the male rat: reversal with oxytocin</article-title>
<source/>
<italic toggle="yes">Psychopharmacology</italic>
<year>1999</year>
<volume>144</volume>
<issue>4</issue>
<fpage>355</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="doi">10.1007/s002130051018</pub-id>
<pub-id pub-id-type="other">2-s2.0-0033057907</pub-id>
<pub-id pub-id-type="pmid">10435408</pub-id>
</element-citation>
</ref>
<ref id="B181">
<label>181</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lancel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Krömer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>I. D.</given-names>
</name>
</person-group>
<article-title>Intracerebral oxytocin modulates sleep-wake behaviour in male rats</article-title>
<source/>
<italic toggle="yes">Regulatory Peptides</italic>
<year>2003</year>
<volume>114</volume>
<issue>2–3</issue>
<fpage>145</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="doi">10.1016/s0167-0115(03)00118-6</pub-id>
<pub-id pub-id-type="other">2-s2.0-0038121751</pub-id>
<pub-id pub-id-type="pmid">12832103</pub-id>
</element-citation>
</ref>
<ref id="B182">
<label>182</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Broussard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vacy</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Broadbear</surname>
<given-names>J. H.</given-names>
</name>
</person-group>
<article-title>Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat</article-title>
<source/>
<italic toggle="yes">Journal of Psychopharmacology</italic>
<year>2012</year>
<volume>26</volume>
<issue>4</issue>
<fpage>532</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="doi">10.1177/0269881111416687</pub-id>
<pub-id pub-id-type="other">2-s2.0-84860188488</pub-id>
<pub-id pub-id-type="pmid">21890582</pub-id>
</element-citation>
</ref>
<ref id="B183">
<label>183</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birnbaumer</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Vasopressin receptors</article-title>
<source/>
<italic toggle="yes">Trends in Endocrinology &amp; Metabolism</italic>
<year>2000</year>
<volume>11</volume>
<issue>10</issue>
<fpage>406</fpage>
<lpage>410</lpage>
<pub-id pub-id-type="doi">10.1016/s1043-2760(00)00304-0</pub-id>
<pub-id pub-id-type="other">2-s2.0-0033664793</pub-id>
<pub-id pub-id-type="pmid">11091117</pub-id>
</element-citation>
</ref>
<ref id="B184">
<label>184</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roper</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>O’Carroll</surname>
<given-names>A.-M.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lolait</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The vasopressin Avpr1b receptor: molecular and pharmacological studies</article-title>
<source/>
<italic toggle="yes">Stress</italic>
<year>2011</year>
<volume>14</volume>
<issue>1</issue>
<fpage>98</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="doi">10.3109/10253890.2010.512376</pub-id>
<pub-id pub-id-type="other">2-s2.0-78650384767</pub-id>
<pub-id pub-id-type="pmid">20828336</pub-id>
</element-citation>
</ref>
<ref id="B185">
<label>185</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jard</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barberis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Audigier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tribollet</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Neurohypophyseal hormone receptor systems in brain and periphery</article-title>
<source/>
<italic toggle="yes">Progress in Brain Research</italic>
<year>1987</year>
<volume>72</volume>
<fpage>173</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="doi">10.1016/s0079-6123(08)60206-x</pub-id>
<pub-id pub-id-type="other">2-s2.0-0023476138</pub-id>
<pub-id pub-id-type="pmid">3039574</pub-id>
</element-citation>
</ref>
<ref id="B186">
<label>186</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thibonnier</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Coles</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Thibonnier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shoham</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists</article-title>
<source/>
<italic toggle="yes">Annual Review of Pharmacology and Toxicology</italic>
<year>2001</year>
<volume>41</volume>
<issue>1</issue>
<fpage>175</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.pharmtox.41.1.175</pub-id>
<pub-id pub-id-type="other">2-s2.0-0035029158</pub-id>
</element-citation>
</ref>
<ref id="B187">
<label>187</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>N. G.</given-names>
</name>
<name>
<surname>Guillon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fabio</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Vasopressin antagonists as anxiolytics and antidepressants: recent developments</article-title>
<source/>
<italic toggle="yes">Recent Patents on CNS Drug Discovery</italic>
<year>2008</year>
<volume>3</volume>
<issue>2</issue>
<fpage>77</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.2174/157488908784534586</pub-id>
<pub-id pub-id-type="other">2-s2.0-49149103265</pub-id>
<pub-id pub-id-type="pmid">18537767</pub-id>
</element-citation>
</ref>
<ref id="B188">
<label>188</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griebel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Holsboer</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?</article-title>
<source/>
<italic toggle="yes">Nature Reviews Drug Discovery</italic>
<year>2012</year>
<volume>11</volume>
<issue>6</issue>
<fpage>462</fpage>
<lpage>478</lpage>
<pub-id pub-id-type="doi">10.1038/nrd3702</pub-id>
<pub-id pub-id-type="other">2-s2.0-84861850317</pub-id>
<pub-id pub-id-type="pmid">22596253</pub-id>
</element-citation>
</ref>
<ref id="B189">
<label>189</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landgraf</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Keßler</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Bunck</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I</article-title>
<source/>
<italic toggle="yes">Neuroscience &amp; Biobehavioral Reviews</italic>
<year>2007</year>
<volume>31</volume>
<issue>1</issue>
<fpage>89</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2006.07.003</pub-id>
<pub-id pub-id-type="other">2-s2.0-33845333408</pub-id>
<pub-id pub-id-type="pmid">16934871</pub-id>
</element-citation>
</ref>
<ref id="B190">
<label>190</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Locke</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tracy</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Hypothalamic- pituitary- adrenal axis and depression symptom effects on an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial</article-title>
<source/>
<italic toggle="yes">Brain and Behavior</italic>
<year>2017</year>
<volume>7</volume>
<issue>3</issue>
<pub-id pub-id-type="publisher-id">e00628</pub-id>
<pub-id pub-id-type="doi">10.1002/brb3.628</pub-id>
<pub-id pub-id-type="other">2-s2.0-85012101625</pub-id>
</element-citation>
</ref>
<ref id="B191">
<label>191</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kramer</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Cutler</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Feighner</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Distinct mechanism for antidepressant activity by blockade of central substance P receptors</article-title>
<source/>
<italic toggle="yes">Science</italic>
<year>1998</year>
<volume>281</volume>
<issue>5383</issue>
<fpage>1640</fpage>
<lpage>1645</lpage>
<pub-id pub-id-type="doi">10.1126/science.281.5383.1640</pub-id>
<pub-id pub-id-type="other">2-s2.0-0032508514</pub-id>
<pub-id pub-id-type="pmid">9733503</pub-id>
</element-citation>
</ref>
<ref id="B192">
<label>192</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keller</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ball</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder</article-title>
<source/>
<italic toggle="yes">Biological Psychiatry</italic>
<year>2006</year>
<volume>59</volume>
<issue>3</issue>
<fpage>216</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2005.07.013</pub-id>
<pub-id pub-id-type="other">2-s2.0-32144442187</pub-id>
<pub-id pub-id-type="pmid">16248986</pub-id>
</element-citation>
</ref>
<ref id="B193">
<label>193</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ratti</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bettica</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies</article-title>
<source/>
<italic toggle="yes">Journal of Psychopharmacology</italic>
<year>2013</year>
<volume>27</volume>
<issue>5</issue>
<fpage>424</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="doi">10.1177/0269881113480990</pub-id>
<pub-id pub-id-type="other">2-s2.0-84876584503</pub-id>
<pub-id pub-id-type="pmid">23539641</pub-id>
</element-citation>
</ref>
<ref id="B194">
<label>194</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ionescu</surname>
<given-names>D. F.</given-names>
</name>
<name>
<surname>Papakostas</surname>
<given-names>G. I.</given-names>
</name>
</person-group>
<article-title>Experimental medication treatment approaches for depression</article-title>
<source/>
<italic toggle="yes">Translational Psychiatry</italic>
<year>2017</year>
<volume>7</volume>
<issue>3</issue>
<fpage>p. e1068</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2017.33</pub-id>
<pub-id pub-id-type="other">2-s2.0-85037596689</pub-id>
</element-citation>
</ref>
<ref id="B195">
<label>195</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ratti</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bellew</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bettica</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Psychopharmacology</italic>
<year>2011</year>
<volume>31</volume>
<issue>6</issue>
<fpage>727</fpage>
<lpage>733</lpage>
<pub-id pub-id-type="doi">10.1097/jcp.0b013e31823608ca</pub-id>
<pub-id pub-id-type="other">2-s2.0-80755175887</pub-id>
<pub-id pub-id-type="pmid">22020354</pub-id>
</element-citation>
</ref>
<ref id="B196">
<label>196</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reichmann</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Holzer</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Neuropeptide Y: a stressful review</article-title>
<source/>
<italic toggle="yes">Neuropeptides</italic>
<year>2016</year>
<volume>55</volume>
<fpage>99</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1016/j.npep.2015.09.008</pub-id>
<pub-id pub-id-type="other">2-s2.0-84957839481</pub-id>
<pub-id pub-id-type="pmid">26441327</pub-id>
</element-citation>
</ref>
<ref id="B197">
<label>197</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enman</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Sabban</surname>
<given-names>E. L.</given-names>
</name>
<name>
<surname>McGonigle</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Van Bockstaele</surname>
<given-names>E. J.</given-names>
</name>
</person-group>
<article-title>Targeting the neuropeptide Y system in stress-related psychiatric disorders</article-title>
<source/>
<italic toggle="yes">Neurobiology of Stress</italic>
<year>2015</year>
<volume>1</volume>
<fpage>33</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1016/j.ynstr.2014.09.007</pub-id>
<pub-id pub-id-type="other">2-s2.0-84921903040</pub-id>
<pub-id pub-id-type="pmid">25506604</pub-id>
</element-citation>
</ref>
<ref id="B198">
<label>198</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Redrobe</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Dumont</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Quirion</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Neuropeptide Y (NPY) and depression: from animal studies to the human condition</article-title>
<source/>
<italic toggle="yes">Life Sciences</italic>
<year>2002</year>
<volume>71</volume>
<issue>25</issue>
<fpage>2921</fpage>
<lpage>2937</lpage>
<pub-id pub-id-type="doi">10.1016/s0024-3205(02)02159-8</pub-id>
<pub-id pub-id-type="other">2-s2.0-0037044697</pub-id>
<pub-id pub-id-type="pmid">12384178</pub-id>
</element-citation>
</ref>
<ref id="B199">
<label>199</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Plasma neuropeptide Y in patients with major depressive disorder</article-title>
<source/>
<italic toggle="yes">Neuroscience Letters</italic>
<year>1996</year>
<volume>216</volume>
<issue>1</issue>
<fpage>57</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1016/0304-3940(96)13008-1</pub-id>
<pub-id pub-id-type="other">2-s2.0-0030595309</pub-id>
<pub-id pub-id-type="pmid">8892391</pub-id>
</element-citation>
</ref>
<ref id="B200">
<label>200</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heilig</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism</article-title>
<source/>
<italic toggle="yes">J. Psychiatr. Res.</italic>
<year>2004</year>
<volume>38</volume>
<issue>2</issue>
<fpage>113</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="doi">10.1016/s0022-3956(03)00101-8</pub-id>
<pub-id pub-id-type="other">2-s2.0-9144240389</pub-id>
<pub-id pub-id-type="pmid">14757324</pub-id>
</element-citation>
</ref>
<ref id="B201">
<label>201</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozsoy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Olguner Eker</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Abdulrezzak</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>The effects of antidepressants on neuropeptide Y in patients with depression and anxiety</article-title>
<source/>
<italic toggle="yes">Pharmacopsychiatry</italic>
<year>2016</year>
<volume>49</volume>
<issue>1</issue>
<fpage>26</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1055/s-0035-1565241</pub-id>
<pub-id pub-id-type="other">2-s2.0-84955453043</pub-id>
<pub-id pub-id-type="pmid">26789271</pub-id>
</element-citation>
</ref>
<ref id="B202">
<label>202</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Redrobe</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY- induced antidepressant-like activity in the mouse forced swimming test</article-title>
<source/>
<italic toggle="yes">Neuropsychopharmacology</italic>
<year>2002</year>
<volume>26</volume>
<issue>5</issue>
<fpage>615</fpage>
<lpage>624</lpage>
<pub-id pub-id-type="doi">10.1016/s0893-133x(01)00403-1</pub-id>
<pub-id pub-id-type="other">2-s2.0-0036196933</pub-id>
<pub-id pub-id-type="pmid">11927186</pub-id>
</element-citation>
</ref>
<ref id="B203">
<label>203</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Redrobe</surname>
<given-names>J. P.</given-names>
</name>
</person-group>
<article-title>Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test</article-title>
<source/>
<italic toggle="yes">Peptides</italic>
<year>2005</year>
<volume>26</volume>
<issue>8</issue>
<fpage>1394</fpage>
<lpage>1400</lpage>
<pub-id pub-id-type="doi">10.1016/j.peptides.2005.03.029</pub-id>
<pub-id pub-id-type="other">2-s2.0-22544481724</pub-id>
<pub-id pub-id-type="pmid">16042979</pub-id>
</element-citation>
</ref>
<ref id="B204">
<label>204</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stogner</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>P. V.</given-names>
</name>
</person-group>
<article-title>Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats</article-title>
<source/>
<italic toggle="yes">European Journal of Pharmacology</italic>
<year>2000</year>
<volume>387</volume>
<issue>2</issue>
<fpage>R9</fpage>
<lpage>R10</lpage>
<pub-id pub-id-type="doi">10.1016/s0014-2999(99)00800-6</pub-id>
<pub-id pub-id-type="other">2-s2.0-0033983360</pub-id>
<pub-id pub-id-type="pmid">10650166</pub-id>
</element-citation>
</ref>
<ref id="B205">
<label>205</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishida</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor</article-title>
<source/>
<italic toggle="yes">Hippocampus</italic>
<year>2007</year>
<volume>17</volume>
<issue>4</issue>
<fpage>271</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="doi">10.1002/hipo.20264</pub-id>
<pub-id pub-id-type="other">2-s2.0-34247548709</pub-id>
<pub-id pub-id-type="pmid">17265460</pub-id>
</element-citation>
</ref>
<ref id="B206">
<label>206</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Painsipp</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Herzog</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Holzer</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Implication of neuropeptide-Y Y2 receptors in the effects of immune stress on emotional, locomotor and social behavior of mice</article-title>
<source/>
<italic toggle="yes">Neuropharmacology</italic>
<year>2008</year>
<volume>55</volume>
<issue>1</issue>
<fpage>117</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.05.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-45649084837</pub-id>
<pub-id pub-id-type="pmid">18508096</pub-id>
</element-citation>
</ref>
<ref id="B207">
<label>207</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tasan</surname>
<given-names>R. O.</given-names>
</name>
</person-group>
<article-title>Increased novelty-induced motor activity and reduced depression-like behavior in neuropeptide Y (NPY)-Y4 receptor knockout mice</article-title>
<source/>
<italic toggle="yes">Neuroscience</italic>
<year>2009</year>
<volume>158</volume>
<issue>4</issue>
<fpage>1717</fpage>
<lpage>1730</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.11.048</pub-id>
<pub-id pub-id-type="other">2-s2.0-60149094545</pub-id>
<pub-id pub-id-type="pmid">19121371</pub-id>
</element-citation>
</ref>
<ref id="B208">
<label>208</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Seese</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>The role of galanin system in modulating depression, anxiety, and addiction-like behaviors after chronic restraint stress</article-title>
<source/>
<italic toggle="yes">Neuroscience</italic>
<year>2013</year>
<volume>246</volume>
<fpage>82</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.04.046</pub-id>
<pub-id pub-id-type="other">2-s2.0-84878371955</pub-id>
<pub-id pub-id-type="pmid">23639882</pub-id>
</element-citation>
</ref>
<ref id="B209">
<label>209</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuteeva</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hökfelt</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wardi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ogren</surname>
<given-names>S. O.</given-names>
</name>
</person-group>
<article-title>Galanin, Galanin Receptor Subtypes and Depression-Like Behaviour</article-title>
<source/>
<italic toggle="yes">Experientia Supplementum</italic>
<year>2010</year>
<volume>102</volume>
<fpage>163</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1007/978-3-0346-0228-0_12</pub-id>
<pub-id pub-id-type="other">2-s2.0-79952275138</pub-id>
</element-citation>
</ref>
<ref id="B210">
<label>210</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millón</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Flores-Burgess</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Narváez</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The neuropeptides Galanin and Galanin(1–15) in depression-like behaviours</article-title>
<source/>
<italic toggle="yes">Neuropeptides</italic>
<year>2017</year>
<volume>64</volume>
<fpage>39</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1016/j.npep.2017.01.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-85011990332</pub-id>
<pub-id pub-id-type="pmid">28196617</pub-id>
</element-citation>
</ref>
<ref id="B211">
<label>211</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juhasz</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hullam</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Eszlari</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain galanin system genes interact with life stresses in depression-related phenotypes</article-title>
<source/>
<italic toggle="yes">Proceedings of the National Academy of Sciences</italic>
<year>2014</year>
<volume>111</volume>
<issue>16</issue>
<fpage>E1666</fpage>
<lpage>E1673</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1403649111</pub-id>
<pub-id pub-id-type="other">2-s2.0-84899101173</pub-id>
</element-citation>
</ref>
<ref id="B212">
<label>212</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.-J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.-T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.-Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.-Q. D.</given-names>
</name>
</person-group>
<article-title>Plasma galanin is a biomarker for severity of major depressive disorder</article-title>
<source/>
<italic toggle="yes">The International Journal of Psychiatry in Medicine</italic>
<year>2014</year>
<volume>48</volume>
<issue>2</issue>
<fpage>109</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.2190/pm.48.2.d</pub-id>
<pub-id pub-id-type="other">2-s2.0-84922253319</pub-id>
<pub-id pub-id-type="pmid">25377152</pub-id>
</element-citation>
</ref>
<ref id="B213">
<label>213</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flores-Burgess</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Millón</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gago</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Galanin (1-15) enhancement of the behavioral effects of Fluoxetine in the forced swimming test gives a new therapeutic strategy against depression</article-title>
<source/>
<italic toggle="yes">Neuropharmacology</italic>
<year>2017</year>
<volume>118</volume>
<fpage>233</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.03.010</pub-id>
<pub-id pub-id-type="other">2-s2.0-85017154657</pub-id>
<pub-id pub-id-type="pmid">28288814</pub-id>
</element-citation>
</ref>
<ref id="B214">
<label>214</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saar</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lahe</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Langel</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel systemically active galanin receptor 2 ligands in depression-like behavior</article-title>
<source/>
<italic toggle="yes">Journal of Neurochemistry</italic>
<year>2013</year>
<volume>127</volume>
<issue>1</issue>
<fpage>114</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.12274</pub-id>
<pub-id pub-id-type="other">2-s2.0-84884906508</pub-id>
<pub-id pub-id-type="pmid">23600864</pub-id>
</element-citation>
</ref>
<ref id="B215">
<label>215</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saar</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Runesson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Järv</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kurrikoff</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Langel</surname>
<given-names>Ü</given-names>
</name>
</person-group>
<article-title>Novel galanin receptor subtype specific ligand in depression like behavior</article-title>
<source/>
<italic toggle="yes">Neurochemical Research</italic>
<year>2013</year>
<volume>38</volume>
<issue>2</issue>
<fpage>398</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-012-0933-8</pub-id>
<pub-id pub-id-type="other">2-s2.0-84876407438</pub-id>
<pub-id pub-id-type="pmid">23192661</pub-id>
</element-citation>
</ref>
<ref id="B216">
<label>216</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barr</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Kinney</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>M. N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests</article-title>
<source/>
<italic toggle="yes">Neuroscience Letters</italic>
<year>2006</year>
<volume>405</volume>
<issue>1-2</issue>
<fpage>111</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2006.06.033</pub-id>
<pub-id pub-id-type="other">2-s2.0-33746722657</pub-id>
<pub-id pub-id-type="pmid">16854525</pub-id>
</element-citation>
</ref>
<ref id="B217">
<label>217</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swanson</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Blackburn</surname>
<given-names>T. P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>From the Cover: anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299</article-title>
<source/>
<italic toggle="yes">Proceedings of the National Academy of Sciences</italic>
<year>2005</year>
<volume>102</volume>
<issue>48</issue>
<fpage>17489</fpage>
<lpage>17494</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0508970102</pub-id>
<pub-id pub-id-type="other">2-s2.0-28444496672</pub-id>
</element-citation>
</ref>
<ref id="B218">
<label>218</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haber</surname>
<given-names>S. N.</given-names>
</name>
<name>
<surname>Knutson</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>The reward circuit: linking primate anatomy and human imaging</article-title>
<source/>
<italic toggle="yes">Neuropsychopharmacology</italic>
<year>2010</year>
<volume>35</volume>
<issue>1</issue>
<fpage>4</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2009.129</pub-id>
<pub-id pub-id-type="other">2-s2.0-72049086941</pub-id>
<pub-id pub-id-type="pmid">19812543</pub-id>
</element-citation>
</ref>
<ref id="B219">
<label>219</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alcaro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Panksepp</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective</article-title>
<source/>
<italic toggle="yes">Brain Research Reviews</italic>
<year>2007</year>
<volume>56</volume>
<issue>2</issue>
<fpage>283</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainresrev.2007.07.014</pub-id>
<pub-id pub-id-type="other">2-s2.0-36549082065</pub-id>
<pub-id pub-id-type="pmid">17905440</pub-id>
</element-citation>
</ref>
<ref id="B220">
<label>220</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russo</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>E. J.</given-names>
</name>
</person-group>
<article-title>The brain reward circuitry in mood disorders</article-title>
<source/>
<italic toggle="yes">Nature Reviews Neuroscience</italic>
<year>2013</year>
<volume>14</volume>
<issue>9</issue>
<fpage>609</fpage>
<lpage>625</lpage>
<pub-id pub-id-type="doi">10.1038/nrn3381</pub-id>
<pub-id pub-id-type="other">2-s2.0-84883182497</pub-id>
<pub-id pub-id-type="pmid">23942470</pub-id>
</element-citation>
</ref>
<ref id="B221">
<label>221</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heshmati</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>S. J.</given-names>
</name>
</person-group>
<article-title>Anhedonia and the brain reward circuitry in depression</article-title>
<source/>
<italic toggle="yes">Current Behavioral Neuroscience Reports</italic>
<year>2015</year>
<volume>2</volume>
<issue>3</issue>
<fpage>146</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="doi">10.1007/s40473-015-0044-3</pub-id>
<pub-id pub-id-type="pmid">26525751</pub-id>
</element-citation>
</ref>
<ref id="B222">
<label>222</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nestler</surname>
<given-names>E. J.</given-names>
</name>
</person-group>
<article-title>Role of the brain’s reward circuitry in depression: transcriptional mechanisms</article-title>
<source/>
<italic toggle="yes">International Review of Neurobiology</italic>
<year>2015</year>
<volume>124</volume>
<fpage>151</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1016/bs.irn.2015.07.003</pub-id>
<pub-id pub-id-type="other">2-s2.0-84975852986</pub-id>
<pub-id pub-id-type="pmid">26472529</pub-id>
</element-citation>
</ref>
<ref id="B223">
<label>223</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunlop</surname>
<given-names>B. W.</given-names>
</name>
<name>
<surname>Nemeroff</surname>
<given-names>C. B.</given-names>
</name>
</person-group>
<article-title>The role of dopamine in the pathophysiology of depression</article-title>
<source/>
<italic toggle="yes">Archives of General Psychiatry</italic>
<year>2007</year>
<volume>64</volume>
<issue>3</issue>
<fpage>p. 327</fpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.64.3.327</pub-id>
<pub-id pub-id-type="other">2-s2.0-33847767095</pub-id>
</element-citation>
</ref>
<ref id="B224">
<label>224</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berridge</surname>
<given-names>K. C.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>DiFeliceantonio</surname>
<given-names>A. G.</given-names>
</name>
</person-group>
<article-title>The tempted brain eats: pleasure and desire circuits in obesity and eating disorders</article-title>
<source/>
<italic toggle="yes">Brain Research</italic>
<year>2010</year>
<volume>1350</volume>
<fpage>43</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2010.04.003</pub-id>
<pub-id pub-id-type="other">2-s2.0-77956180425</pub-id>
<pub-id pub-id-type="pmid">20388498</pub-id>
</element-citation>
</ref>
<ref id="B225">
<label>225</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perogamvros</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The roles of the reward system in sleep and dreaming</article-title>
<source/>
<italic toggle="yes">Neuroscience &amp; Biobehavioral Reviews</italic>
<year>2012</year>
<volume>36</volume>
<issue>8</issue>
<fpage>1934</fpage>
<lpage>1951</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2012.05.010</pub-id>
<pub-id pub-id-type="other">2-s2.0-84864803468</pub-id>
<pub-id pub-id-type="pmid">22669078</pub-id>
</element-citation>
</ref>
<ref id="B226">
<label>226</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robledo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Berrendero</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ozaita</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maldonado</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Advances in the field of cannabinoid-opioid cross-talk: advances in cannabinoid-opioid cross-talk</article-title>
<source/>
<italic toggle="yes">Addiction Biology</italic>
<year>2008</year>
<volume>13</volume>
<issue>2</issue>
<fpage>213</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1111/j.1369-1600.2008.00107.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-43749109782</pub-id>
<pub-id pub-id-type="pmid">18482431</pub-id>
</element-citation>
</ref>
<ref id="B227">
<label>227</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perchuk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bierbower</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Canseco-Alba</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Developmental and behavioral effects in neonatal and adult mice following prenatal activation of endocannabinoid receptors by capsaicin</article-title>
<source/>
<italic toggle="yes">Acta Pharmacologica Sinica</italic>
<year>2018</year>
<pub-id pub-id-type="doi">10.1038/s41401-018-0073-z</pub-id>
<pub-id pub-id-type="other">2-s2.0-85049630913</pub-id>
</element-citation>
</ref>
<ref id="B228">
<label>228</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knoll</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>Carlezon</surname>
<given-names>W. A.</given-names>
</name>
</person-group>
<article-title>Dynorphin, stress, and depression</article-title>
<source/>
<italic toggle="yes">Brain Research</italic>
<year>2010</year>
<volume>1314</volume>
<fpage>56</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2009.09.074</pub-id>
<pub-id pub-id-type="other">2-s2.0-75149118146</pub-id>
<pub-id pub-id-type="pmid">19782055</pub-id>
</element-citation>
</ref>
<ref id="B229">
<label>229</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lutz</surname>
<given-names>P.-E.</given-names>
</name>
<name>
<surname>Kieffer</surname>
<given-names>B. L.</given-names>
</name>
</person-group>
<article-title>Opioid receptors: distinct roles in mood disorders</article-title>
<source/>
<italic toggle="yes">Trends in Neurosciences</italic>
<year>2013</year>
<volume>36</volume>
<issue>3</issue>
<fpage>195</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2012.11.002</pub-id>
<pub-id pub-id-type="other">2-s2.0-84875273292</pub-id>
<pub-id pub-id-type="pmid">23219016</pub-id>
</element-citation>
</ref>
<ref id="B230">
<label>230</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tenore</surname>
<given-names>P. L.</given-names>
</name>
</person-group>
<article-title>Psychotherapeutic benefits of opioid agonist therapy</article-title>
<source/>
<italic toggle="yes">Journal of Addictive Diseases</italic>
<year>2008</year>
<volume>27</volume>
<issue>3</issue>
<fpage>49</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="doi">10.1080/10550880802122646</pub-id>
<pub-id pub-id-type="other">2-s2.0-58149145632</pub-id>
</element-citation>
</ref>
<ref id="B231">
<label>231</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Merrer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>J. A. J.</given-names>
</name>
<name>
<surname>Befort</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kieffer</surname>
<given-names>B. L.</given-names>
</name>
</person-group>
<article-title>Reward processing by the opioid system in the brain</article-title>
<source/>
<italic toggle="yes">Physiological Reviews</italic>
<year>2009</year>
<volume>89</volume>
<issue>4</issue>
<fpage>1379</fpage>
<lpage>1412</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00005.2009</pub-id>
<pub-id pub-id-type="other">2-s2.0-70349682196</pub-id>
<pub-id pub-id-type="pmid">19789384</pub-id>
</element-citation>
</ref>
<ref id="B232">
<label>232</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berrocoso</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sánchez-Blázquez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Garzón</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mico</surname>
<given-names>J. A.</given-names>
</name>
</person-group>
<article-title>Opiates as antidepressants</article-title>
<source/>
<italic toggle="yes">Current Pharmaceutical Design</italic>
<year>2009</year>
<volume>15</volume>
<issue>14</issue>
<fpage>1612</fpage>
<lpage>1622</lpage>
<pub-id pub-id-type="doi">10.2174/138161209788168100</pub-id>
<pub-id pub-id-type="other">2-s2.0-67650602317</pub-id>
<pub-id pub-id-type="pmid">19442177</pub-id>
</element-citation>
</ref>
<ref id="B233">
<label>233</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scarone</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gambini</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Calabrese</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Asymmetrical distribution of beta-endorphin in cerebral hemispheres of suicides: preliminary data</article-title>
<source/>
<italic toggle="yes">Psychiatry Research</italic>
<year>1990</year>
<volume>32</volume>
<issue>2</issue>
<fpage>159</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="doi">10.1016/0165-1781(90)90082-g</pub-id>
<pub-id pub-id-type="other">2-s2.0-0025332919</pub-id>
<pub-id pub-id-type="pmid">2142310</pub-id>
</element-citation>
</ref>
<ref id="B234">
<label>234</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kennedy</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Koeppe</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Zubieta</surname>
<given-names>J.-K.</given-names>
</name>
</person-group>
<article-title>Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women</article-title>
<source/>
<italic toggle="yes">Archives of General Psychiatry</italic>
<year>2006</year>
<volume>63</volume>
<issue>11</issue>
<fpage>p. 1199</fpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.63.11.1199</pub-id>
<pub-id pub-id-type="other">2-s2.0-33750721274</pub-id>
</element-citation>
</ref>
<ref id="B235">
<label>235</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zubieta</surname>
<given-names>J.-K.</given-names>
</name>
<name>
<surname>Ketter</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Bueller</surname>
<given-names>J. A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Regulation of human affective responses by anterior cingulate and limbic <italic>µ</italic>-opioid neurotransmission</article-title>
<source/>
<italic toggle="yes">Archives of General Psychiatry</italic>
<year>2003</year>
<volume>60</volume>
<issue>11</issue>
<fpage>p. 1145</fpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.60.11.1145</pub-id>
<pub-id pub-id-type="other">2-s2.0-0242678438</pub-id>
<pub-id pub-id-type="pmid">14609890</pub-id>
</element-citation>
</ref>
<ref id="B236">
<label>236</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zalsman</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Molcho</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dwork</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>J. J.</given-names>
</name>
</person-group>
<article-title>Postmortem mu-opioid receptor binding in suicide victims and controls</article-title>
<source/>
<italic toggle="yes">Journal of Neural Transmission</italic>
<year>2005</year>
<volume>112</volume>
<issue>7</issue>
<fpage>949</fpage>
<lpage>954</lpage>
<pub-id pub-id-type="doi">10.1007/s00702-004-0239-3</pub-id>
<pub-id pub-id-type="other">2-s2.0-20944440764</pub-id>
<pub-id pub-id-type="pmid">15937639</pub-id>
</element-citation>
</ref>
<ref id="B237">
<label>237</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ribeiro</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>Y. R.</given-names>
</name>
<name>
<surname>Stohler</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Zubieta</surname>
<given-names>J.-K.</given-names>
</name>
</person-group>
<article-title>Interface of physical and emotional stress regulation through the endogenous opioid system and <italic>µ</italic>-opioid receptors</article-title>
<source/>
<italic toggle="yes">Progress in Neuro-Psychopharmacology and Biological Psychiatry</italic>
<year>2005</year>
<volume>29</volume>
<issue>8</issue>
<fpage>1264</fpage>
<lpage>1280</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2005.08.011</pub-id>
<pub-id pub-id-type="other">2-s2.0-27944463696</pub-id>
<pub-id pub-id-type="pmid">16256255</pub-id>
</element-citation>
</ref>
<ref id="B238">
<label>238</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scherrer</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Salas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Copeland</surname>
<given-names>L. A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased risk of depression recurrence after initiation of prescription opioids in noncancer pain patients</article-title>
<source/>
<italic toggle="yes">The Journal of Pain</italic>
<year>2016</year>
<volume>17</volume>
<issue>4</issue>
<fpage>473</fpage>
<lpage>482</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpain.2015.12.012</pub-id>
<pub-id pub-id-type="other">2-s2.0-84957692778</pub-id>
<pub-id pub-id-type="pmid">26884282</pub-id>
</element-citation>
</ref>
<ref id="B239">
<label>239</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grattan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Saunders</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>C. I.</given-names>
</name>
<name>
<surname>Von Korff</surname>
<given-names>M. R.</given-names>
</name>
</person-group>
<article-title>Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse</article-title>
<source/>
<italic toggle="yes">The Annals of Family Medicine</italic>
<year>2012</year>
<volume>10</volume>
<issue>4</issue>
<fpage>304</fpage>
<lpage>311</lpage>
<pub-id pub-id-type="doi">10.1370/afm.1371</pub-id>
<pub-id pub-id-type="other">2-s2.0-84863945886</pub-id>
<pub-id pub-id-type="pmid">22778118</pub-id>
</element-citation>
</ref>
<ref id="B240">
<label>240</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merrill</surname>
<given-names>J. O.</given-names>
</name>
<name>
<surname>Von Korff</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Banta-Green</surname>
<given-names>C. J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prescribed opioid difficulties, depression and opioid dose among chronic opioid therapy patients</article-title>
<source/>
<italic toggle="yes">General Hospital Psychiatry</italic>
<year>2012</year>
<volume>34</volume>
<issue>6</issue>
<fpage>581</fpage>
<lpage>587</lpage>
<pub-id pub-id-type="doi">10.1016/j.genhosppsych.2012.06.018</pub-id>
<pub-id pub-id-type="other">2-s2.0-84867865577</pub-id>
<pub-id pub-id-type="pmid">22959422</pub-id>
</element-citation>
</ref>
<ref id="B241">
<label>241</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scherrer</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Svrakic</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Freedland</surname>
<given-names>K. E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prescription opioid analgesics increase the risk of depression</article-title>
<source/>
<italic toggle="yes">Journal of General Internal Medicine</italic>
<year>2014</year>
<volume>29</volume>
<issue>3</issue>
<fpage>491</fpage>
<lpage>499</lpage>
<pub-id pub-id-type="doi">10.1007/s11606-013-2648-1</pub-id>
<pub-id pub-id-type="other">2-s2.0-84896710600</pub-id>
<pub-id pub-id-type="pmid">24165926</pub-id>
</element-citation>
</ref>
<ref id="B242">
<label>242</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berrocoso</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sora</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Uhl</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Sánchez-Blázquez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mico</surname>
<given-names>J. A.</given-names>
</name>
</person-group>
<article-title>Active behaviours produced by antidepressants and opioids in the mouse tail suspension test</article-title>
<source/>
<italic toggle="yes">The International Journal of Neuropsychopharmacology</italic>
<year>2013</year>
<volume>16</volume>
<issue>1</issue>
<fpage>151</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="doi">10.1017/s1461145711001842</pub-id>
<pub-id pub-id-type="other">2-s2.0-84871479775</pub-id>
<pub-id pub-id-type="pmid">22217458</pub-id>
</element-citation>
</ref>
<ref id="B243">
<label>243</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vergura</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Balboni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Spagnolo</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)- Bid (UFP-512), a novel selective delta opioid receptor agonist</article-title>
<source/>
<italic toggle="yes">Peptides</italic>
<year>2008</year>
<volume>29</volume>
<issue>1</issue>
<fpage>93</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1016/j.peptides.2007.10.012</pub-id>
<pub-id pub-id-type="other">2-s2.0-37449031281</pub-id>
<pub-id pub-id-type="pmid">18069089</pub-id>
</element-citation>
</ref>
<ref id="B244">
<label>244</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Contet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kieffer</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Befort</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Mu opioid receptor: a gateway to drug addiction</article-title>
<source/>
<italic toggle="yes">Current Opinion in Neurobiology</italic>
<year>2004</year>
<volume>14</volume>
<issue>3</issue>
<fpage>370</fpage>
<lpage>378</lpage>
<pub-id pub-id-type="doi">10.1016/j.conb.2004.05.005</pub-id>
<pub-id pub-id-type="other">2-s2.0-2942577559</pub-id>
<pub-id pub-id-type="pmid">15194118</pub-id>
</element-citation>
</ref>
<ref id="B245">
<label>245</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fava</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Memisoglu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thase</surname>
<given-names>M. E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial</article-title>
<source/>
<italic toggle="yes">American Journal of Psychiatry</italic>
<year>2016</year>
<volume>173</volume>
<issue>5</issue>
<fpage>499</fpage>
<lpage>508</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2015.15070921</pub-id>
<pub-id pub-id-type="other">2-s2.0-84965139878</pub-id>
<pub-id pub-id-type="pmid">26869247</pub-id>
</element-citation>
</ref>
<ref id="B246">
<label>246</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benyhe</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Toth</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wollemann</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of synthetic analogues of human opiorphin on rat brain opioid receptors</article-title>
<source/>
<italic toggle="yes">Journal of Physiology and Pharmacology</italic>
<year>2014</year>
<volume>65</volume>
<issue>4</issue>
<fpage>525</fpage>
<lpage>530</lpage>
<pub-id pub-id-type="pmid">25179084</pub-id>
</element-citation>
</ref>
<ref id="B247">
<label>247</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Javelot</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Messaoudi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Garnier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rougeot</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Human opiorphin is a naturally occurring antidepressant acting selectively on enkephalin-dependent delta-opioid pathways</article-title>
<source/>
<italic toggle="yes">Journal of Physiology and Pharmacology</italic>
<year>2010</year>
<volume>61</volume>
<issue>3</issue>
<fpage>355</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="pmid">20610867</pub-id>
</element-citation>
</ref>
<ref id="B248">
<label>248</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Q.-Z.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>S.-S.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>X.-Z.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>A.-M.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>W.-W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>The antidepressant- like effect of human opiorphin via opioid-dependent pathways in mice</article-title>
<source/>
<italic toggle="yes">Neuroscience Letters</italic>
<year>2011</year>
<volume>489</volume>
<issue>2</issue>
<fpage>131</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2010.12.002</pub-id>
<pub-id pub-id-type="other">2-s2.0-78651414247</pub-id>
<pub-id pub-id-type="pmid">21145938</pub-id>
</element-citation>
</ref>
<ref id="B249">
<label>249</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Marzo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fontana</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cadas</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Formation and inactivation of endogenous cannabinoid anandamide in central neurons</article-title>
<source/>
<italic toggle="yes">Nature</italic>
<year>1994</year>
<volume>372</volume>
<issue>6507</issue>
<fpage>686</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="doi">10.1038/372686a0</pub-id>
<pub-id pub-id-type="other">2-s2.0-0028589390</pub-id>
<pub-id pub-id-type="pmid">7990962</pub-id>
</element-citation>
</ref>
<ref id="B250">
<label>250</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugiura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sukagawa</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis: involvement of Ca<sup>2+</sup>-dependent transacylase and phosphodiesterase activities</article-title>
<source/>
<italic toggle="yes">Biochemical and Biophysical Research Communications</italic>
<year>1996</year>
<volume>218</volume>
<issue>1</issue>
<fpage>113</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1006/bbrc.1996.0020</pub-id>
<pub-id pub-id-type="other">2-s2.0-0030066244</pub-id>
<pub-id pub-id-type="pmid">8573114</pub-id>
</element-citation>
</ref>
<ref id="B251">
<label>251</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zajkowska</surname>
<given-names>Z. E.</given-names>
</name>
<name>
<surname>Englund</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zunszain</surname>
<given-names>P. A.</given-names>
</name>
</person-group>
<article-title>Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response</article-title>
<source/>
<italic toggle="yes">Pharmacogenomics</italic>
<year>2014</year>
<volume>15</volume>
<issue>5</issue>
<fpage>687</fpage>
<lpage>698</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.14.40</pub-id>
<pub-id pub-id-type="other">2-s2.0-84899836826</pub-id>
<pub-id pub-id-type="pmid">24798725</pub-id>
</element-citation>
</ref>
<ref id="B252">
<label>252</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agrawal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>E. C.</given-names>
</name>
<name>
<surname>Littlefield</surname>
<given-names>A. K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression</article-title>
<source/>
<italic toggle="yes">Archives of General Psychiatry</italic>
<year>2012</year>
<volume>69</volume>
<issue>7</issue>
<fpage>732</fpage>
<lpage>740</lpage>
<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2011.2273</pub-id>
<pub-id pub-id-type="other">2-s2.0-84863558278</pub-id>
<pub-id pub-id-type="pmid">22393204</pub-id>
</element-citation>
</ref>
<ref id="B253">
<label>253</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitjans</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gastó</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Catalán</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fañanás</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Arias</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes</article-title>
<source/>
<italic toggle="yes">Journal of Psychopharmacology</italic>
<year>2012</year>
<volume>26</volume>
<issue>10</issue>
<fpage>1391</fpage>
<lpage>1398</lpage>
<pub-id pub-id-type="doi">10.1177/0269881112454229</pub-id>
<pub-id pub-id-type="other">2-s2.0-84866256149</pub-id>
<pub-id pub-id-type="pmid">22826533</pub-id>
</element-citation>
</ref>
<ref id="B254">
<label>254</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colino</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Herranz-Herrer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gil-Benito</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cannabinoid receptors, mental pain and suicidal behavior: a systematic review</article-title>
<source/>
<italic toggle="yes">Current Psychiatry Reports</italic>
<year>2018</year>
<volume>20</volume>
<issue>3</issue>
<fpage>p. 19</fpage>
<pub-id pub-id-type="doi">10.1007/s11920-018-0880-4</pub-id>
<pub-id pub-id-type="other">2-s2.0-85044239320</pub-id>
</element-citation>
</ref>
<ref id="B255">
<label>255</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kranaster</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hoyer</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Aksay</surname>
<given-names>S. S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study</article-title>
<source/>
<italic toggle="yes">European Archives of Psychiatry and Clinical Neuroscience</italic>
<year>2017</year>
<volume>267</volume>
<issue>8</issue>
<fpage>781</fpage>
<lpage>786</lpage>
<pub-id pub-id-type="doi">10.1007/s00406-017-0789-7</pub-id>
<pub-id pub-id-type="other">2-s2.0-85016077164</pub-id>
<pub-id pub-id-type="pmid">28342110</pub-id>
</element-citation>
</ref>
<ref id="B256">
<label>256</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.-K.</given-names>
</name>
</person-group>
<article-title>Molecular neurobiology and promising new treatment in depression</article-title>
<source/>
<italic toggle="yes">International Journal of Molecular Sciences</italic>
<year>2016</year>
<volume>17</volume>
<issue>3</issue>
<fpage>p. 381</fpage>
<pub-id pub-id-type="doi">10.3390/ijms17030381</pub-id>
<pub-id pub-id-type="other">2-s2.0-84961251622</pub-id>
</element-citation>
</ref>
<ref id="B257">
<label>257</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starowicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cristino</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Di Marzo</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications</article-title>
<source/>
<italic toggle="yes">Current Pharmaceutical Design</italic>
<year>2008</year>
<volume>14</volume>
<issue>1</issue>
<fpage>42</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="pmid">18220817</pub-id>
</element-citation>
</ref>
<ref id="B258">
<label>258</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khairatkar-Joshi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Szallasi</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>TRPV1 antagonists: the challenges for therapeutic targeting</article-title>
<source/>
<italic toggle="yes">Trends in Molecular Medicine</italic>
<year>2009</year>
<volume>15</volume>
<issue>1</issue>
<fpage>14</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1016/j.molmed.2008.11.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-58149483491</pub-id>
<pub-id pub-id-type="pmid">19097938</pub-id>
</element-citation>
</ref>
<ref id="B259">
<label>259</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benarroch</surname>
<given-names>E. E.</given-names>
</name>
</person-group>
<article-title>The locus ceruleus norepinephrine system: functional organization and potential clinical significance</article-title>
<source/>
<italic toggle="yes">Neurology</italic>
<year>2009</year>
<volume>73</volume>
<issue>20</issue>
<fpage>1699</fpage>
<lpage>1704</lpage>
<pub-id pub-id-type="doi">10.1212/wnl.0b013e3181c2937c</pub-id>
<pub-id pub-id-type="other">2-s2.0-73449128978</pub-id>
<pub-id pub-id-type="pmid">19917994</pub-id>
</element-citation>
</ref>
<ref id="B260">
<label>260</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>You</surname>
<given-names>I. J.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M. J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alterations in the emotional and memory behavioral phenotypes of transient receptor potential vanilloid type 1-deficient mice are mediated by changes in expression of 5-HT<sub>1</sub> A, GABA(A), and NMDA receptors</article-title>
<source/>
<italic toggle="yes">Neuropharmacology</italic>
<year>2012</year>
<volume>62</volume>
<issue>2</issue>
<fpage>1034</fpage>
<lpage>1043</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.10.013</pub-id>
<pub-id pub-id-type="other">2-s2.0-84855939044</pub-id>
<pub-id pub-id-type="pmid">22074644</pub-id>
</element-citation>
</ref>
<ref id="B261">
<label>261</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manna</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Umathe</surname>
<given-names>S. N.</given-names>
</name>
</person-group>
<article-title>A possible participation of transient receptor potential vanilloid type 1 channels in the antidepressant effect of fluoxetine</article-title>
<source/>
<italic toggle="yes">European Journal of Pharmacology</italic>
<year>2012</year>
<volume>685</volume>
<issue>1–3</issue>
<fpage>81</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2012.04.023</pub-id>
<pub-id pub-id-type="other">2-s2.0-84861346968</pub-id>
<pub-id pub-id-type="pmid">22542657</pub-id>
</element-citation>
</ref>
<ref id="B262">
<label>262</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayase</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors</article-title>
<source/>
<italic toggle="yes">BMC Pharmacology</italic>
<year>2011</year>
<volume>11</volume>
<issue>1</issue>
<fpage>p. 6</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2210-11-6</pub-id>
<pub-id pub-id-type="other">2-s2.0-79960562968</pub-id>
</element-citation>
</ref>
<ref id="B263">
<label>263</label>
<element-citation publication-type="book">
<collab>National Library of Medicine</collab>
<source/>
<italic toggle="yes">Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients (Ketamine)</italic>
<year>2018</year>
<publisher-loc>Bethesda, MD, USA</publisher-loc>
<publisher-name>National Library of Medicine</publisher-name>
<comment>ClinicalTrials.gov. NCT02935595, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT02935595">http://clinicaltrials.gov/show/NCT02935595</ext-link></comment>
</element-citation>
</ref>
<ref id="B264">
<label>264</label>
<element-citation publication-type="book">
<collab>National Library of Medicine</collab>
<source/>
<italic toggle="yes">Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer</italic>
<year>2018</year>
<publisher-loc>Bethesda, MD, USA</publisher-loc>
<publisher-name>National Library of Medicine</publisher-name>
<comment>ClinicalTrials.gov. NCT02836288, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT02836288">http://clinicaltrials.gov/show/NCT02836288</ext-link></comment>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="fig1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Expanding views on the neurobiology of depression. GABA: <italic>γ</italic>-aminobutyric acid; BDNF: brain-derived neurotrophic factor. Current neuropsychopharmacological approaches to depression are centered on the monoamine hypothesis. Nevertheless, the imperfect results obtained in clinical practice with currently available antidepressant drugs have propelled the discovery of various potential pharmacological targets beyond noradrenaline, dopamine, and serotonin.</p>
</caption>
<graphic xlink:href="APS2019-7943481.001"></graphic>
</fig>
<fig id="fig2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Effects of ketamine on the glutamatergic synapse. Ketamine acts as an NMDA antagonist on GABAergic interneurons, as well as on postsynaptic glutamatergic neurons. Antagonism in the former results in disinhibition of presynaptic glutamatergic neurons, thus favoring activation of AMPAR in postsynaptic glutamatergic neurons. This, along with activation of voltage-dependent calcium channels, results in activation of the PI3K pathway which leads to increased mTOR activity. Furthermore, antagonism of NMDAR leads to inhibition of the nitric oxide pathway, which in turn leads to Rheb stabilization and mTOR pathway potentiation. mTOR increases p70s6K activity, which promotes BDNF signaling. BDNF activity is also favored by the inactivation of eEf2K secondary to NMDAR antagonism.</p>
</caption>
<graphic xlink:href="APS2019-7943481.002"></graphic>
</fig>
<fig id="fig3" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Neuropeptide pharmacotherapeutic targets in depression. OXT: oxytocin; LHA: lateral nucleus; PVH: paraventricular nucleus; DMH: dorsomedial nucleus; VMH: ventromedial nucleus; ARC: arcuate nucleus; AVPR1B: arginine vasopressin receptor 1B; NK1: neurokinin 1. Key findings regarding the current knowledge on neuropeptides in the neuropsychopharmacology of depression include the following: (1) Abundant preclinical and clinical evidence suggests oxytocin may significantly contribute to the improvement of depression-related symptoms such as sexual dysfunction, anhedonia, and sleep disturbances. (2) AVPR1B antagonists appear to reduce symptoms of anxiety and depression in both animal and human models. (3) Several modulators of neuropeptide signaling have shown antidepressant activity; however, further research is required to characterize their significance and utility.</p>
</caption>
<graphic xlink:href="APS2019-7943481.003"></graphic>
</fig>
<fig id="fig4" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Pharmacotherapeutic targets for depression in reward neurocircuits. <sup>∗</sup>Agonist. <sup>∗</sup><sup>∗</sup>Antagonist. <sup>∗</sup><sup>∗</sup><sup>∗</sup>Modulator. <italic>μ</italic>: <italic>µ</italic>-opioid receptor. <italic>δ</italic>: <italic>δ</italic>-opioid receptor. κ: κ-opioid receptor. CB1: cannabinoid receptor 1. CB2: cannabinoid receptor 2. TRPV1: transient receptor potential cation channel V1. Research on pharmacotherapeutic targets for depression in the reward system remains principally preclinical. Currently available results presume some potential clinical utility for these substances for the treatment of depression, with varying degrees of efficacy and differing pharmacological profiles.</p>
</caption>
<graphic xlink:href="APS2019-7943481.004"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>